Form 8-K

8-K — Sanara MedTech Inc.

Accession: 0001493152-26-035196

Filed: 2026-07-29

Period: 2026-07-29

CIK: 0000714256

SIC: 3842 (ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES)

Item: Entry into a Material Definitive Agreement

Item: Regulation FD Disclosure

Item: Financial Statements and Exhibits

Documents

8-K — form8-k.htm (Primary)

EX-2.1 (ex2-1.htm)

EX-10.1 (ex10-1.htm)

EX-99.1 (ex99-1.htm)

GRAPHIC (ex99-1_001.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: form8-k.htm · Sequence: 1

false

0000714256

2026-07-29

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

WASHINGTON,

D.C. 20549

FORM

8-K

CURRENT

REPORT

Pursuant

to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date

of Report (Date of earliest event reported): July 29, 2026

SANARA

MEDTECH INC.

(Exact

name of registrant as specified in its charter)

Texas

001-39678

59-2219994

(State

or other jurisdiction

incorporation)

(Commission

File

Number)

(I.R.S.

Employer

Identification

No.)

1200

Summit Avenue, Suite 414

Fort

Worth, Texas

76102

(Address

of principal executive offices)

(Zip

Code)

Registrant’s

telephone number, including area code: (817) 529-2300

(Former

Name or Former Address, if Changed Since Last Report)

Check

the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under

any of the following provisions (see General Instruction A.2. below):

☒

Written

communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting

material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement

communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement

communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities

registered pursuant to Section 12(b) of the Act:

Title

of each class

Trading

Symbol(s)

Name

of exchange on which registered

Common

Stock, $0.001 Par Value

SMTI

The

Nasdaq Capital Market

Indicate

by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405

of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging

growth company ☐

an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying

with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item

1.01 Entry into a Material Definitive Agreement.

Agreement

and Plan of Merger

July 29, 2026, Sanara MedTech Inc. (the “Company”) entered into an Agreement and Plan of Merger (the “Merger Agreement”)

by and among the Company, MiMedx Group, Inc., a Florida corporation (“Parent”) and Mustang Merger Sub, Inc., a Texas corporation

and a wholly-owned subsidiary of Parent (“Merger Subsidiary”). Upon the terms and conditions set forth in the Merger Agreement,

Merger Subsidiary will be merged with and into the Company (the “Merger”), with the Company surviving the Merger as a wholly-owned

subsidiary of Parent. Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to them in the Merger

Agreement.

The

Board of Directors of the Company (the “Board”) unanimously (i) determined that the Merger Agreement and the transactions

contemplated by the Merger Agreement, including the Merger, are advisable, fair to and in the best interests of the Company and its stockholders,

(ii) approved the execution, delivery and performance by the Company of the Merger Agreement and the consummation of the transactions

contemplated thereby, including the Merger, (iii) declared advisable the Merger Agreement and the transactions contemplated thereby,

(iv) resolved to recommend that the Company’s stockholders vote to approve and adopt the Merger Agreement and the transactions

contemplated thereby (the “Company Board Recommendation”) and (v) directed that the Merger Agreement be submitted to the

Company’s stockholders for their approval and adoption. The Board of Directors of Parent unanimously approved the Merger Agreement

and the Transactions, including, the Merger and the issuance by Parent of common stock, par value $0.001 per share of Parent (the “Parent

Common Stock”)

Merger

Consideration

Pursuant

to the Merger Agreement, and upon the terms and subject to the conditions described therein, at the effective time of the Merger (the

“Effective Time”), each share of Common Stock, par value $0.001 per share of the Company (“Company Stock”) issued

and outstanding immediately prior to the Effective Time (other than (i) shares held by a holder who is entitled to demand and properly

demands appraisal of such shares in accordance with Chapter 10, Subchapter H of the Texas Business Organizations Code and (ii) shares

held by the Company, Parent or any of their respective subsidiaries (each, an “Excluded Company Share”)), will be cancelled

and converted into the right to receive $33.00 per share in cash, without interest (the “Per Share Cash Consideration”) and

0.4735 shares of Parent Common Stock (the “Per Share Stock Consideration,” and together with the Per Share Cash Consideration,

the “Merger Consideration”). The Per Share Stock Consideration represents a value of $2.00 per share, calculated based on

the average closing price of Parent Common Stock for the five consecutive trading days immediately prior to July 29, 2026. At the Effective

Time, each Excluded Company Share will automatically be cancelled and extinguished without any consideration paid for such Excluded Company

Share.

The

shares of Parent Common Stock to be issued in connection with the Merger will be listed on the Nasdaq Stock Market. In connection with

the issuance of Parent Common Stock as Merger Consideration, Parent will file with the U.S. Securities and Exchange Commission (the “SEC”)

a registration statement on Form S-4 (the “Registration Statement”), which will include the proxy statement of the Company

for its stockholder meeting relating to the Transactions.

Treatment

of Equity Awards

Pursuant

to the Merger Agreement, immediately prior to the Effective Time, (a) each share of restricted Company Stock, granted pursuant to the

Company’s Restated 2014 Omnibus Long-Term Incentive Plan, the Company’s 2024 Omnibus Long-Term Incentive Plan, or otherwise,

whether vested or unvested, which is outstanding as of immediately prior to the Effective Time and which is subject to restrictions on

transfer and/or forfeiture (the “Company Restricted Stock”), will automatically be canceled and converted automatically into

the right to receive from the Company, at or promptly after the Effective Time, an amount (i) in cash (less applicable tax withholdings)

equal to the Per Share Cash Consideration and (ii) a number of shares of Parent common stock equal to the Per Share Stock Consideration

(the “Restricted Stock Consideration”); and (b) immediately prior to the Effective Time, each option that represents the

right to acquire Company Stock, which is outstanding as of immediately prior to the Effective Time (each, a “Company Option”)

shall, by virtue of the Merger and without any action on the part of the Company, Parent or the holder of such Company Option, automatically

be cancelled and converted automatically into the right to receive from the Company, at or promptly after the Effective Time, an amount

in cash (less applicable taxes) equal to the Merger Consideration (with the Per Share Stock Consideration based on the closing price

of the shares of Parent common stock on the last trading day prior to the Closing Date) less the exercise price payable in respect of

such Company Option (the “Option Consideration”).

Representations,

Warranties and Covenants

The

Merger Agreement contains customary representations, warranties and covenants, including, among others, covenants

relating to the Company’s conduct of its business between the date of the Merger Agreement and the earlier of the Effective Time

and the termination of the Merger Agreement, and the Company’s obligation to convene a meeting of the Company’s stockholders

to consider and vote upon the adoption and approval of the Merger Agreement.

Additionally,

the Company is bound by a covenant not to solicit, initiate, or knowingly take any action to facilitate or encourage any competing acquisition

proposals. However, at any time before receiving the Company Stockholder Approval (as defined below), if the Board determines in good

faith, after consultation with its financial advisors and outside legal counsel, that an unsolicited competing acquisition proposal is

or would reasonably be expected to lead to a Superior Proposal and the Board’s failure to engage would be reasonably likely to

be inconsistent with its fiduciary duties, then the Company is permitted to engage in discussions or negotiations with the third party,

subject to certain requirements set forth in the Merger Agreement. If, at any time before receiving the Company Stockholder Approval,

the Company has received an unsolicited Superior Proposal, then the Board may make an Adverse Recommendation Change and/or cause the

Company to terminate the Merger Agreement, subject to certain requirements set forth in the Merger Agreement, including first providing

Parent with customary match rights. In addition, subject to certain conditions and requirements, including first providing Parent customary

match rights, the Board may effect an Adverse Recommendation Change (but not terminate the Merger Agreement) in response to an “Intervening

Event”.

Conditions

to the Transactions

The

stockholders of the Company will be asked to vote on the adoption of the Merger Agreement and the approval of the Merger and the other

transactions contemplated thereby at a meeting of the Company’s stockholders. The Merger is not subject to a financing condition,

but is subject to the satisfaction or waiver (where permitted by applicable law) of certain closing conditions, including:

●

the

adoption and approval of the Merger Agreement by the affirmative vote of the holders of a majority of the outstanding shares of Common

Stock entitled to vote thereon (the “Company Stockholder Approval”);

●

the

absence of any law, ruling, injunction or order that restrains, enjoins, renders illegal or otherwise prohibits the consummation of the

Merger;

●

the

expiration or earlier termination of all applicable waiting periods under the Hart-Scott-Rodino Antitrust Improvements Act, and receipt

of certain other applicable approvals, clearances or expirations of waiting periods under the antitrust laws and foreign direct investment

laws of other jurisdictions;

●

other

customary closing conditions, including the accuracy of each party’s representations

and warranties and each party’s compliance with its covenants and agreements contained

in the Merger Agreement (subject to certain qualifications as to materiality);

●

the

registration statement on Form S-4, pursuant to which the shares of Parent common stock issuable in connection with the Merger being

registered with the SEC and declared effective by the SEC, and the absence of a stop order suspending such registration statement,

and the shares of Parent common stock to be issued in connection with the Merger being approved for listing on Nasdaq;

●

the

absence of a Material Adverse Effect since the date of the Merger Agreement.

Termination

The

Merger Agreement may be terminated by mutual written agreement of the Company and Parent. In addition, either party may terminate the

Merger Agreement if:

●

the

Merger has not been consummated on or before July 29, 2027 (the “End Date”), provided that either Company or Parent may

extend the End Date to January 29, 2028 in the event that the requisite antitrust approvals have not been obtained by the End Date;

●

court or other governmental authority issues a final, non-appealable order permanently restraining, enjoining or otherwise prohibiting

the consummation of the Merger;

●

the

Company Stockholder Approval is not obtained at a meeting of the Company’s stockholders (or any adjournment or postponement

thereof taken in accordance with the Merger Agreement); or

●

the other party breaches any of its representations, warranties or covenants, the breach would cause certain closing conditions not

to be satisfied, and the breach is not curable or, if curable, is not cured within the time period set forth in the Merger Agreement.

addition, the Merger Agreement may be terminated (i) by the Company, prior to obtaining the Company Stockholder Approval, to enter into

a definitive agreement with respect to a Superior Proposal, subject to compliance with the applicable provisions of the Merger Agreement

and payment of the Termination Fee described below, and (ii) by Parent if at any time prior to obtaining the Company Stockholder Approval

the Board effects an Adverse Recommendation Change.

the Merger Agreement is terminated under certain circumstances, the Company would be obligated to pay Parent a termination fee of $22,540,785.00

in cash (the “Parent Termination Fee”). The Parent Termination Fee would be payable, among other circumstances, if: (i) the

Merger Agreement is terminated by Parent following the Board’s Adverse Recommendation Change; (ii) the Company terminates the Merger

Agreement to enter into a definitive agreement with respect to a Superior Proposal; or (iii) following the public disclosure of an alternative

acquisition proposal with respect to the Company, the Merger Agreement is terminated for failure to obtain the Company Stockholder Approval

and, within 12 months after such termination, the Company enters into a definitive agreement for, or consummates, certain alternative

acquisition transactions. Furthermore, Parent will be required to pay to the Company a termination fee of $9,660,336.00 if the Company

terminates the Merger Agreement because of a failure of Parent to consummate the Merger when required to do so by the Merger Agreement.

In no event will either party be required to pay its applicable termination fee on more than one occasion.

the Merger Agreement is consummated, the Company Stock will be delisted from the Nasdaq Capital Market and deregistered under the Securities

Exchange Act of 1934, as amended (the “Exchange Act”).

copy of the Merger Agreement is attached hereto as Exhibit 2.1 and is incorporated herein by reference. The foregoing description of

the Merger Agreement does not purport to be complete and is qualified in its entirety by reference to the full texts of the Merger Agreement.

The Merger Agreement has been filed to provide information to investors regarding its terms. It is not intended to provide any other

factual information about the Company, Parent, or Merger Subsidiary during the period prior to the consummation of the Merger. The Merger

Agreement and the summary should not be relied upon as disclosure about the Company, Parent, or Merger Subsidiary. None of the Company’s

stockholders or any other third parties should rely on the representations, warranties and covenants in the Merger Agreement or any descriptions

thereof as characterizations of the actual state of facts or conditions of the Company, Parent, or Merger Subsidiary, or any of their

respective subsidiaries or affiliates. The representations and warranties contained in the Merger Agreement are the product of negotiations

among the parties thereto and that the parties made to, and solely for the benefit of, each other as of specified dates. The assertions

embodied in those representations and warranties are subject to qualifications and limitations agreed to by the respective parties and

are also qualified in important part by confidential disclosure schedules delivered in connection with the Merger Agreement. The representations

and warranties may have been made for the purpose of allocating contractual risk between the parties to the agreements instead of establishing

these matters as facts, and may be subject to standards of materiality applicable to the contracting parties that differ from those applicable

to investors.

Voting

Agreement

Concurrently

with the execution of the Merger Agreement, on July 29, 2026, Parent entered into a voting agreement (the “Voting Agreement”)

with the Company and certain stockholders of the Company (the “Specified Stockholders”). Pursuant to the Voting Agreement,

each of the Specified Stockholders has agreed, among other things, to vote, or cause to be voted, all of the shares beneficially owned

by such Specified Stockholder (the “Shares”) in favor of the adoption of the Merger Agreement and against any alternative

acquisition proposal, in each case, subject to certain conditions.

of the date of the Merger Agreement, the Specified Stockholders collectively held approximately 38.9% of the total voting power of the

Shares. The Voting Agreement also contains restrictions on, among other things, the transfer of the Shares held by the Specified Stockholders.

The

Voting Agreement will terminate upon the earliest of (a) the termination of the Merger Agreement in accordance with its terms, (b) the

Effective Time, (c) the termination of the Voting Agreement by written agreement of the parties thereto, (d) the date on which the Board

makes an Adverse Recommendation Change, or (e) such date and time as the Merger Agreement shall have been, without the prior written

consent of the Company’s stockholders, amended or supplemented, or any provision thereof waived, in a manner that changes the form

of the consideration or reduces the amount of the Merger Consideration payable (or issuable) in respect of the Shares.

The

foregoing summary of the Voting Agreement does not purport to be complete and is subject to, and qualified in its entirety by, the full

text of such agreement, a copy of which is attached hereto as Exhibit 10.1 and is incorporated herein by reference.

Item

7.01 Regulation FD Disclosure.

July 29, 2026, the Company issued a press release announcing its entry into the Merger Agreement. A copy of the press release is attached

as Exhibit 99.1 and is incorporated herein by reference.

The

information in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed “filed”

for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject

to the liabilities under that section. Further, the information in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1,

shall not be deemed to be incorporated by reference into the filings of the Company under the Securities Act of 1933, as amended, or

the Exchange Act, whether made before or after the date hereof and regardless of any general incorporation language in such filing. Item

7.01 of this Current Report on Form 8-K will not be deemed an admission as to the materiality of any information in this Current Report

on Form 8-K that is required to be disclosed solely by Regulation FD.

Forward-Looking

Statements

This

communication relates to a proposed business combination transaction between MiMedx Group, Inc. (“MiMedx”) and Sanara MedTech

Inc. (“Sanara”). This communication contains certain forward-looking statements within the meaning of the Private Securities

Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act

of 1934, as amended, which include all statements that do not relate solely to historical or current facts, such as statements regarding

the timing of the proposed transaction and the anticipated benefits of the proposed transaction. These forward-looking statements are

and will be, subject to many risks, uncertainties and factors which may cause future events to be materially different from these forward-looking

statements or anything implied therein. These risks and uncertainties include, but are not limited to: uncertainties as to the timing

of the proposed transaction; the timing, receipt and terms and conditions of any required governmental or regulatory approvals of the

proposed transaction that could reduce the anticipated benefits of or cause the parties to abandon the proposed transaction; risks related

to the satisfaction of the conditions to closing the proposed transaction (including the failure to obtain necessary regulatory approvals

or the approval of Sanara’s stockholders) in the anticipated timeframe or at all; the risk that any announcements relating to the

proposed transaction could have adverse effects on the market price of Sanara’s or MiMedx’s stock; disruption from the proposed

transaction making it more difficult to maintain business and operational relationships, including retaining and hiring key personnel;

the occurrence of any event, change or other circumstances that could give rise to the termination of the merger agreement, including

in certain circumstances requiring Sanara to pay a termination fee; risks related to disruption of management’s attention from

Sanara’s ongoing business operations due to the proposed transaction; significant transaction costs; the risk of litigation and/or

regulatory actions related to the proposed transaction; global economic conditions; adverse industry and market conditions; the ability

to retain management and other personnel; risks associated with the development and process for obtaining regulatory approval for new

products, the extent of product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, uncertainties

associated with the development and process for obtaining regulatory approval for new products, the ability to consummate and integrate

acquisitions, and other risks, contingencies and uncertainties detailed in Sanara’s most recent annual report on Form 10-K and

subsequent reports filed with the Securities and Exchange Commission (the “SEC”). While the list of risks and uncertainties

presented here is, and the discussion of risks and uncertainties to be presented in the proxy statement that will be filed by Sanara

with the SEC in connection with the proposed transaction will be, considered representative, no such list or discussion should be considered

a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization

of forward-looking statements. Consequences of material differences in results as compared with those anticipated in the forward-looking

statements could include, among other things, business disruption, operational problems, financial loss, and legal liability to third

parties and similar risks, any of which could have a material adverse effect on the completion of the proposed transaction and/or Sanara’s

consolidated financial condition, results of operations, credit rating or liquidity.

light of the significant uncertainties in these forward-looking statements, Sanara cannot assure you that the forward-looking statements

in this communication will prove to be accurate, and you should not regard these statements as a representation or warranty by Sanara,

its directors, officers or employees or any other person that Sanara will achieve its objectives and plans in any specified time frame,

or at all. Any forward-looking statements in this communication are based upon information available to Sanara on the date of this communication.

Subject to applicable law, Sanara does not undertake to publicly update or revise its forward-looking statements.

Important

Additional Information

connection with the proposed transaction, MiMedx intends to file with the SEC a registration statement on Form S-4 that will include

a proxy statement of Sanara and that also constitutes a prospectus of MiMedx. Each of MiMedx and Sanara may also file other relevant

documents with the SEC regarding the proposed transaction. This communication is not a substitute for the proxy statement/prospectus

or registration statement or any other document that MiMedx or Sanara may file with the SEC. The definitive proxy statement/prospectus

(if and when available) will be mailed to stockholders of Sanara. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE REGISTRATION STATEMENT,

PROXY STATEMENT/PROSPECTUS AND ANY OTHER RELEVANT DOCUMENTS THAT MAY BE FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS

TO THESE DOCUMENTS, CAREFULLY AND IN THEIR ENTIRETY IF AND WHEN THEY BECOME AVAILABLE BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT

INFORMATION ABOUT THE PROPOSED TRANSACTION. Investors and security holders will be able to obtain free copies of the registration statement

and proxy statement/prospectus (if and when available) and other documents containing important information about MiMedx, Sanara and

the proposed transaction, once such documents are filed with the SEC through the website maintained by the SEC at http://www.sec.gov.

Copies of the documents filed with the SEC by MiMedx will be available free of charge on MiMedx’s website at https://investors.mimedx.com/.

Copies will also be available at no charge at the Investors Relations section of Sanara’s website at https://ir.sanaramedtech.com/.

Participants

in the Solicitation

Sanara,

MiMedx and certain of their respective directors and executive officers may be deemed to be participants in the solicitation of proxies

in respect of the proposed transaction. Information about the directors and executive officers of Sanara, including a description of

their direct or indirect interests, by security holdings or otherwise, is set forth in Sanara’s proxy statement for its 2026 Annual

Meeting of Stockholders, which was filed with the SEC on April 17, 2026. Information about the directors and executive officers of MiMedx,

including a description of their direct or indirect interests, by security holdings or otherwise, is set forth in MiMedx’s proxy

statement for its 2026 Annual Meeting of Stockholders, which was filed with the SEC on April 29, 2026. Other information regarding the

participants in the proxy solicitations and a description of their direct and indirect interests, by security holdings or otherwise,

will be contained in the proxy statement/prospectus and other relevant materials to be filed with the SEC regarding the proposed transaction

when such materials become available. Investors should read the proxy statement/prospectus carefully when it becomes available before

making any voting or investment decisions. You may obtain free copies of these documents from Sanara and MiMedx using the sources indicated

above.

Offer or Solicitation

This

communication does not constitute an offer to sell or the solicitation of an offer to subscribe for or buy any securities or a solicitation

of any vote or approval with respect to the proposed transactions or otherwise, nor shall there be any sale, issuance or transfer of

securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under

the securities laws of such jurisdiction.

Item

9.01 Financial Statements and Exhibits.

(d)

Exhibits.

The

following exhibits are included with this report:

Exhibit

No.

Exhibit

Description

2.1

Agreement and Plan of Merger, dated as of July 29, 2026, by and among Sanara MedTech Inc., MiMedx Group, Inc., and Mustang Merger Sub, Inc.*

10.1

Voting Agreement, dated as of July 29, 2026, by and among MiMedx Group, Inc., Sanara MedTech Inc., and certain stockholders identified in an exhibit thereto*

99.1

Press Release issued by Sanara MedTech Inc. on July 29, 2026.

104

Cover

Page Interactive Data File (embedded within the Inline XBRL document).

Schedules (or similar attachments) have been omitted pursuant to Item 601(a)(5) of Regulation S-K.

The Company hereby undertakes to furnish supplemental copies of any of the omitted schedules upon request by the SEC.

SIGNATURES

Pursuant

to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by

the undersigned hereunto duly authorized.

Sanara

MedTech Inc.

Date:

July

29, 2026

By:

/s/

Elizabeth B. Taylor

Elizabeth

B. Taylor

Chief

Financial Officer

EX-2.1

Filename: ex2-1.htm · Sequence: 2

Exhibit

2.1

Execution

Version

AGREEMENT

AND PLAN OF MERGER

dated

as of

July

29, 2026

among

SANARA

MEDTECH INC.,

MIMEDX

GROUP, INC.

and

MUSTANG

MERGER SUB, INC.

TABLE

OF CONTENTS

Article 1 Definitions

Section

1.1

Definitions

Section

1.2

Other

Definitional and Interpretative Provisions

Article 2 The Merger

Section

2.1

The

Merger

Section

2.2

Conversion

of Shares

Section

2.3

Surrender

and Payment

Section

2.4

Closing

of Transfer Books

Section

2.5

Dissenting

Section

2.6

Treatment

of Equity Awards

Section

2.7

Certain

Adjustments

Section

2.8

Equity

Awards; Withholding Rights

Article 3 The Surviving Corporation

Section

3.1

Certificate

of Incorporation

Section

3.2

Bylaws

Section

3.3

Directors

and Officers

Article 4 Representations and Warranties of the Company

Section

4.1

Corporate

Existence and Power

Section

4.2

Corporate

Authorization

Section

4.3

Governmental

Authorization

Section

4.4

Non-contravention

Section

4.5

Capitalization

Section

4.6

Subsidiaries

Section

4.7

SEC

Filings and the Sarbanes-Oxley Act

Section

4.8

Financial

Statements

Section

4.9

Disclosure

Documents

Section

4.10

Absence

of Certain Changes

Section

4.11

Undisclosed Material Liabilities

Section

4.12

Compliance

with Laws and Court Orders

Section

4.13

Regulatory

Matters

Section

4.14

Litigation

Section

4.15

Permits

Section

4.16

Properties

Section

4.17

Intellectual

Property

Section

4.18

Taxes

Section

4.19

Employee

Benefit Plans and Labor and Employment Matters

Section

4.20

Environmental

Matters

Section

4.21

Material

Contracts

Section

4.22

Party Transactions

Section

4.23

Brokers

Section

4.24

Opinion

of the Company’s Financial Advisor

Section

4.25

Takeover

Laws

Section

4.26

Insurance

Section

4.27

Other Representations and Warranties

Section

4.28

Exclusivity

of Parent Representations and Warranties

Section

4.29

Reliance

Article 5 Representations and Warranties of Parent

Section

5.1

Corporate

Existence and Power

Section

5.2

Corporate

Authorization

Section

5.3

Governmental

Authorization

Section

5.4

Non-contravention

Section

5.5

Disclosure

Documents

Section

5.6

SEC

Filings and the Sarbanes-Oxley Act

Section

5.7

Brokers

Section

5.8

Financing

Section

5.9

Solvency

Section

5.10

Ownership

of Company Stock

Section

5.11

Stockholder

and Management Arrangements

Section

5.12

Exclusivity

of Representations and Warranties

Article 6 Covenants of the Company

Section

6.1

Conduct

of the Company

Section

6.2

Company

Stockholder Meeting

Section

6.3

Solicitation; Other Offers

Section

6.4

Access

to Information

Section

6.5

Resignations

Section

6.6

Payoff

Letters; Lien Releases; Transaction Expenses.

Section

6.7

Financing

Cooperation

Article 7 Covenants of Parent

Section

7.1

Conduct

of Parent

Section

7.2

Obligations

of Merger Subsidiary

Section

7.3

Voting

of Shares

Section

7.4

Director

and Officer Liability

Section

7.5

Employee

Matters

Section

7.6

Financing

Article 8 Covenants of Parent and the Company

Section

8.1

Regulatory

Authorizations and Consents

Section

8.2

Proxy

Statement and Registration Statement

Section

8.3

Public

Announcements

Section

8.4

Further

Assurances

Section

8.5

Notices

of Certain Events

Section

8.6

Section

16 Matters

Section

8.7

Transaction

Litigation

Section

8.8

Takeover

Laws

Section

8.9

Stock

Exchange Listing; Delisting and Deregistration

Article 9 Conditions to the Merger

Section

9.1

Conditions

to the Obligations of Each Party

Section

9.2

Conditions

to the Obligations of Parent and Merger Subsidiary

Section

9.3

Conditions

to the Obligations of the Company

Article 10 Termination

Section

10.1

Termination

Section

10.2

Effect

of Termination

Article 11 Miscellaneous

Section

11.1

Notices

Section

11.2

Survival of Representations, Warranties and Agreements

Section

11.3

Amendments

and Waivers

Section

11.4

Expenses

and Termination Fee

Section

11.5

Binding

Effect; Benefit; Assignment

Section

11.6

Governing

Law

Section

11.7

Jurisdiction

Section

11.8

WAIVER

OF JURY TRIAL

Section

11.9

Counterparts;

Effectiveness

Section

11.10

Entire

Agreement

Section

11.11

Severability

Section

11.12

Specific

Performance

Section

11.13

Recourse

Section

11.14

Debt

Financing Sources

iii

AGREEMENT

AND PLAN OF MERGER

AGREEMENT

AND PLAN OF MERGER (this “Agreement”) dated as of July 29, 2026 among Sanara MedTech Inc., a Texas corporation

(the “Company”), MiMedx Group, Inc., a Florida corporation (“Parent”), and Mustang

Merger Sub, Inc., a Texas corporation and a wholly-owned subsidiary of Parent (“Merger Subsidiary”).

I T N E S S E T H:

WHEREAS,

upon the terms and subject to the conditions set forth in this Agreement, Merger Subsidiary will be merged with and into the Company,

with the Company continuing as the Surviving Corporation, and each issued and outstanding share of Company Stock immediately prior to

the Effective Time (other than shares to be canceled in accordance with Section 2.2 and Dissenting Shares) will be converted into

the right to receive the Merger Consideration;

WHEREAS,

the Company Board has unanimously (i) determined that this Agreement and the Transactions, including the Merger, are advisable, fair

to and in the best interests of the Company and its stockholders; (ii) approved the execution, delivery and performance by the Company

of this Agreement and the consummation of the transactions contemplated hereby, including the Merger (the “Transactions”);

(iii) declared advisable this Agreement and the Transactions on the terms and subject to the conditions set forth herein; (iv) recommended

that the Company’s stockholders vote to approve and adopt this Agreement; and (v) directed that this Agreement be submitted to

the Company’s stockholders for their approval and adoption;

WHEREAS,

the Board of Directors of Parent has approved and declared advisable this Agreement and the Transactions, including the Merger and the

issuance of Parent Common Stock in connection with the Merger;

WHEREAS,

the Board of Directors of Merger Subsidiary has approved and declared advisable this Agreement and the Transactions, including the Merger;

WHEREAS,

in order to induce Parent to enter into this Agreement and cause the Transactions to be consummated, certain stockholders of the Company

are executing voting and support agreements in favor of Parent concurrently with the execution and delivery of this Agreement (the “Voting

Agreements”), providing among other things, that each such person shall vote in favor of and support the Merger and the other

Transactions contemplated hereby; and

WHEREAS,

each of the parties hereto desires to make certain representations, warranties, covenants and agreements in connection with the Merger

and the Transactions and also to prescribe certain conditions to the Merger as specified herein.

NOW,

THEREFORE, in consideration of the foregoing and the representations, warranties, covenants and agreements contained herein, the parties

hereto agree as follows:

Article

Definitions

Section

1.1 Definitions.

(a) As

used herein, the following terms have the following meanings:

“1933

Act” means the Securities Act of 1933.

“1934

Act” means the Securities Exchange Act of 1934.

“Acquisition

Proposal” means, other than the Transactions, any offer or proposal from a Third Party relating to any transaction or series

of related transactions involving (i) any acquisition or purchase, directly or indirectly, of 20% or more of the consolidated assets

of the Company and its Subsidiaries or 20% or more of any class of equity or voting securities of the Company or any of its Subsidiaries

whose net revenues, net income or assets, individually or in the aggregate, constitute 20% or more of the consolidated net revenues,

net income or assets of the Company and its Subsidiaries; (ii) any tender offer (including a self-tender offer) or exchange offer that,

if consummated, would result in a Third Party beneficially owning 20% or more of any class of equity or voting securities of the Company

or any of its Subsidiaries whose net revenues, net income or assets, individually or in the aggregate, constitute 20% or more of the

consolidated net revenues, net income or assets of the Company and its Subsidiaries; (iii) a merger, consolidation, share exchange, business

combination, reorganization, recapitalization, liquidation, dissolution or other similar transaction involving the Company or any of

its Subsidiaries whose net revenues, net income or assets, individually or in the aggregate, constitute 20% or more of the consolidated

net revenues, net income or assets of the Company and its Subsidiaries and that would have any of the effects specified in clause (i);

or (iv) any combination of any of the foregoing.

“Affiliate”

means, with respect to any Person, any other Person directly or indirectly controlling, controlled by, or under common control with such

Person. For purposes of this definition, the term “control” (including the correlative meanings of the terms “controlled

by” and “under common control with”), as used with respect to any Person, means the possession, direct or indirect,

of the power to direct or cause the direction of the management and policies of such Person, whether through the ownership of voting

securities, by Contract or otherwise.

“Antitrust

Laws” means, collectively, the Sherman Act of 1890, 15 U.S.C. §§ 1 et seq., the Clayton Act, 15 U.S.C. §§

12-27 (including the HSR Act), the Federal Trade Commission Act, 15 U.S.C. §§ 41 et seq and any other Applicable Law that is

designed or intended to preserve or protect competition, prohibit and restrict agreements in restraint of trade or monopolization, attempted

monopolization, restraints of trade and abuse of a dominant position, or to regulate, prohibit or prevent acquisitions, mergers or other

business combinations and similar transactions, the effect of which may be to lessen or impede competition or to tend to create or strengthen

a dominant position or to create a monopoly.

“Applicable

Date” means January 1, 2024.

“Applicable

Law” means, with respect to any Person, any domestic or foreign federal, state or local law (statutory, common or otherwise),

constitution, treaty, convention, ordinance, code, rule, regulation, order, injunction, judgment, decree, ruling or other similar requirement

enacted, adopted, promulgated or applied by a Governmental Authority that is binding upon or applicable to such Person.

“Business

Day” means a day, other than Saturday, Sunday or other day on which commercial banks in Dallas, Texas and New York, New York

are authorized or required by Applicable Law to close.

“CARES

Act” means the Coronavirus Aid, Relief and Economic Security Act and any similar or conforming legislation in any U.S. jurisdiction,

and any subsequent legislation relating to the COVID-19 pandemic, including the Health and Economic Recovery Omnibus Emergency Solutions

Act.

“Code”

means the Internal Revenue Code of 1986, as amended.

“Company

Balance Sheet” means the consolidated balance sheet of the Company as of the Company Balance Sheet Date and the footnotes thereto

set forth in the Company 10-Q.

“Company

Balance Sheet Date” means March 31, 2026.

“Company

Board” means the board of directors of the Company.

“Company

Disclosure Schedule” means the disclosure schedule dated the date hereof regarding this Agreement that has been provided by

the Company to Parent and Merger Subsidiary.

“Company

Employee” means an employee of the Company or any of its Subsidiaries.

“Company

Equity Plans” means the Company’s Restated 2014 Omnibus Long-Term Incentive Plan, the Company’s 2024 Omnibus Long-Term

Incentive Plan and the Precision Healing, Inc. 2020 Stock Option and Grant Plan, in each case, as amended, modified or restated from

time to time.

“Company

IT Systems” means all software, computer hardware, servers, networks, platforms, peripherals, and similar or related items

of automated, computerized, or other information technology networks and systems (including telecommunications networks and systems for

voice, data, and video) owned, leased, licensed, or used (including through cloud-based or other Third Party service providers) by the

Company or any of its Subsidiaries.

“Company

Option” means each option that represents the right to purchase Company Stock, granted pursuant to the Company Equity Plan

or otherwise, whether vested or unvested, which is outstanding as of immediately prior to the Effective Time.

“Company

Restricted Stock” means each restricted stock award with respect to a share of Company Stock, granted pursuant to the Company

Equity Plan or otherwise, whether vested or unvested, which is outstanding as of immediately prior to the Effective Time and which is

subject to Restrictions on transfer and/or forfeiture.

“Company

Stock” means the Common Stock, par value $0.001 per share, of the Company.

“Company

10-Q” means the Company’s quarterly report on Form 10-Q for the fiscal period ended March 31, 2026.

“Confidentiality

Agreement” means the confidentiality agreement dated December 15, 2025 between the Company and Parent.

“Contract”

means any contract, agreement, lease, sublease, license, note, mortgage, bond, indenture or other legally binding obligation, commitment

or undertaking, written or oral (but excluding for purposes of this Agreement any statements of work, purchase orders, service orders

or other similar documents entered into in the ordinary course of business).

“Data

Privacy and Security Requirements” means to the extent relating to data privacy, protection, or security, or any consumer protection

laws, or telemarketing-related laws concerning email, telephone calls and text messages, and applying to the conduct of the business

of the Company or any of its Subsidiaries: (i) all Applicable Laws including any related security breach notification requirements; (ii)

the external past and present policies that are or were adopted by the Company or any of its Subsidiaries during such time period in

which the Company or its Subsidiaries were or are bound thereby; and (iii) Contracts to which the Company or any its Subsidiaries are

parties.

“Debt

Financing Sources” means, in its capacity as such, any lender or similar debt financing sources providing the Debt Financing

(including the parties to any joinder agreements, credit agreements or other definitive agreements relating thereto) and their respective

Affiliates, and such lender’s or other debt financing source’s (and their respective Affiliates’) former, current and

future equity holders, members, partners, employees, officers, directors, managers, controlling persons, attorneys, agents, advisors

or other representatives or the heirs, executors, successors, or assigns of any of the foregoing.

“Employee

Plan” means any (i) “employee benefit plan” as defined in Section 3(3) of ERISA or (ii) any profit sharing, bonus,

incentive, commission, individual consulting agreement, employment agreement, equity or equity-based compensation, phantom equity, pension,

retirement, severance, deferred compensation, change in control, retention, stay bonus, excess benefit, supplemental unemployment, post-retirement

medical or life insurance, welfare or incentive plan, or sick leave, long-term disability, medical, hospitalization, life insurance,

other insurance plan, or other employee benefit plan, programs, agreements, understandings or arrangements, in each case that is sponsored,

maintained or contributed to by the Company or any of its Subsidiaries, or under which the Company and/or its Subsidiaries could have

any obligation or liability.

“Environmental

Laws” means any and all statutes, laws, regulations or rules that have as their principal purpose the protection of the environment.

“ERISA”

means the Employee Retirement Income Security Act of 1974.

“ERISA

Affiliate” means, with respect to the Company or any of its Subsidiaries, any other entity, trade or business that is a member

of a group described in Section 414(b),(c), (m) or (o) of the Code or Section 4001(b)(l) of ERISA that includes the Company or any Subsidiary,

or that is a member of the same “controlled group” as the Company or any of its Subsidiaries pursuant to Section 4001(a)(14)

of ERISA.

“FDA”

means the United States Food and Drug Administration (21 U.S.C. §301 et seq.).

“FDCA”

means the Food, Drug, and Cosmetic Act.

“GAAP”

means generally accepted accounting principles in the United States.

“Government

Official” means (i) any officer or employee of any Governmental Authority, (ii) any person acting in an official capacity on

behalf of a Governmental Authority, (iii) any officer or employee of a political party or any person acting in an official capacity on

behalf of a political party, or (iv) any candidate for political office.

“Governmental

Authority” means any transnational, domestic or foreign federal, state or local governmental, regulatory, self-regulatory or

administrative authority, department, court, agency or official, including any political subdivision or instrumentality thereof or any

arbitral body (whether public or private).

“Hazardous

Substances” means any pollutants, contaminants, wastes, or other materials or substances that are regulated or for which liability

or standards of conduct may be imposed under any Environmental Law, and shall include oil, petroleum, petroleum-derived substances, radiation

and radioactive materials, polychlorinated biphenyls, urea formaldehyde, perfluoroalkyl and polyfluoroalkyl substances, silica, radon,

dust, noise, odors, mold, microbial matter, and asbestos or any materials containing asbestos.

“Healthcare

Laws” means all healthcare Applicable Laws applicable to the Company and the operation of its business, including, without

limitation, all Applicable Laws applicable to the ownership, research, development, testing, manufacture, quality, safety, accreditation,

packaging, storage, use, distribution, labeling, sale, offer for sale, import, export or disposal of any product manufactured or distributed

by the Company, including in relation to the United States, the Federal FDCA, the Public Health Service Act (42 U.S.C. § 201 et

seq.), the Federal Controlled Substances Act (21 U.S.C. §801 et seq.), all Applicable Laws concerning fraud and abuse,

including the federal Anti-Kickback Statute (42 U.S.C. § 1320a- 7b(b)), the federal False Claims Act (42 U.S.C. § 1320a-7b(a)),

as amended, the federal Exclusion statute (42 U.S.C. § 1320a- 7) and the federal Civil Monetary Penalties Law (42 U.S.C. §

1320a-7a), and any state analogs, as well as applicable laws of any foreign Governmental Authority, and including in each case the applicable

implementing regulations, together with any rules, requirements and guidance promulgated or issued thereunder, Applicable Laws related

to the licensure, certification, accreditation, qualification or authority required to transact business relating to the operation of

the business, the so-called federal “sunshine” law or Open Payments law (42 U.S.C. § 1320a-7h).

“HSR

Act” means the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended.

“Indebtedness”

means, with respect to the Company, (i) all indebtedness for borrowed money, (ii) all obligations evidenced by bonds, debentures, notes

or similar instruments (including any letter of credit, surety bond, banker’s acceptance or similar reimbursement agreement or

obligation, in each case, solely to the extent drawn), (iii) all obligations to pay the deferred purchase price of property or services

(excluding trade accounts payable arising in the ordinary course of business of the Company), (iv) all obligations under leases required

to be capitalized in accordance with GAAP, (v) all obligations under any direct or indirect guaranties in respect of, or obligations

(contingent or otherwise) to purchase or otherwise acquire, or otherwise to assure a creditor against loss in respect of, indebtedness

for borrowed money or obligations of others of the kinds referred to in clauses (i) through (iv) above, (vi) all obligations of the Company

(including with respect to any ERISA Affiliate) for underfunded or unfunded pension, deferred compensation plans or similar plans and

any withdrawal liability or similar obligation arising under ERISA, and (vii) all obligations of the kinds referred to in clauses (i)

through (v) above of other Persons secured by any Lien on any property or asset of the Company.

“Intellectual

Property” means all of the following, anywhere in the world: (i) patents, patent applications and inventions, designs and improvements

described and claimed therein, patentable inventions and other patent rights (including any divisions, continuations, continuations-in-part,

reissues, reexaminations, or interferences thereof, whether or not patents are issued on any such applications and whether or not any

such applications are modified, withdrawn, or resubmitted) (“Patents”); (ii) trademarks, service marks, trade dress,

trade names, brand names, designs, logos, or corporate names, whether registered or unregistered, and all registrations and applications

for registration thereof, and all goodwill related thereto (“Trademarks”); (iii) copyrights and mask works, including

all renewals and extensions thereof, copyright registrations and applications for registration thereof, and non-registered copyrights

(“Copyrights”); (iv) trade secrets, know-how, inventions, processes, procedures, databases, confidential business

information, concepts, ideas, designs, research or development information, techniques, technical information, specifications, operating

and maintenance manuals, engineering drawings, methods, technical data, discoveries, modifications, extensions, improvements, and other

proprietary information and rights (whether or not patentable or subject to copyright, mask work, or trade secret protection) (collectively,

“Trade Secrets”); (v) computer software programs, including all source code, object code, and documentation related

thereto; and (vi) domain names, Internet addresses and other computer identifiers, websites, web pages and similar rights and items.

“Knowledge”

means (i) with respect to the Company, the actual knowledge of the individuals listed on Section 1.1 of the Company Disclosure

Schedule after due inquiry of their direct reports and (ii) with respect to Parent, the actual knowledge of the individuals listed on

Section 1.1 of the Parent Disclosure Schedule after due inquiry of their direct reports.

“Lien”

means, with respect to any property or asset, any mortgage, lien, pledge, charge, security interest, encumbrance or other adverse claim

of any kind in respect of such property or asset. For purposes of this Agreement, a Person shall be deemed to own subject to a Lien any

property or asset that it has acquired or holds subject to the interest of a vendor or lessor under any conditional sale agreement, capital

lease or other title retention agreement relating to such property or asset.

“Material

Adverse Effect” means, with respect to the Company, any fact, event, circumstance, occurrence or effect (an “Effect”)

that, individually or in the aggregate, (i) prevents or materially impairs or would reasonably be expected to prevent or materially impair

the ability of the Company to consummate the Merger on the terms and conditions of this Agreement by the End Date or (ii) has had, or

would reasonably be expected to have a material adverse effect on the financial condition, business, assets or results of operations

of the Company and its Subsidiaries, taken as a whole; provided, however, that none of the following, either alone or in combination,

shall be taken into account in determining whether there has been, is, or would reasonably be expected to be a Material Adverse Effect

for purposes of this clause (ii): (A) changes in GAAP, (B) changes in the financial or securities markets or in general economic or political

conditions, (C) changes in Applicable Law or the enforcement or interpretation thereof, (D) changes or proposed changes in reimbursement

rates or coverage limitations applicable to the products or services of the Company or its Subsidiaries, (E) changes generally affecting

the industry in which the Company or its Subsidiaries operate, (F) hostilities, acts of war, sabotage or terrorism, or any escalation

or worsening thereof, (G) the announcement, pendency or consummation of the Transactions, (H) any failure by the Company and its Subsidiaries

to meet any internal or published budgets, projections, forecasts or predictions of financial performance for any period (it being understood

that this clause (H) shall not prevent a party from asserting that any Effect not otherwise excluded that may have contributed to such

failure independently constitutes or contributes to a Material Adverse Effect), (I) any action taken (or omitted to be taken) by Parent

or Merger Subsidiary or their respective Affiliates, representatives or agents after the date of this Agreement, (J) any action taken

by the Company or any of its Subsidiaries after the date of this Agreement at the request of Parent or that is required, expressly contemplated

or expressly permitted pursuant to this Agreement, (K) changes in the market price or trading volume of the shares of Company Stock (it

being understood that this clause (K) shall not prevent a party from asserting that any Effect not otherwise excluded that may have contributed

to such change independently constitutes or contributes to a Material Adverse Effect), or (L) earthquakes, hurricanes, tsunamis, tornadoes,

floods, mudslides, wild fires or other natural disasters, weather conditions, epidemics, pandemics or disease outbreaks and other force

majeure events; provided, further, however, that, with respect to clauses (A),(B), (C), (F) and (L), such Effect shall be taken

into account in determining whether a “Material Adverse Effect” has occurred to the extent it has a disproportionate adverse

effect on the Company and its Subsidiaries, taken as a whole, relative to other participants in the industries in which the Company and

its Subsidiaries operate.

“Order”

means any orders, judgments, injunctions, awards, decrees or writs handed down, adopted or imposed by any Governmental Authority.

“Parent

Common Stock” means the common stock, par value $0.001 per share, of Parent.

“Parent

Disclosure Schedule” means the disclosure schedule dated the date hereof regarding this Agreement that has been provided by

Parent to the Company.

“Parent

Material Adverse Effect” means an Effect that, individually or in the aggregate, prevents or materially impairs, or would reasonably

be expected to prevent or materially impair, the ability of Parent or Merger Subsidiary to consummate the Merger.

“Permits”

means all permits, licenses, consents, approvals, franchises, authorizations, approvals, privileges, certificates, waivers, exemptions,

variances, exclusionary or inclusionary orders and other concessions, or similar rights issued by or filed with any Governmental Authority

or other authority possessing legal or contractual right to issue or grant any such rights.

“Permitted

Liens” means (i) Liens disclosed on the Company Balance Sheet or notes thereto or securing liabilities reflected on the Company

Balance Sheet or notes thereto or any Liens securing liabilities incurred in the ordinary course of business following the Company Balance

Sheet Date, (ii) Liens for Taxes, assessments and similar charges that are not yet due or payable or are being contested in good faith

and for which adequate reserves have been established on the financial statements of the Company in accordance with GAAP, (iii) mechanic’s,

materialman’s, carrier’s, repairer’s and other similar Liens arising or incurred in the ordinary course of business

or that are not yet due and payable or are being contested in good faith, (iv) any matters of record, Liens and other imperfections of

title that do not, individually or in the aggregate, materially and adversely impair the continued use, occupancy and operation of the

property to which they relate in the business of the Company and its Subsidiaries as currently conducted, (v) any Liens on title affecting

a lessor’s (or sublessor’s) interest in any of the Leased Real Property or affecting the interest of a subtenant of Company

or its Subsidiaries therein, (vi) zoning, entitlement, building codes and other land use regulations, ordinances or other Applicable

Laws imposed by any Governmental Authorities having jurisdiction over the Real Property that, in each case, do not adversely affect in

any material respect the current use or value of the Real Property, (vii) non-exclusive licenses of Intellectual Property granted in

the ordinary course of business, and (viii) any state of facts that an accurate survey of the Real Property would disclose and that,

individually or in the aggregate, do not materially and adversely impair the continued use, occupancy and operation of the applicable

Real Property.

“Person”

means an individual, corporation, general or limited partnership, limited liability company, association, statutory or grantor trust

or other entity or organization, including any Governmental Authority.

“Personal

Information” means (i) any information that can be used to identify, locate, or contact an individual, alone or when combined

with other personal or identifying information, (ii) any information that constitutes “personal data,” “personal information,”

“protected health information” or other similar terms as defined by Applicable Law.

“Privacy

Laws” means all Applicable Laws worldwide relating to data privacy, protection or security or the receipt, or processing of

Personal Information and all binding guidance thereunder issued by a Governmental Authority, including all Applicable Laws governing

cybercrime and breach notification, Section 5 of the Federal Trade Commission Act, California Consumer Privacy Act of 2018 as amended

by the California Privacy Rights Act of 2020, state data breach notification Laws, state data security Applicable Laws, state social

security number protection Laws, EU General Data Protection Regulation 2016/679, EU Privacy and Electronic Communications Directive 2002/58/EC,

any successor or implementing legislation or regulation to any of the foregoing and any Applicable Law concerning requirements for any

outbound communications and/or electronic marketing (including e-mail marketing, telemarketing and text messaging).

“Proceeding”

means any cause of action, claim, demand, proceeding, arbitration, suit, hearing, litigation, audit, complaint, charge, examination,

indictment or investigation (whether civil, criminal, administrative, judicial or investigative) by or before any Governmental Authority.

“Products”

means those products developed, tested, manufactured, stored, distributed, promoted, marketed, sold and otherwise commercialized by the

Company or its Subsidiaries, including those Products set forth on Schedule 1.2.

“Registration

Statement” means the registration statement on Form S-4, as amended or supplemented from time to time, pursuant to which shares

of Parent Common Stock issuable in connection with the Merger will be registered with the SEC.

“Regulatory

Authority” means any local, state, federal, national, or multinational governmental health regulatory agency or authority within

a regulatory jurisdiction, with the authority to grant approvals, licenses, registrations or authorizations necessary for the development,

manufacture, use, and sale of a medical device product. For clarity, references in this Agreement to Regulatory Authority shall be deemed

to include the FDA.

“Regulatory

Approval” means, with respect to a particular jurisdiction, such approvals, clearances, permits, licenses, registrations and/or

authorizations by any Regulatory Authority as are necessary for the development, manufacture, use or sale of any Product in such jurisdiction,

excluding any approval of pricing and/or reimbursement for such Product in such jurisdiction.

“Sanctioned

Country” means a country, region, or territory which is the subject of country-wide or territory-wide economic sanctions, including,

as of the date of this Agreement, Cuba, Iran, North Korea, Syria, the Crimea region of Ukraine, the so-called Donetsk People’s

Republic of Ukraine and the so-called Luhansk People’s Republic of Ukraine.

“Sanctioned

Person” means any Person that (i) appears on the “List of Specially Designated Nationals and Blocked Persons” maintained

by the United States Department of the Treasury’s Office of Foreign Assets Control (“OFAC”), the U.K. Sanctions

List, the E.U. Consolidated Financial Screening List, or is otherwise the target of any Sanctions, including U.S. Executive Order 14024

issued on April 15, 2021, U.S. Executive Order 13662 issued on March 20, 2014, and any directives or designations issued pursuant thereto;

(ii) is operating in, organized in, a national of, ordinarily resident in, or an agency or instrumentality of the government of Venezuela

or a Sanctioned Country; or (iii) is directly or indirectly owned 50% or more in the aggregate, or controlled by or acting for or on

behalf of one or more Persons described in clauses (i) and (ii), above.

“Sanctions”

means all economic or financial sanctions or trade embargoes imposed, administered, or enforced by (i) the U.S. government, including

those administered by OFAC or the U.S. Department of State, or (ii) the United Nations Security Council, the European Union, any European

Union member state, His Majesty’s Treasury of the United Kingdom, the Government of Canada or other relevant sanctions Governmental

Authority.

“Sarbanes-Oxley

Act” means the Sarbanes-Oxley Act of 2002.

“SEC”

means the Securities and Exchange Commission.

“Security

Incident” means an event (cyber or otherwise) that actually compromises, or is reasonably likely to compromise, the confidentiality,

integrity, or availability of, or any other cyber or other security incident with respect to, any Company IT System.

“Subsidiary”

means, with respect to any Person, of which such first Person directly or indirectly owns or has the power to vote or control securities

or other ownership interests (a) representing fifty percent (50%) or more of any class or series of capital stock or other securities

or equity interests of such Person or (b) having ordinary voting power to elect a majority of the board of directors (or other persons

performing similar functions) of such Person.

“Takeover

Laws” means any “moratorium,” “control share acquisition,” “fair price,” “supermajority,”

“affiliate transactions,” or “business combination statute or regulation” or other similar state anti-takeover

law, including TBOC §§ 21.601–21.610.

“Tax”

means any and all federal, state, local, or foreign income, gross receipts, license, payroll, employment, excise, severance, stamp, occupation,

premium, windfall profits, environmental, customs, duties, capital stock, franchise, margin, gross margin, profits, withholding, social

security (or similar), unemployment, disability, real property, personal property, ad valorem, capital, documentary, goods and services,

intangible, inventory, recording, sales, use, transfer, registration, value added, alternative or add-on minimum, estimated, or other

tax of any kind whatsoever, including any interest, penalty, or addition thereto, whether disputed or not.

“Tax

Return” means any return, declaration, report, claim for refund, or information return or statement relating to Taxes, including

any schedule or attachment thereto, and including any amendment thereof, supplied or required to be supplied to a Governmental Authority.

“TBOC”

means the Texas Business Organizations Code.

“Third

Party” means any Person, including any “group” as defined in Section 13(d) of the 1934 Act, other than Parent or

any of its Affiliates.

(b) Unless

otherwise defined in Section 1.1(a), each of the following terms is defined on the page set forth opposite such term:

Acceptable

Confidentiality Agreement

Adverse

Recommendation Change

Alternative

Acquisition Agreement

Alternative

Financing

Annual

Bonus

Bankruptcy

and Equity Exception

Clearance

Date

Closing

Date

Company

Board Recommendation

Company

Enforcement Expenses

Company

Group

Company

Intellectual Property

Company

SEC Documents

Company

Securities

Company

Stockholder Approval

Company

Stockholder Meeting

Company

Subsidiary Securities

Continuation

Period

Continuing

Employee

Converted

Customary

Payment Date

D&O

Insurance

Debt

Commitment Letter

Debt

Financing

Dissenting

Divestiture

Action

Effect

Effective

Time

Electronic

Delivery

e-mail

End Date

Exchange

Agent

HIPAA

Indemnified

Person

Insurance

Policies

Internal

Controls

Intervening

Event

Labor

Agreement

Leased

Real Property

Material

Contract

Merger

Consideration

Nasdaq

Notice

Period

OFAC

Option

Consideration

Owned

Intellectual Property

Owned

Real Property

Parent

Enforcement Expenses

Parent

SEC Documents

Parent

Termination Fee

Per Share

Cash Consideration

Per Share

Stock Consideration

PHI

Prime

Rate

Proxy

Statement

Real

Property

Real

Property Lease

Representatives

Restricted

Stock Consideration

Separation

Agreement

Superior

Proposal

Surviving

Corporation

Surviving

Corporation Plan

Termination

Fee

Transaction

Litigation

Transactions

Voting

Agreements

WARN

Act

Willful

Breach

Section

1.2 Other Definitional and Interpretative Provisions.

The words “hereof,” “herein” and “hereunder” and words of like import

used in this Agreement shall refer to this Agreement as a whole and not to any particular provision of this Agreement. The captions herein

are included for convenience of reference only and shall be ignored in the construction or interpretation hereof. References to Articles,

Sections and Schedules are to Articles, Sections and Schedules of this Agreement unless otherwise specified. All Schedules annexed hereto

or referred to herein are hereby incorporated in and made a part of this Agreement as if set forth in full herein. Any capitalized terms

used in any Schedule but not otherwise defined therein shall have the meaning as defined in this Agreement. Any singular term in this

Agreement shall be deemed to include the plural, and any plural term the singular. Whenever the words “include,” “includes”

or “including” are used in this Agreement, they shall be deemed to be followed by the words “without limitation,”

whether or not they are in fact followed by those words or words of like import. “Writing,” “written” and comparable

terms refer to printing, typing and other means of reproducing words (including electronic media) in a visible form. References to any

statute or Applicable Law shall be deemed to refer to such statute or Applicable Law as amended or superseded from time to time and to

any rules or regulations promulgated thereunder. References to any Contract are to that Contract as amended, modified or supplemented

from time to time in accordance with the terms hereof and thereof. References to any Person include the successors and permitted assigns

of that Person. References from or through any date mean, unless otherwise specified, from and including or through and including, respectively.

References to “law,” “laws” or to a particular statute or law shall be deemed also to include any Applicable

Law promulgated under such statute or law. The word “shall” shall be construed to have the same meaning and effect of the

word “will.” The phrase “to the extent” shall mean the degree to which, and such phrase shall not mean simply

“if.” The phrases “delivered” or “made available,” when used in this Agreement, shall mean that the

information shall have been (i) posted in the virtual data room titled “Project Spur” established by the Company or its Representatives

at least one (1) Business Day prior to the date hereof, and remained accessible to Parent and its Representatives at all times through

the Closing or (ii) filed or furnished by the Company with the SEC and publicly available at least one (1) Business Day prior to the

date hereof. Unless the context otherwise requires, “neither,” “nor,” “any,” “either”

and “or” shall not be exclusive. References to any period of days shall be deemed to be the relevant number of calendar days,

unless otherwise specified.

Article

The Merger

Section

2.1 The Merger.

(a) On

the terms and subject to the conditions set forth in this Agreement, at the Effective Time, Merger Subsidiary shall be merged (the “Merger”)

with and into the Company in accordance with the TBOC, whereupon the separate existence of Merger Subsidiary shall cease, and the Company

shall be the surviving corporation in the Merger (the “Surviving Corporation”). The Merger shall have the effects

specified in this Agreement and the TBOC.

(b) Subject

to the provisions of ‎Article 9, the closing of the Merger (the “Closing”) shall take place via the electronic

exchange of documents and signature pages as soon as possible, but in any event no later than three (3) Business Days after the date

the conditions set forth in ‎Article 9 have been satisfied or, to the extent permissible, waived by the party or parties entitled

to the benefit of such conditions (other than conditions that by their nature are to be satisfied at the Closing, but subject to the

satisfaction or, to the extent permissible, waiver of those conditions at the Closing), or at such other place, at such other time or

on such other date as Parent and the Company may mutually agree in writing (the date on which the Closing actually occurs, the “Closing

Date”).

the Closing, the Company shall file a certificate of merger with the Secretary of State of the State of Texas and make all other filings

required by the TBOC in connection with the Merger. The Merger shall become effective at the time the certificate of merger is duly filed

with and accepted by, the Secretary of State of the State of Texas or such later date and time as may be agreed to by the parties and

specified in the certificate of merger (the “Effective Time”).

Section

2.2 Conversion of Shares. At

the Effective Time:

(a) Except

as otherwise provided in Section 2.2(b) or Section 2.5, each share of Company Stock issued and outstanding immediately

prior to the Effective Time (except for Company Stock to be canceled under Section 2.2(b) and Dissenting Shares) (each, a “Converted

Share”) shall be converted into the right to receive (i) $33.00 in cash, without interest (the “Per Share Cash Consideration”),

and (ii) 0.4735 shares of Parent Common Stock (the “Per Share Stock Consideration”, and together with the Per Share

Cash Consideration, the “Merger Consideration”). As of the Effective Time, all such shares of Company Stock shall

no longer be outstanding and shall automatically be canceled and retired and shall cease to exist, and shall thereafter represent only

the right to receive the Merger Consideration to be paid in accordance with Section 2.3, without interest.

(b) Each

share of Company Stock held by the Company as treasury stock or owned by any Subsidiary of the Company or Parent or any Subsidiary of

Parent immediately prior to the Effective Time shall be canceled, and no payment shall be made with respect thereto.

share of common stock of Merger Subsidiary outstanding immediately prior to the Effective Time shall be converted into and become one

share of common stock of the Surviving Corporation and shall constitute the only outstanding shares of capital stock of the Surviving

Corporation.

Section

2.3 Surrender and Payment.

(a) Prior

to the Effective Time, Parent shall appoint Broadridge Corporate Issuer Solutions, LLC (the “Exchange Agent”) for

the purpose of exchanging for the Merger Consideration uncertificated shares of Company Stock (the “Shares”). At or

prior to the Effective Time, Parent shall deposit with the Exchange Agent the aggregate (i) amount of cash payable in respect of the

Converted Shares under Section 2.2(a)(i) and Section 2.3(b), and (ii) number of whole shares of Parent Common Stock, subject

to Section 2.3(b), issuable under Section 2.2(a)(ii). Promptly after the Effective Time (and after receipt by the Exchange

Agent from the Company’s transfer agent of all information reasonably necessary to enable the Exchange Agent to effect the mailing

set forth in this Section 2.3) (provided that Parent and the Surviving Corporation shall use reasonable best efforts to

obtain such information to enable such mailing to occur not later than two (2) Business Days after the Effective Time), the Surviving

Corporation shall (and Parent shall cause the Surviving Corporation to) send, or cause the Exchange Agent to send, to each holder of

certificated shares of Company Stock at the Effective Time a letter of transmittal and instructions (which shall be in a form reasonably

acceptable to the Company and approved by the Company prior to Closing) for use in such exchange.

(b) No

fraction of a share of Parent Common Stock shall be issued as a result of or in connection with the Merger. In lieu of the issuance of

any such fraction of a share to which a former holder of Converted Shares would otherwise be entitled, Parent shall pay to the Exchange

Agent an amount in cash, without interest, determined by multiplying such fraction by the closing price of a share of Parent Common Stock

on Nasdaq on the last trading day immediately preceding the Closing Date (rounded to the nearest cent). As soon as reasonably practicable

after the determination of the amount of cash, if any, to be paid to holders of Converted Shares in lieu of any fractional share interests

in Parent Common Stock, the Exchange Agent shall make available such amounts, without interest, to the holders of Converted Shares entitled

to receive such cash.

holder of shares of Company Stock that have been converted into the right to receive the Merger Consideration shall be entitled to receive,

upon receipt of (i) an “agent’s message” by the Exchange Agent (or such other evidence, if any, of transfer as the

Exchange Agent may reasonably request), in the case of uncertificated Shares, or (ii) a properly completed letter of transmittal (or

affidavit in lieu thereof pursuant to Section 2.3(f)), in the case of certificated Shares, the Merger Consideration in respect

of the Company Stock represented by a Share. Until so surrendered or transferred, as the case may be, each such Share shall represent

after the Effective Time for all purposes only the right to receive such Merger Consideration without interest thereon.

(d) If

any portion of the Merger Consideration is to be paid to a Person other than the Person in whose name the transferred Share is registered,

it shall be a condition to such payment that (i) such Share shall be properly transferred and (ii) the Person requesting such payment

shall pay to the Exchange Agent any transfer or other Taxes required as a result of such payment to a Person other than the registered

holder of such Share or establish to the satisfaction of the Exchange Agent that such Tax has been paid or is not payable.

(e) After

the Effective Time, there shall be no further registration of transfers of shares of Company Stock. If, after the Effective Time, Shares

are presented to the Surviving Corporation or the Exchange Agent, they shall be canceled and exchanged for the Merger Consideration in

accordance with the procedures set forth in this Article 2.

(f) If

any certificate in respect of a certificated Share shall have been lost, stolen or destroyed, upon the making of an affidavit of that

fact by the Person claiming such certificate to be lost, stolen or destroyed and, if required by the Surviving Corporation, the posting

by such Person of a bond, in such reasonable amount as the Surviving Corporation may direct, as indemnity against any claim that may

be made against it with respect to such Certificate, the Exchange Agent will issue, in exchange for such lost, stolen or destroyed certificate,

the Merger Consideration to be paid in respect of the shares of Company Stock represented by such certificate, as contemplated by this

‎Article 2.

(g) Any

portion of the Merger Consideration made available to the Exchange Agent pursuant to ‎Section 2.3(a) that remains unclaimed

by the holders of shares of Company Stock twelve (12) months after the Effective Time shall be returned to Surviving Corporation, upon

demand, and any such holder who has not exchanged shares of Company Stock for the Merger Consideration in accordance with this ‎Section

2.3 prior to that time shall thereafter look only to Surviving Corporation for payment of the Merger Consideration in respect of

such shares without any interest thereon. Notwithstanding the foregoing, Parent shall not be liable to any holder of shares of Company

Stock for any amounts paid to a public official pursuant to applicable abandoned property, escheat or similar Applicable Laws. To the

extent permitted by Applicable Law, any amounts remaining unclaimed by such holders of Company Stock five (5) years after the Effective

Time, or at such earlier date as is immediately prior to the time at which such amounts would otherwise escheat to or become property

of any Governmental Authority, shall become the property of the Surviving Corporation free and clear of any claims or interest of any

such holders (and their successors, assigns or personal representatives) previously entitled thereto.

Section

2.4 Closing of Transfer Books. At

the Effective Time, the stock transfer books of the Company shall be closed with respect to all shares of Company Stock outstanding immediately

prior to the Effective Time and no further transfer of any such shares of Company Stock shall be made on such stock transfer books after

the Effective Time.

Section

2.5 Dissenting Shares.

(a) Notwithstanding

anything to the contrary contained in this Agreement, shares of Company Stock held by a holder who is entitled to demand and properly

demands appraisal of such shares in accordance with Chapter 10, Subchapter H of the TBOC and does not vote such shares in favor of adoption

of this Agreement or consent in writing thereto (any such shares being referred to as “Dissenting Shares” until such

time as such holder effectively withdraws or fails to perfect or otherwise loses such holder’s appraisal rights under Chapter 10,

Subchapter H of the TBOC with respect to such shares) shall not be converted into or represent the right to receive Merger Consideration

in accordance herewith, but shall be entitled only to such rights as are granted by the TBOC to a holder of Dissenting Shares. At the

Effective Time, Dissenting Shares shall no longer be outstanding and shall automatically be canceled and shall cease to exist, and each

holder of Dissenting Shares shall cease to have any rights with respect thereto, except the right to receive the fair value of such Dissenting

Shares in accordance with the provisions of Chapter 10, Subchapter H of the TBOC.

(b) If

any Dissenting Shares shall lose their status as such (through failure to perfect appraisal rights under Chapter 10, Subchapter H of

the TBOC or otherwise), then such shares shall be deemed to have been converted as of the Effective Time into the right to receive the

Merger Consideration and shall represent only the right to receive the Merger Consideration in accordance herewith, without interest

thereon, and shall not thereafter be Dissenting Shares.

Company shall give Parent: (i) prompt notice of (A) any demand for appraisal received by the Company prior to the Effective Time pursuant

to the TBOC; and (B) any withdrawal or attempted withdrawal of any such demand; and (ii) the opportunity to direct all negotiations and

proceedings with respect to any such demand, notice or instrument. Prior to the Effective Time, the Company shall not, without the prior

written consent of Parent or as otherwise required by an order, decree, ruling or injunction of a court of competent jurisdiction, make

any payment with respect to, or settle or compromise or offer to settle or compromise, any such demand, or agree to do any of the foregoing.

Section

2.6 Treatment of Equity Awards.

(a) Restricted

Stock. Immediately prior to the Effective Time, each share of Company Restricted Stock, whether or not vested, shall, by virtue of

the Merger and without any action on the part of the Company, Parent or the holder of such Company Restricted Stock, automatically be

canceled and converted automatically into the right to receive from the Company, at or promptly after the Effective Time, an amount (i)

in cash (less applicable Tax withholdings as provided in Section 2.8 on the entire Restricted Stock Consideration) equal to the

Per Share Cash Consideration and (ii) a number of shares of Parent Common Stock equal to the Per Share Stock Consideration (the “Restricted

Stock Consideration”).

(b) Options.

Immediately prior to the Effective Time, each Company Option, whether or not vested, shall, by virtue of the Merger and without any action

on the part of the Company, Parent or the holder of such Company Option, automatically be canceled and converted automatically into the

right to receive from the Company, at or promptly after the Effective Time, an amount in cash (less applicable Tax withholdings as provided

in Section 2.8) equal to the difference between (i) the Merger Consideration (with the Per Share Stock Consideration value based

on the closing price of the Parent Common Stock on the last trading day prior to the Closing Date) and (ii) the exercise price payable

in respect of such Company Option (the “Option Consideration”).

at the Effective Time. As of the Effective Time, the Company Equity Plans shall immediately terminate and no holder of Company Restricted

Stock or Company Options shall have any rights to acquire, or other rights in respect of, the capital stock of the Company, the Surviving

Corporation or any of their Subsidiaries, pursuant to the Company Equity Plans or otherwise, except the rights contemplated by this Section

2.6. Following the Effective Time, no Company Restricted Stock, Company Option or other equity interest in the Company or other right

with respect to shares of Company Stock that was outstanding immediately prior to the Effective Time shall remain outstanding.

(d) Further

Actions. Prior to the Effective Time, the Company Board (or, if appropriate, any committee thereof administering any Company Equity

Plan) shall take such actions as are necessary or appropriate to approve and effectuate the foregoing provisions of this Section 2.6,

including making any determinations and/or resolutions of the Company Board or a committee thereof or any administrator of such Company

Equity Plan as may be necessary.

Section

2.7 Certain Adjustments. If,

during the period between the date of this Agreement and the Effective Time, any change in the outstanding shares of capital stock of

the Company or Parent shall occur, including by reason of any reclassification, recapitalization, stock split or combination, exchange

or readjustment of shares, or any stock dividend thereon with a record date during such period, but excluding any change that results

from any vesting, settlement or exercise of Company Restricted Stock or Company Options outstanding as of the date hereof, the Merger

Consideration and any other amounts payable pursuant to this Agreement shall be appropriately adjusted to provide Parent and the holders

of Company Stock (including holders of Company Restricted Stock and Company Options) the same economic effect as contemplated by Sections

2.2 and 2.6. For the avoidance of doubt, to the extent any adjustments may be required pursuant to this ‎Section 2.7

with respect to Company Restricted Stock or Company Options, such adjustments will be made in a manner consistent with the relevant adjustment

provisions of the Company Equity Plan to which such Company Restricted Stock or Company Options relate.

Section

2.8 Equity Awards; Withholding Rights. Parent

shall cause (i) the Surviving Corporation to pay through the payroll system of the Surviving Corporation or its Affiliate to each holder

of Company Restricted Stock or Company Options that is or was a Company employee, the cash component of the Restricted Stock Consideration,

including cash in lieu of fractional shares of Parent Common Stock, or the Option Consideration, as applicable, of such Company employee

less any required withholding Taxes and without interest, and (ii) the Exchange Agent to issue the Parent Common Stock portion of the

Restricted Stock Consideration to the holders of a Company Restricted Stock, in each case, within five (5) Business Days following the

Effective Time. Notwithstanding any provision contained herein to the contrary, each of the Exchange Agent, the Surviving Corporation

and Parent shall be entitled to deduct and withhold from the consideration otherwise payable to any Person pursuant to this ‎Article

2 such amounts as it is required to deduct and withhold with respect to the making of such payment under any provision of federal,

state, local or foreign tax law. To the extent that amounts are so withheld and timely paid over to the appropriate Governmental Authority

by the Exchange Agent, the Surviving Corporation or Parent, as the case may be, such amounts shall be treated for all purposes of this

Agreement as having been paid to the Person in respect of whom the Exchange Agent, the Surviving Corporation or Parent, as the case may

be, made such deduction and withholding.

Article

The Surviving Corporation

Section

3.1 Certificate of Incorporation. Subject

to ‎Section 7.4(b), the certificate of incorporation of the Company shall, by virtue of the Merger, be amended at the Effective

Time in its entirety to read as the certificate of incorporation of Merger Subsidiary in effect immediately prior to the Effective Time,

except that Article 1 thereof shall provide that the name of the Surviving Corporation shall be “Sanara MedTech Inc.”

Such certificate of incorporation, as so amended, shall be the certificate of incorporation of the Surviving Corporation until thereafter

amended in accordance with Applicable Law and such certificate of incorporation.

Section

3.2 Bylaws. At the

Effective Time, the bylaws of Merger Subsidiary in effect as of immediately prior to the Effective Time shall be the bylaws of the Surviving

Corporation until amended in accordance with Applicable Law, the certificate of incorporation and such bylaws.

Section

3.3 Directors and Officers. The

parties shall take all requisite actions so that, except as may be determined by Parent prior to the Closing, from and after the Effective

Time, until successors are duly elected or appointed and qualified or until their earlier, death, resignation or removal in accordance

with Applicable Law, the certificate of incorporation and the bylaws of the Surviving Corporation, (i) the directors of Merger Subsidiary

immediately prior to the Effective Time shall be the directors of the Surviving Corporation and (ii) the officers of Merger Subsidiary

immediately prior to the Effective Time shall be the officers of the Surviving Corporation.

Article

Representations and Warranties of the Company

Except

as set forth in (i) any Company SEC Document filed at least one (1) Business Day before the date hereof (but excluding any risk factor

disclosures contained under the heading “Risk Factors” (other than any factual information contained therein), any disclosure

of risks explicitly included in any “forward-looking statements” disclaimer, and any other disclosures contained or referenced

therein of information, factors or risks to the extent they are predictive, cautionary or forward-looking in nature (other than any factual

information contained therein)), provided that in no event shall any disclosure in any Company SEC Document apply to or qualify

any representation or warranty contained in Section 4.5(a) or Section 4.5(b), or (ii) the Company Disclosure Schedule (each

section of which qualifies the correspondingly numbered representation and warranty or covenant to the extent specified therein, provided

that any disclosure set forth with respect to any particular section shall be deemed to be disclosed in reference to all other applicable

sections of this Agreement (other than Section 4.5(a) or Section 4.5(b)) if the relevance of such disclosure to such other

sections is reasonably apparent on its face), the Company hereby represents and warrants to Parent and Merger Subsidiary as follows:

Section

4.1 Corporate Existence and Power. The

Company is a corporation duly incorporated, validly existing and in good standing under the laws of the State of Texas and has all corporate

powers and all governmental licenses, authorizations, permits, consents and approvals required to carry on its business as now conducted,

except for those licenses, authorizations, permits, consents and approvals the absence of which would not reasonably be expected to have,

individually or in the aggregate, a Material Adverse Effect. The Company is duly qualified to do business as a foreign corporation and

is in good standing in each jurisdiction where such qualification is necessary, except for those jurisdictions where failure to be so

qualified would not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect.

Section

4.2 Corporate Authorization.

(a) The

execution, delivery and performance by the Company of this Agreement and the consummation by the Company of the Transactions are within

the Company’s corporate powers and, except for the Company Stockholder Approval (as defined below), have been duly authorized by

all necessary corporate action on the part of the Company. The affirmative vote of the holders of a majority of the outstanding shares

of Company Stock is the only vote of the holders of the Company’s capital stock necessary to approve and adopt this Agreement and

consummate the Transactions, including the Merger (the “Company Stockholder Approval”). This Agreement has been duly

executed and delivered by the Company and constitutes a legal, valid and binding agreement of the Company, enforceable against the Company

in accordance with its terms, subject to applicable bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium and other

laws affecting creditors’ rights generally and general principles of equity (the “Bankruptcy and Equity Exception”).

(b) At

a meeting duly called and held, the Company Board has unanimously (i) determined that this Agreement and the Transactions, including

the Merger, are advisable, fair to and in the best interests of the Company and its stockholders; (ii) approved the execution, delivery

and performance by the Company of this Agreement and the consummation of the Transactions; (iii) declared advisable this Agreement and

the Transactions; (iv) resolved to recommend that the Company’s stockholders vote to approve and adopt this Agreement and the Transactions

(such recommendation, the “Company Board Recommendation”), which Company Board Recommendation has not been withdrawn,

rescinded or modified in any way as of the date of this Agreement; and (v) directed this Agreement be submitted to the Company stockholders

for adoption at the Company Stockholder Meeting.

and complete copies of the Company’s certificate of incorporation and bylaws, in each case as in effect on the date of this Agreement,

are included in the Company SEC Documents.

Section

4.3 Governmental Authorization. The

execution, delivery and performance by the Company of this Agreement and the consummation by the Company of the Transactions require

no action by or in respect of, or filing with, any Governmental Authority other than (i) the filing of a certificate of merger with respect

to the Merger with the Secretary of State of the State of Texas and appropriate documents with the relevant authorities of other states

in which the Company is qualified to do business, (ii) compliance with any applicable requirements of the HSR Act and those filings set

forth in Section 8.1(b) of the Company Disclosure Schedule, (iii) compliance with any applicable requirements of the 1934 Act,

and any other applicable state or federal securities laws and (iv) any actions or filings the absence of which would not reasonably be

expected to have, individually or in the aggregate, a Material Adverse Effect.

Section

4.4 Non-contravention. Except

as set forth on Section 4.4 of the Company Disclosure Schedule, the execution, delivery and performance by the Company of this

Agreement and the consummation of the Transactions do not and will not (i) contravene, conflict with, or result in any violation or breach

of any provision of the certificate of incorporation or bylaws of the Company or similar organizational documents of any of the Company’s

Subsidiaries, (ii) assuming compliance with the matters referred to in ‎Section 4.3, contravene, conflict with or result in

any violation or breach of any provision of any Applicable Law, (iii) assuming compliance with the matters referred to in Section

4.3, require any notice, consent or other action by any Person under, constitute a default under, or cause or permit the termination,

cancellation, acceleration or other change of any right or obligation or the loss of any benefit to which the Company or any of its Subsidiaries

is entitled under any provision of any Material Contract binding upon the Company or any of its Subsidiaries or (iv) result in the creation

or imposition of any Lien (other than a Permitted Lien) on any asset of the Company or any of its Subsidiaries, with only such exceptions,

in the case of each of clauses (ii) through (iv), as would not reasonably be expected to have, individually or in the aggregate, a Material

Adverse Effect.

Section

4.5 Capitalization.

(a) The

authorized capital stock of the Company consists of 20,000,000 shares of Company Stock and 2,000,000 shares of preferred stock, par value

$1.00 per share. As of July 27, 2026, there were no outstanding shares of preferred stock of the Company and 9,193,061 outstanding

shares of Company Stock. All outstanding shares of capital stock of the Company have been, and all shares that may be issued pursuant

to the Company Equity Plans will be, when issued in accordance with the respective terms thereof, duly authorized, validly issued, fully

paid and nonassessable and not subject to subscription or preemptive rights.

(b) As

of July 27, 2026, the Company has reserved 1,000,000 shares of Company Stock for issuance pursuant to the Company Equity

Plans. As of July 27, 2026, there was outstanding (x) Company Restricted Stock with respect to 410,877 shares of Company Stock

and (y) Company Options with respect to 10,218 shares of Company Stock. Other than the Company Restricted Stock and Company Options described

in the prior sentence and as set forth on Schedule 4.5(d) of the Company Disclosure Schedule, there are no other awards outstanding

under the Company Equity Plans or otherwise as of July 27, 2026.

as set forth in this ‎Section 4.5 and for changes since July 27, 2026 resulting from the vesting of Company Restricted

Stock or exercise of Company Options, in each case outstanding on such date or granted to the extent not prohibited by this Agreement,

there are no issued, reserved for issuance or outstanding (i) shares of capital stock or other voting securities of or ownership interests

in the Company, (ii) securities of the Company convertible into or exchangeable for shares of capital stock or other voting securities

of or ownership interests in the Company or (iii) warrants, calls, options or other rights to acquire from the Company, or other obligation

of the Company to issue, any capital stock, voting securities or securities convertible into or exchangeable for capital stock or voting

securities of the Company or (iv) restricted shares, stock appreciation rights, performance units, contingent value rights, “phantom”

stock or similar securities or rights that are derivative of, or provide economic benefits based, directly or indirectly, on the value

or price of, any capital stock of or voting security of the Company (the items in clauses ‎(i) through ‎(iv) being referred to

collectively as the “Company Securities” ). There are no outstanding obligations of the Company or any of its Subsidiaries

to repurchase, redeem or otherwise acquire any of the Company Securities. The Company has no accrued and unpaid dividends with respect

to any outstanding shares of Company Stock or Company Restricted Stock.

(d) Section

4.5(d) of the Company Disclosure Schedule lists each award of Company Restricted Stock and each award of Company Options as of July

27, 2026, whether or not granted under any Company Equity Plan, including (i) the name or employee identification number of the holder

of such Company Restricted Stock and/or Company Options, (ii) the Company Equity Plan under which the award was granted; (iii) the number

of shares of Company Stock subject to such outstanding award of Company Restricted Stock or Company Option, (iv) the date on which such

Company Restricted Stock or Company Option was granted or issued, (v) the applicable vesting schedule of such Company Restricted Stock

or Company Option, (vi) the exercise price for the Company Option and (vi) whether the holder of such Company Restricted Stock made a

timely Section 83(b) election with respect to such award.

Section

4.6 Subsidiaries.

(a) Each

Subsidiary of the Company has been duly organized, is validly existing and (where applicable) in good standing under the laws of its

jurisdiction of organization, has all organizational powers and all governmental licenses, authorizations, permits, consents and approvals

required to carry on its business as now conducted, except for those licenses, authorizations, permits, consents and approvals the absence

of which would not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect. Each such Subsidiary

is duly qualified to do business as a foreign entity and is in good standing in each jurisdiction where such qualification is necessary,

except for those jurisdictions where failure to be so qualified would not reasonably be expected to have, individually or in the aggregate,

a Material Adverse Effect.

(b) All

of the outstanding capital stock of or other voting securities of, or ownership interests in, each Subsidiary of the Company, is owned

by the Company, directly or indirectly, free and clear of any Liens, other than Permitted Liens, and is duly authorized, validly issued,

fully paid and nonassessable. As of the date hereof, there are no issued, reserved for issuance or outstanding (i) securities of the

Company or any of its Subsidiaries convertible into, or exchangeable for, shares of capital stock or other voting securities of, or ownership

interests in, any Subsidiary of the Company, (ii) warrants, calls, options or other rights to acquire from the Company or any of its

Subsidiaries, or other obligations of the Company or any of its Subsidiaries to issue, any capital stock or other voting securities of,

or ownership interests in, or any securities convertible into, or exchangeable for, any capital stock or other voting securities of,

or ownership interests in, any Subsidiary of the Company or (iii) restricted shares, stock appreciation rights, performance units, contingent

value rights, “phantom” stock or similar securities or rights that are derivative of, or provide economic benefits based,

directly or indirectly, on the value or price of, any capital stock or other voting securities of, or ownership interests in, any Subsidiary

of the Company (the items in clauses ‎(i) through ‎(iii) being referred to collectively as the “Company Subsidiary Securities”).

There are no outstanding obligations of the Company or any of its Subsidiaries to repurchase, redeem or otherwise acquire any of the

Company Subsidiary Securities.

4.6(c) of the Company Disclosure Schedule sets forth the name, jurisdiction of incorporation or organization (as applicable), entity

form and the Company’s direct or indirect percentage ownership of each Subsidiary of the Company. The Company does not (i) own

or hold the right to acquire any equity securities, ownership interests, profit-sharing interests or voting interests (including voting

debt) of, or securities exchangeable or exercisable therefor, or investments in, any Person other than a Subsidiary of the Company or

(ii) have any obligation to make any investment or capital contribution in any other Person other than a Subsidiary of the Company.

Section

4.7 SEC Filings and the Sarbanes-Oxley Act.

(a) The

Company has filed with or furnished to the SEC, on a timely basis, all reports, schedules, forms, statements, prospectuses, registration

statements, certifications and other documents required to be publicly filed or furnished by the Company, including pursuant to the 1933

Act, the 1934 Act or the Sarbanes-Oxley Act, since the Applicable Date (collectively, together with any exhibits and schedules thereto

and other information incorporated therein, the “Company SEC Documents”).

(b) As

of its filing date or on the date on which it was furnished (or, if amended, as of the date of such amendment), each Company SEC Document

complied as to form in all material respects with the applicable requirements of the 1933 Act, the 1934 Act and the Sarbanes-Oxley Act,

as the case may be.

of its filing date or on the date on which it was furnished (or, if amended, as of the date of such amendment), each Company SEC Document

filed pursuant to the 1933 Act, the 1934 Act and the Sarbanes-Oxley Act did not contain any untrue statement of a material fact or omit

to state any material fact required to be stated therein or necessary in order to make the statements made therein, in the light of the

circumstances under which they were made, not misleading.

(d) The

Company and each of its officers are in compliance in all material respects with the applicable provisions of the Sarbanes-Oxley Act.

The management of the Company has complied in all material respects with Rule 13a-15 or 15d-15 under the 1934 Act, and designed, and

maintained at all times since the Applicable Date, disclosure controls and procedures to ensure that material information relating to

the Company, including its consolidated Subsidiaries, is recorded, processed and made known on a timely basis to the management of the

Company and any other individuals responsible for the preparation of the Company’s filings with the SEC. Since the Applicable Date,

no executive officer of the Company has failed to make the certifications required of such executive officer under Sections 302 or 906

of the Sarbanes-Oxley Act with respect to the Company SEC Documents.

(e) Since

the Applicable Date, none of the Company, any of its Subsidiaries or, to the Knowledge of the Company, the Company’s auditors,

has identified or been made aware of (A) any significant deficiencies or material weaknesses in the design, maintenance or operation

of internal control over financial reporting (“Internal Controls”) which would adversely affect the Company’s

ability to record, process, summarize and report financial data or (B) any fraud, whether or not material, that involves management or

other employees who have a significant role in the Company’s Internal Controls or the preparation of financial statements.

(f) To

the Knowledge of the Company, as of the date of this Agreement, none of the Company SEC Documents is the subject of an ongoing SEC review

or outstanding SEC comment. As of the date of this Agreement, there are no SEC inquiries or investigations, or other inquiries by any

Governmental Entities pending or, to the Knowledge of the Company, threatened regarding the Company’s accounting practices. Since

the Applicable Date, there have been no internal investigations of the Company or any of its Subsidiaries regarding the Company’s

accounting practices, revenue recognition or other accounting or auditing issues, discussed with, reviewed by or initiated by or at the

direction of the chief executive officer, chief financial officer, general counsel or similar legal officer, the Company Board or any

committee of the Company Board.

Section

4.8 Financial Statements. The

audited consolidated financial statements and unaudited consolidated interim financial statements of the Company and its consolidated

Subsidiaries included or incorporated by reference in the Company SEC Documents (including the related notes and schedules) (a) have

complied, as of their respective dates, in all material respects with the then-applicable accounting requirements of the 1933 Act and

the 1934 Act and the rules and regulations of the SEC with respect thereto, (b) have been prepared in all material respects in accordance

with GAAP consistently applied during the periods involved (except as may be indicated therein or in the notes thereto or, in the case

of the unaudited financial statements, for normal and recurring year-end adjustments and as may be permitted by the SEC on Form 10-Q,

Form 8-K, Regulation S-X or any successor or like form under the Exchange Act) and (c) fairly present in all material respects, the consolidated

financial position of the Company and its consolidated Subsidiaries as of the dates thereof and their consolidated results of operations

and cash flows for the periods then ended (subject to normal and recurring year-end audit adjustments and the absence of footnotes in

the case of any unaudited interim financial statements).

Section

4.9 Disclosure Documents.

(a) The

proxy statement of the Company to be filed with the SEC in connection with the Merger (the “Proxy Statement”) will,

when filed, comply as to form in all material respects with the applicable requirements of the 1934 Act. At the time the Proxy Statement

and any amendment or supplement thereto is first mailed to the stockholders of the Company and at the time of the Company Stockholder

Meeting, the Proxy Statement, as supplemented or amended, if applicable, will not contain any untrue statement of a material fact or

omit to state any material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances

under which they were made, not misleading. The representations and warranties contained in this ‎Section 4.9(a) will not

apply to statements or omissions included or incorporated by reference in the Proxy Statement based upon information supplied by Parent,

Merger Subsidiary or any of their respective Representatives specifically for use or incorporation by reference therein.

(b) The

information supplied by the Company for inclusion in the Registration Statement will not, at the time the Registration Statement and

any amendment or supplement thereto is filed with the SEC, contain any untrue statement of a material fact or omit to state any material

fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they

were made, not misleading. The representations and warranties contained in this Section 4.9(b) will not apply to statements or omissions

included or incorporated by reference in the Registration Statement based upon information supplied by Parent, Merger Subsidiary or any

of their Representatives specifically for use or incorporation by reference therein.

Section

4.10 Absence of Certain Changes. Since

the Company Balance Sheet Date through the date of this Agreement, (a) the business of the Company and its Subsidiaries has been conducted

in the ordinary course in all material respects; (b) there has not been any Effect that has had or would reasonably be expected to have,

individually or in the aggregate, a Material Adverse Effect; and (c) neither the Company nor any of its Subsidiaries has taken any action

that would have required Parent’s consent pursuant to Section 6.1(b)(i), 6.1(b)(ii), 6.1(b)(iv), 6.1(b)(v), 6.1(b)(vi),

6.1(b)(vii), 6.1(b)(x), 6.1(b)(xi), 6.1(b)(xiv), 6.1(b)(xv) or 6.1(b)(xvi) had the covenants

set forth therein applied since the Company Balance Sheet Date.

Section

4.11 No Undisclosed Material Liabilities. There

are no liabilities or obligations, whether accrued, contingent, absolute or otherwise of the Company or any of its Subsidiaries that

would be required by GAAP to be reflected or reserved against on a consolidated balance sheet of the Company and its Subsidiaries (or

disclosed in the notes thereto), other than: (i) liabilities or obligations disclosed and provided for in the Company Balance Sheet or

in the notes thereto; (ii) liabilities or obligations incurred in the ordinary course of business consistent with past practices since

the Company Balance Sheet Date (other than liabilities that arise out of or relate to any breach or violation of, or default under, any

Contract or any violation of Law), none of which has had, or would reasonably be expected to be, individually or in the aggregate, material

to the Company and its Subsidiaries, taken as a whole; (iii) liabilities or obligations with respect to legal, financial advisory or

similar professional fees and expenses incurred in connection with the Transactions, and (iv) liabilities or obligations that would not

reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect. Neither the Company nor any of its Subsidiaries

is a party to, or has any commitment to become a party to, any “off balance sheet arrangement” within the meaning of Item

303 of Regulation S-K promulgated under the 1933 Act.

Section

4.12 Compliance with Laws and Court Orders.

(a) The

Company and each of its Subsidiaries is, and since the Applicable Date has been, in compliance with all Applicable Laws and all Orders

applicable to the Company or any of its Subsidiaries, except for failures to comply or violations that would not reasonably be expected

to have, individually or in the aggregate, a Material Adverse Effect. Except as set forth on Schedule 4.12(a), since Applicable

Date neither the Company nor its Subsidiaries has received any written or, to the Knowledge of the Company, verbal communication from

any Governmental Authority alleging any noncompliance with any Applicable Laws, Healthcare Laws, or any Orders applicable to the Company

or any of its Subsidiaries, and no investigation by any Governmental Authority regarding an alleged or actual material violation of any

such Applicable Law, Healthcare Law, or Order is pending or, to the Knowledge of the Company, threatened, in each case except as would

not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect.

(b) Except

as would not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect, in the past five (5) years,

neither the Company nor any of its Subsidiaries, nor, to the Knowledge of the Company, any director, officer, agent or employee of the

Company or any of its Subsidiaries has (i) taken any action, directly or indirectly, that would result in a violation by any such Persons

of the U.S. Foreign Corrupt Practices Act of 1977, the Anti-Kickback Act of 1986, the U.K. Bribery Act of 2010, or any other anti-bribery,

anti-corruption, or anti-money laundering Applicable Law, (ii) used any funds of the Company for unlawful contributions, gifts, entertainment

or other unlawful expenses relating to political activity, or (iii) given, offered, promised or authorized the giving of money or anything

of value, to any Government Official, for the purpose of (A) influencing an act or decision of such Government Official or improperly

inducing such Government Official to use his or her influence or position to affect any act or decision of a Governmental Authority,

(B) obtaining an improper business advantage, or (C) obtaining or retaining business.

as would not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect, in the past five (5) years,

neither the Company nor any of its Subsidiaries, nor, to the Knowledge of the Company, any directors, officers, agents or employees of

the Company or any of its Subsidiaries, (i) has been a Sanctioned Person; (ii) has engaged in or otherwise participated in, or assisted

or facilitated any direct or indirect dealing or transaction with, or for the benefit of, a Sanctioned Person; or (iii) has otherwise

violated applicable Sanctions.

(d) Neither

the Company nor any of its Subsidiaries is required to be registered as an investment company under the Investment Company Act of 1940,

as amended, and the rules and regulations promulgated thereunder.

Section

4.13 Regulatory Matters.

(a) Since

January 1, 2023, each of the Company and its Subsidiaries is and has been operating in compliance in all material respects with all Healthcare

Laws.

(b) Since

January 1, 2023, the Products have been developed, tested, manufactured, stored, sourced, packaged, used, distributed, labeled, promoted,

marketed, sold and otherwise commercialized, as applicable, in compliance in all material respects with all Applicable Law, including

all Healthcare Laws.

as set forth on Section 4.13(c) of the Company Disclosure Schedule, since January 1, 2023, neither the Company nor any of its

Subsidiaries has received any (i) written, or to the Company’s Knowledge, oral notice from the FDA or any other Governmental Authority

alleging that the Company or any of its Subsidiaries has been or is in violation in any material respect of (A) any Applicable Law, including

any Healthcare Law with respect to the development, testing, manufacturing, storage, distribution, promotion, marketing, sale, or commercialization

of the Products, or (B) any other Applicable Law, the violation of which is cause for civil penalties or mandatory or permissive exclusion

from Medicare, Medicaid, or any other state or federal health care program; (ii) written notice of inspectional observation (including

those recorded on form FDA 483), establishment inspection report, warning letter, notice of adverse finding, penalty, fine, sanction,

request for recall, notice of violation or “untitled letters”, or other remedial action with respect to the Products from

any Governmental Authority; or (iii) other written documents issued by any Governmental Authority alleging lack of compliance by the

Company or any of its Subsidiaries in any material respect with any Applicable Law, including any Healthcare Law with respect to the

Products. Since January 1, 2021, there have been no Proceedings pending or, to the Company’s Knowledge, threatened with respect

to the Company’s or its Subsidiaries’ violation of any Applicable Law, including any Healthcare Law, with respect to the

development, testing, manufacturing, storage, distribution, promotion, marketing, sale, or commercialization of the Products.

(d) Since

January 1, 2023, (i) the Company and its Subsidiaries have complied in all material respects with all Applicable Laws in connection with

the preparation and submission to the FDA and any other Regulatory Authority with respect to the Products, and (ii) all reports, documents,

data, forms, applications, records, claims and notices required to be filed, maintained or furnished to the FDA or any other Governmental

Authority by the Company and its Subsidiaries with respect to the Products have been so filed, maintained or furnished and were true,

accurate and complete in all material respects on the date filed (or were corrected in or supplemented by a subsequent filing).

(e) Since

January 1, 2023, the Company and its Subsidiaries have operated in compliance in all material respects with all required Regulatory Approvals.

(f) Neither

the Company nor any of its Subsidiaries has received, since January 1, 2023, any written or, to the Company’s Knowledge, oral notice

from any Governmental Authority with respect to, and, to the Company’s Knowledge, no event has occurred that would reasonably be

expected to result in, the loss, termination, suspension, withdrawal or revocation of any Regulatory Approval with respect to any of

the Products or the loss, withdrawal or revocation of any of the Products.

(g) Since

January 1, 2023, no Products have been subject to, nor, to the Knowledge of the Company, are there any facts or circumstances reasonably

likely to lead to, any (i) recalls, field notifications, warnings, “dear doctor” letters, safety alerts, detentions, holds,

or other notices of action relating to an alleged lack of safety or regulatory compliance, (ii) correction, removal action, or other

market withdrawal, or (iii) suspension, withdrawal or discontinuation as a result of any action by FDA or any other Governmental Authority.

To the Company’s Knowledge, no event has occurred, and no condition or circumstance exists, that would reasonably be expected to

(with or without notice or lapse of time or both) give rise to or serve as a basis for any recall, correction, removal action, market

withdrawal or other similar action of any Product.

(h) Since

January 1, 2023, neither the Company nor any of its Subsidiaries have made any materially false or fraudulent statements on, or material

omissions from, any notifications, applications, approvals, reports and other submission to any Governmental Authority with respect to

its business, including any such statement or omission that would reasonably be expected to provide a basis for the FDA to invoke its

policy respecting “Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities”.

(i) Neither

the Company nor any of its Subsidiaries nor, to the Company’s Knowledge, any of their employees, agents, or independent contractors

has been suspended, excluded, debarred, or convicted of any crime or engaged in any conduct that would reasonably be expected to result

in (i) debarment under 21 U.S.C. Section 335(a) or (b) or any similar Applicable Law, (ii) exclusion under 42 U.S.C. Section 1320a-7

or any similar Applicable Law or (iii) prohibition from participating in any procurement program of or otherwise contracting with any

Governmental Authority. Neither the Company nor any of its Subsidiaries nor, to the Company’s Knowledge, any of its respective

directors, officers, employees, or agents is a party to any corporate integrity agreement, monitoring agreement, consent decree, settlement

order, or other similar written agreement, in each case, entered into with or imposed by any Governmental Authority.

(j) Any

Contracts between the Company or any of its Subsidiaries and personnel, whether employed, contracted or otherwise engaged, who provide

clinical services on behalf of or to the Company or its business comply in all material respects will applicable Healthcare Laws. .

(k) To

the Knowledge of the Company, since January 1, 2023, none of the Company or its Subsidiaries have received any written inquiries from

the HHS Office of Civil Rights, any state Attorney General or any other Governmental Authority regarding material noncompliance with

Privacy Laws. Since January 1, 2023, the Company and its Subsidiaries have complied in all material respects with, any applicable Business

Associate Agreements (as defined under the Health Insurance Portability and Accountability Act of 1996 (42 U.S.C. § 1320d et seq.),

as amended, by the Health Information Technology for Economic and Clinical Health Act and its implementing regulations (collectively

“HIPAA”)). Since January 1, 2023, to the Knowledge of the Company, there has been no material unauthorized use or

disclosure of protected health information (“PHI”) by the Company, its Subsidiaries, or its personnel. Since January

1, 2023, the Company has complied in all material respects with its obligations under HIPAA, including with respect to conducting security

risk assessment, and has addressed all material identified deficiencies, if any..

Section

4.14 Litigation. As

of the date hereof, there is no Proceeding pending against, or, to the Knowledge of the Company, threatened against, the Company or any

of its Subsidiaries or, to the Knowledge of the Company, against any director, officer or employee of the Company or any of its Subsidiaries,

that would reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect. Neither the Company nor any of

its Subsidiaries is a party to or subject to the provisions of any Order or any settlement, compromise, conciliation or similar agreement

with any Person, in each case, that would reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect.

Section

4.15 Permits. Since

January 1, 2023, the Company and its Subsidiaries have held and currently hold all Permits necessary for the lawful conduct of their

businesses, except as would not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect. All such

Permits are valid and in full force and effect. All material fees payable to any Governmental Authority with respect to such Permits

have been timely paid. Since January 1, 2023, neither the Company nor any of its Subsidiaries has received written notice from any Governmental

Authority of any actual or possible violation of any Permit or of any actual or possible revocation, suspension, refusal to renew, cancellation,

rescission, loss, expiration, modification, or limitation of any Permit, except as would not reasonably be expected to have, individually

or in the aggregate, a Material Adverse Effect. No event has occurred and, to the Knowledge of the Company, no circumstances exist that,

with or without notice or lapse of time or both, would reasonably be expected to result in any revocation, suspension, lapse, rescission,

loss, refusal to renew, cancellation, modification, or limitation of any such Permit. To the Knowledge of the Company, any required material

updates, changes, corrections, or modifications to, or material notifications, submissions, filings, or information required by, any

Permit have been submitted to the relevant Governmental Authority, except as would not reasonably be expected to have, individually or

in the aggregate, a Material Adverse Effect.

Section

4.16 Properties.

(a) Except

as set forth on Section 4.16(a) of the Company Disclosure Schedule and except as would not reasonably be expected to have, individually

or in the aggregate, a Material Adverse Effect, the Company and its Subsidiaries have good title to, or valid and enforceable leasehold

interests in, all property and assets reflected on the Company Balance Sheet or acquired after the Company Balance Sheet Date (except

for properties and assets that have been disposed of since the Company Balance Sheet Date in the ordinary course of business), free and

clear of all Liens other than Permitted Liens.

(b) As

of the date hereof, ‎Section 4.16(b) of the Company Disclosure Schedule sets forth a true and complete list of (i) all material

real property owned by the Company or any of its Subsidiaries (the “Owned Real Property”), and (ii) all material real

property leased by or for the benefit of the Company or any of its Subsidiaries (the “Leased Real Property” and, together

with the Owned Real Property, the “Real Property”). The Company has delivered or made available to Parent copies of

(i) all material Contracts and all material amendments and modifications thereof that are in the possession of the Company with respect

to the Owned Real Property, and (ii) all material leases or subleases, and all material amendments and modifications thereof, with respect

to the Leased Real Property (each, a “Real Property Lease”).

Owned Real Property is the only real property owned by the Company or a Subsidiary thereof and used in connection with the business of

the Company and its Subsidiaries. Except as would not reasonably be expected to have, individually or in the aggregate, a Material Adverse

Effect, (i) the Company or a Subsidiary thereof has good, marketable and insurable fee simple title to the parcel of Owned Real Property

owned by the Company or such Subsidiary, free and clear of all Liens except for Permitted Liens, (ii) the interest of the Company or

applicable Subsidiary thereof in the Owned Real Property has not been conveyed, leased, pledged, or otherwise transferred or encumbered,

whether in whole or in part, (iii) neither the Company nor any Subsidiary thereof is a lessor, sublessor or grantor under any lease,

sublease, consent, license or other instrument granting to another Person any right to the possession, use, occupancy or enjoyment of

the Owned Real Property, and (iv) no Person, other than the Company or a Subsidiary thereof, has any right, option, right of first refusal

or any other Contract, whether oral or written, with respect to the purchase, assignment or transfer of all or any portion of the Owned

Real Property.

(d) Except

as would not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect, (i) the Company or a Subsidiary

thereof has a valid and existing leasehold interest in each Leased Real Property, free and clear of all Liens except for Permitted Liens,

(ii) each Real Property Lease is valid and in full force and effect (subject to the Bankruptcy and Equity Exception), (iii) neither the

Company nor any of its Subsidiaries, nor to the Company’s Knowledge any other party to a Real Property Lease, has violated any

provision of, or taken or failed to take any act which, with or without notice, lapse of time, or both, would constitute a material breach

or default under the provisions of such Real Property Lease, and neither the Company nor any of its Subsidiaries has received or given

notice that it has materially breached, violated or defaulted under any Real Property Lease, and (iv) there is no sublease, license,

occupancy agreement, option to purchase, right of first refusal, right of first offer or other Contract granting the Company or its Subsidiaries

or, to the Company’s Knowledge, any other Person, any right to acquire, sublease or use the Leased Real Property, and no Person

(other than the Company or a Subsidiary thereof) is in possession of the Leased Real Property.

(e) Except

as has not had and would not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect, the Company

has not received any written notice that all or any portion of Real Property is subject to any governmental order to be sold or is being

condemned, expropriated or otherwise taken by any Governmental Authority with or without payment of compensation therefor.

(f) Except

for any Permitted Liens or as has not had and would not reasonably be expected to have, individually or in the aggregate, a Material

Adverse Effect, (i) there are no Liens (other than Permitted Liens) that prevent the Company or any of its Subsidiaries from using, occupying

or operating any Real Property for its current use, occupancy, or operation, (ii) all structures and other buildings on the Real Property

are in operating condition and none of such structures or buildings is in need of maintenance or repairs except for ordinary, routine

maintenance and repairs, and except for ordinary wear and tear, (iii) no construction (excluding routine maintenance and repair work)

is currently being performed or is anticipated to be performed on the Real Property, (iv) the Real Property has adequate access to public

roads, and (v) all utilities necessary to serve the Real Property and the business of the Company and its Subsidiaries as conducted as

of the date of this Agreement are properly installed, available to and connected with the Real Property in sufficient quantities.

Section

4.17 Intellectual Property.

(a) Except

as would not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect: (i) the conduct of the businesses

of the Company and each of its Subsidiaries is not infringing, misappropriating, or otherwise violating, and since the Applicable Date

has not infringed, misappropriated, or otherwise violated, any Intellectual Property of any other Person, (ii) the Company or one of

its Subsidiaries exclusively owns all Intellectual Property owned or purported to be owned by the Company or one of its Subsidiaries

(the “Owned Intellectual Property”), or licenses or has a valid right to use all other Intellectual Property necessary

for the conduct of its business as currently conducted (the “Company Intellectual Property”); (iii) all Owned Intellectual

Property is subsistent, valid, and enforceable; and (iv) since the Applicable Date, neither the Company nor its Subsidiaries has instituted

or threatened in writing any Proceedings against any Third Party alleging any infringement, misappropriation or other violation of any

Owned Intellectual Property. To the Knowledge of the Company, no Third Party is infringing upon, violating, or misappropriating any Owned

Intellectual Property in any material respect.

(b) The

Company has furnished to Parent a complete and accurate list of (i) all registered and applied for Patents, Trademarks, Copyrights, and

domain names included in the Owned Intellectual Property or that are exclusively licensed by the Company or one of its Subsidiaries and

(ii) all material unregistered trademarks in the Owned Intellectual Property as of the date hereof.

is no Proceeding pending or, to the Knowledge of the Company, threatened against the Company or any of its Subsidiaries alleging that

the Company or any of its Subsidiaries infringes, violates, or otherwise misappropriates, or since the Applicable Date has infringed,

violated, or otherwise misappropriated, any Intellectual Property rights of any Person, in each case except for such Proceedings that

would not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect.

(d) The

Company and its Subsidiaries take, and since the Applicable Date, have taken commercially reasonable actions to protect the confidentiality

of the Trade Secrets of the Company or its Subsidiaries, except as would not reasonably be expected to have, individually or in the aggregate,

a Material Adverse Effect. Since the Applicable Date, all current and former officers and employees of, and consultants and independent

contractors to, the Company or its Subsidiaries whose duties to the Company or its Subsidiaries reasonably contemplate or contemplated

access to Trade Secrets included in the Company Intellectual Property have executed a valid and enforceable written agreement with the

Company or one of its Subsidiaries agreeing to protect the confidentiality of Trade Secrets included in the Company Intellectual Property.

(e) All

current and former officers and employees of, and consultants and independent contractors to, the Company or its Subsidiaries whose duties

to the Company or its Subsidiaries reasonably contemplate or contemplated the development of Intellectual Property have executed a valid

and enforceable written agreement with the Company or one of its Subsidiaries that assigns to such Company or Subsidiary all of such

Person’s rights, title and interest in and to any and all Company Intellectual Property such Person contributed to the creation

or development of, and, to the extent applicable, irrevocably waives such Person’s moral rights in such Intellectual Property,

except as would not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect.

(f) Since

the Applicable Date, there has been no malfunction, failure, continued substandard performance, denial-of-service, any event constituting

a Security Incident, including any cyberattack, or other impairment of the Company IT Systems in each case except as would not reasonably

be expected to have, individually or in the aggregate, a Material Adverse Effect. The Company and its Subsidiaries have taken commercially

reasonable efforts to safeguard the confidentiality, availability, security, and integrity of the Company IT Systems, in each case except

as would not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect.

(g) The

Company and each of its Subsidiaries have complied with all applicable Data Privacy and Security Requirements, including the collection,

use, processing, storage, transfer, and security of Personal Information in the conduct of the Company’s and its Subsidiaries’

businesses, except as would not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect. Since the

Applicable Date, the Company and its Subsidiaries have not received any written notice of any Proceeding by any Governmental Authority

concerning the Company’s or any of its Subsidiaries’ collection, use, processing, storage, transfer, or protection of Personal

Information or actual, alleged, or suspected violation of any Data Privacy and Security Requirement, including concerning privacy, data

security, or data breach notification, and to the Knowledge of Company, there are no facts or circumstances that could reasonably be

expected to give rise to any such Proceedings, except as would not reasonably be expected to have, individually or in the aggregate,

a Material Adverse Effect.

(h) The

Company maintains and, except as would not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect,

is in compliance with a written information security program that: (i) includes reasonable administrative, technical, and physical safeguards

designed to protect and safeguard the availability, confidentiality, and integrity of transactions and Personal Information, including

implementing procedures designed to prevent introduction of any virus or malware, and taking and storing on site and off site backup

copies of such Personal Information; (ii) is designed to protect against unauthorized access to the IT assets or Personal Information

and the systems of any third-party service providers that have access to the IT assets or Personal Information; and (iii) includes breach

notification policies and procedures to provide notice to Persons regarding information security incidents involving acquisition, access,

loss, theft, use or disclosure of Personal Information in an unauthorized manner.

(i) Since

the Applicable Date, except as would not be material, individually or in the aggregate, to the Company and its Subsidiaries, taken as

a whole, no Personal Information in the possession or control of the Company has been subject to any known or suspected data breach or

other Security Incident that presents a risk of unauthorized access, disclosure, use, denial of use, alteration, corruption, destruction,

compromise or loss of such Personal Information or that has caused or would reasonably be expected to cause a disruption to the conduct

of the business.

Section

4.18 Taxes.

(a) All

income Tax Returns and other material Tax Returns required by Applicable Law to be filed with any Governmental Authority by, or on behalf

of, the Company or its Subsidiaries have been filed when due (including extensions) in accordance with all Applicable Law, and all such

Tax Returns are, or shall be at the time of filing, true, correct and complete in all material respects.

(b) The

Company and each of its Subsidiaries has paid (or has had paid on its behalf) to the appropriate Governmental Authority all income Taxes

and other material Taxes due and payable (whether or not shown on a Tax Return), or, where payment is not yet due, has established (or

has had established on its behalf and for its sole benefit and recourse) in accordance with GAAP an adequate accrual for all material

Taxes through the end of the last period for which the Company and its Subsidiaries ordinarily record items on their respective books.

claim has been made in the past five (5) years by a Governmental Authority in a jurisdiction where the Company or any of its Subsidiaries

does not file material Tax Returns that it is or may be subject to material Tax by that jurisdiction or required to file material Tax

Returns in that jurisdiction.

(d) The

Company and each of its Subsidiaries is not and has never been a member of an affiliated group within the meaning of Section 1504(a)

of the Code with which it has filed (or been required to file) consolidated, combined, unitary or similar Tax Returns (other than a group

which the Company is the common parent of). The Company and each of its Subsidiaries has no liability for the Taxes of any Person (other

than the Company or its Subsidiaries) under Section 1.1502-6 of the “Treasury Regulations” (or any similar provision of state,

local or foreign law), as a transferee or successor, by Contract (other than any Contract entered into the principal purpose of which

does not relate to Taxes), or by operation of law.

(e) There

is no Proceeding now pending or, to the Company’s Knowledge, threatened in writing, against or with respect to the Company or its

Subsidiaries in respect of any material Tax, other than any audits with respect to which the Company or its Subsidiaries have paid or

accrued, in accordance with GAAP, any Taxes associated with such audits.

(f) During

the two-year period ending on the date hereof, neither the Company nor any of its Subsidiaries was a distributing corporation or a controlled

corporation in a transaction intended to be governed by Section 355 of the Code.

(g) The

Company and each of its Subsidiaries has properly withheld, and paid over to the appropriate Governmental Authority, all material Taxes

that it was required to withhold from any payment to any employee, independent contractor, creditor, stockholder, vendor or other Person.

(h) Neither

the Company nor any of its Subsidiaries has been party to any “listed transaction” within the meaning of Treasury Regulation

Section 1.6011-4(b)(2).

(i) There

are no Liens, other than Permitted Liens, on any of the assets of the Company or its Subsidiaries in connection with any failure (or

alleged failure) to pay any Tax.

(j) Neither

the Company nor any of its Subsidiaries is a party to or bound by any Tax indemnity, sharing, allocation, gross-up or similar agreement

primarily relating to Taxes (other than any such agreement between any of the Company and any of its Subsidiaries).

(k) Neither

the Company nor any of its Subsidiaries is or has been subject to Tax in any jurisdiction outside the United States by virtue of having

a permanent establishment, trade or business, office or other fixed place of business or other presence in that jurisdiction.

(l) No

equity interest in the Company is a United States real property interest within the meaning of Section 897(c) of the Code.

(m) Neither

the Company nor any of its Subsidiaries will be required to include any material item of income in, or exclude any material item of deduction

from, taxable income for any taxable period (or portion thereof) ending on or after the Closing Date as a result of (i) an open transaction

disposition made on or before the Closing Date, (ii) a prepaid amount, deposit, advanced payment received or paid, or deferred revenue

accrued, on or before the Closing Date, (iii) the application of the installment method of accounting to any transaction occurring on

or before the Closing Date, (iv) any intercompany transactions occurring on or before the Closing Date or any excess loss account in

existence on or before the Closing Date described in Treasury Regulations promulgated under Section 1502 of the Code (or any similar

or corresponding provision of any state, local or non-U.S. Law), (v) any change in its method of accounting for a taxable period (or

portion thereof) ending on or before the Closing Date, including by reason of Section 481 of the Code, or any comparable provisions of

other applicable state, local or non-U.S. Tax Law, or use of an improper method of accounting on or prior to the Closing Date, (vi) any

“closing agreement” under Section 7121 of the Code (or any comparable provisions of other applicable state, local or non-U.S.

Tax Law) entered into with any Governmental Authority on or prior to the Closing Date.

(n) There

have been no private letter rulings issued by the Internal Revenue Service to the Company or any of its Subsidiaries (and any similar

or corresponding ruling or determination of any state, local or non-U.S. Governmental Authority) and there are no pending written requests

for any such rulings (or corresponding determinations).

(o) Neither

the Company nor any of its Subsidiaries has claimed any “employee retention credit” pursuant to Section 2301 of the CARES

Act (or any corresponding or similar provision of state, local or foreign Law) for any taxable period that remains open for audit.

Section

4.19 Employee Benefit Plans and Labor and Employment

Matters.

(a) Section

4.19(a) of the Company Disclosure Schedule contains a correct and complete list of each material Employee Plan. With respect to each

material Employee Plan, true, current and complete copies of the plan document together with all ‎amendments and material contracts

relating thereto (including, for any unwritten plan, a summary of the material terms), have been made available to Parent.

(b) No

Employee Plan is or was within the past six (6) years, and neither the Company nor any ERISA Affiliate has or reasonably expects to have

any material liability or obligation under (including current or potential withdrawal liability): (i) a “defined benefit plan”

(as defined in Section 3(35) of ERISA), (ii) a multiemployer plan, as defined in Section 3(37) of ERISA, (iii) a “multiple employer

plan” as described in Section 413(c) of the Code; or (iv) a “multiple employer welfare arrangement” as described in

Section 3(40) of ERISA.

Employee Plan that is intended to be qualified under Section 401(a) of the Code has received a favorable determination letter from the

IRS or is entitled to rely on a favorable opinion letter from the IRS that such plan is qualified and no event has occurred and no condition

exists with respect to the form or operation of such Employee Plan which would reasonably be expected to cause the loss of such qualification

or exemption.

(d) Except

as has not had, and would not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect, (i) each Employee

Plan has been established and maintained in accordance with and in compliance with its terms and all Applicable Laws, including ERISA

and the Code; (ii) all contributions, premiums and other similar payments to, and payments from, such Employee Plan with respect to any

period ending on or before the Closing Date have been timely made; and (iii) all reports, returns and similar documents required to be

filed with any Governmental Authority or distributed to any plan participant have been duly and timely filed or distributed.

(e) Except

as has not had, and would not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect, the Company,

each Subsidiary and each ERISA Affiliate has complied in all respects with (i) the notice and continuation coverage requirements, and

all other requirements, of Section 4980B of the Code and Parts 6 and 7 of Title I of ERISA, and the regulations thereunder, and (ii)

the affordability and minimum essential coverage requirements, and all other requirements, of the Patient Protection and Affordable Care

Act of 2010, as amended, in each case, with respect to each Employee Plan that is a group health plan.

(f) Section

4.19(f) of the Company Disclosure Schedule sets forth all material Employee Plans, Contracts or other obligations of the Company

or any of its Subsidiaries which provides for health, life or other welfare benefits to past or present employees beyond their retirement

or other termination of service, other than coverage mandated by the Consolidated Omnibus Budget Reconciliation Act of 1985, Section

4980B of the Code, Title I of ERISA or any similar state group health plan continuation Laws, the cost of which is fully paid by such

employees or their dependents.

(g) Neither

the Company nor any of its Subsidiaries has any material obligation (whether pursuant to an Employee Plan or otherwise) to indemnify,

“gross-up”, reimburse or otherwise compensate any individual with respect to the additional Taxes or interest imposed pursuant

to Sections 409A or 4999 of the Code (or any corresponding provision of state, local, or foreign Law).

(h) Except

as has not had, and would not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect, there are

no Proceedings (other than routine claims for benefits) pending or, to the Knowledge of the Company, threatened against or relating to

any of the Employee Plans and, to the Knowledge of the Company, no facts exist which would reasonably be expected to give rise to any

such Proceedings.

(i) Neither

the Company nor any of its Subsidiaries nor any Employee Plan nor, to the Knowledge of the Company, any “disqualified person”

(as defined in Section 4975 of the Code) or “party in interest” (as defined in Section 3(18) of ERISA) has engaged in any

non-exempt prohibited transaction (within the meaning of Section 4975 of the Code or Section 406 of ERISA), except as would not reasonably

be expected to have, individually or in the aggregate, a Material Adverse Effect.

(j) The

Company and its Subsidiaries are in compliance with all Applicable Laws relating to labor and employment, including, those relating to

fair employment practices, anti-discrimination, -harassment, and -retaliation, workplace safety and health, terms and conditions of employment,

wages and hours, the proper classification and treatment of employees as exempt or non-exempt, and the proper classification and treatment

of any independent contractor, except as would not reasonably be expected to have, individually or in the aggregate, a Material Adverse

Effect.

(k) Except

as provided by ‎Section 2.6, neither the execution of this Agreement nor the consummation of the Transactions (either alone

or together with any other event) will (i) entitle any past or present Company Employee, director and/or independent contractor of the

Company or any of its Subsidiaries to any material bonuses, severance pay, unemployment compensation, transaction related payments or

any similar payments, or (ii) accelerate the time of the payment, funding or vesting of, or increase the amount of, any material compensation

and/or material benefits due to any past or present Company Employee, director, independent contractor other individual service provider

of the Company or any of its Subsidiaries. Neither the execution of this Agreement nor the consummation of the Transactions (either alone

or together with any other event) will result in any payments or benefits which would not reasonably be expected to be deductible under

Section 280G of the Code, or which would cause any Tax or penalty under Section 4999 of the Code.

(l) Except

as set forth on Section 4.19(l)(i) of the Company Disclosure Schedule, there are currently, and for the last three (3) years have

been, no pending, or to the Company’s Knowledge, threatened, Proceedings by any employee, independent contractor, former employee,

or former independent contractor of the Company or any of its Subsidiaries before the National Labor Relations Board, the Equal Employment

Opportunity Commission or any other Governmental Authority relating to any labor and employment matters. Except as set forth on Section

4.19(l)(ii) of the Company Disclosure Schedule, to the Company’s Knowledge, none of the employment policies or practices of

the Company or any of its Subsidiaries are currently being audited or investigated by any Governmental Authority or subject to imminent

audit or investigation by any Governmental Authority, except as would not reasonably be expected to have, individually or in the aggregate,

a Material Adverse Effect.

(m) Neither

the Company nor any of its Subsidiaries is a party to or subject to, or is currently negotiating in connection with entering into, any

collective bargaining agreement (each, a “Labor Agreement”). To the Company’s Knowledge, there has been no petition

for representation filed with respect to any Company Employees.

(n) Since

the Applicable Date, neither the Company nor any of its Subsidiaries has effectuated (i) a “plant closing” (as defined in

the Worker Adjustment and Retraining Notification Act of 1988 or similar Applicable Law (the “WARN Act”)) affecting

any site of employment or one or more facilities or operating units within any site of employment or facility of the Company or any of

its Subsidiaries; or (ii) a “mass layoff” (as defined in the WARN Act) affecting any site of employment or facility of the

Company or any of its Subsidiaries; and neither the Company nor any of its Subsidiaries has been affected by any transaction or engaged

in layoffs or employment terminations sufficient in number to trigger application of any similar state or local Applicable Law.

(o) The

Company has furnished to Parent a complete and accurate list of the current employees and officers of the Company and any of its Subsidiaries

as of the date hereof and shows with respect to each such employee: his or her name or employee identification number; direct employing

entity (i.e., the Company or a specific Subsidiary); date of hire; primary location of employment (country, state or province, and city);

job position or title; job department; full- or part-time status; overtime exempt or non-exempt status for wage and hour purposes; base

compensation rate (for overtime exempt employees, annual base salary rate) (for overtime nonexempt employees, base hourly wage rate);

type of incentive compensation if eligible (e.g., commissions, bonuses); annualized target incentive compensation; the frequency of payment

for such incentive compensation (e.g., monthly, quarterly, semi-annually, annually); visa status; annualized vacation or paid time off

(or designation of “flexible” if a non-accrual-based vacation or paid time off system is used); eligibility for severance

and the potential amount of such severance; eligibility for change of control benefits (cash or otherwise) to be paid at the Closing

or otherwise in connection with the Acquisition and the amount of such benefits.

(p) The

Company has furnished to Parent a complete and accurate list of all current independent contractors, consultants or advisors to the Company

or any of its Subsidiaries that the Company and/or the applicable Subsidiary classify as other than employees, describing for each such

independent contractor, consultant, or advisor: his, her or its personal or corporate name; primary location from which services are

performed (country, state or province, and city); designation as to whether such independent contractor regularly performs more or less

than an average of 30 hours per week; most recent rate of all regular, bonus or any other compensation rate; description of services

provided; initial date retained to perform services; the expected end date of services (if known); and whether he, she or it is required

to work, or in fact works, exclusively for the Company or one of its Subsidiaries.

Section

4.20 Environmental Matters.

(a) Except

as would not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect:

(i) no

written notice, order, complaint or penalty has been received by the Company or any of its Subsidiaries arising out of any Environmental

Laws or relating to Hazardous Substances, and there are no Proceedings pending or, to the Company’s Knowledge, threatened which

allege any liability of or violation by the Company or any of its Subsidiaries relating to any Environmental Laws or Hazardous Substances;

and

(ii) neither

the Company nor any of its Subsidiaries, nor any of their respective predecessors or controlled Affiliates, has treated, stored, disposed

of, arranged for or permitted the disposal of, transported, handled, released or exposed any person to any Hazardous Substance, or owned

or operated any property or facility contaminated by any Hazardous Substance, in each case, as has given or would give rise to liabilities

or obligations under any Environmental Laws;

(b) The

Company and each of its Subsidiaries are and have been since the Applicable Date in compliance with all applicable Environmental Laws,

environmental Permits necessary for their operations and any applicable Orders relating to (A) pollution, contamination, protection of

the environment, health, safety or sanitation, (B) emissions, discharges, disseminations, releases or threatened releases of Hazardous

Substances into the air (indoor or outdoor), surface water, groundwater, soil, land surface or subsurface, buildings, facilities, real

or personal property or fixtures or (C) the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling

of Hazardous Substances, in each case except as would not reasonably be expected to have, individually or in the aggregate, a Material

Adverse Effect.

Section

4.21 Material Contracts.

(a) Section

4.21 of the Company Disclosure Schedule sets forth each of the following Contracts to which the Company or any of its Subsidiaries

is a party or bound and has continuing obligations:

(i) any

Contract that constitutes a “material contract” (as such term is defined in Item 601(b)(10) of Regulation S-K of the SEC),

whether or not filed by the Company with the SEC;

(ii) any

Contract limiting in any material respect the ability of the Company or its Subsidiaries (or, after the consummation of the Merger, Parent,

the Surviving Corporation or any of their respective Subsidiaries) to (A) sell any products or services of or to any other Person or

in any geographic region, (B) engage in any line of business or (C) compete with or to obtain products or services from any Person or

limiting the ability of any Person to provide products or services to the Company or its Subsidiaries (or, after the consummation of

the Merger, Parent, the Surviving Corporation or any of their respective Subsidiaries);

(iii) any

Contract with any of the ten (10) largest suppliers by dollar volume of purchases made by the Company and its Subsidiaries during the

twelve (12) months ended December 31, 2025;

(iv) any

distributor, broker, dealer, manufacturer’s representative, franchise, agency, sales promotion, market research, marketing consulting,

advertising and similar Contract requiring payments on an annual or aggregate basis in excess of $500,000;

(v) any

Contract that obligates the Company or any of its Subsidiaries to make directly or indirectly, any advance, loan, extension of credit

or capital commitment or contribution to, or other investment in, any Person, or any capital expenditure in excess of $250,000 individually

or $500,000 in the aggregate;

(vi) any

Contract (A) between the Company and any of its Subsidiaries, on the one hand, and any Affiliate (including any director or executive

officer) thereof, on the other hand, or (B) otherwise of the type that would be required to be disclosed under Item 404 of Regulation

S-K of the SEC;

(vii) any

Contract that (A) grants any right of first refusal, right of first offer or similar right with respect to any material property or asset

of the Company or any of its Subsidiaries or (B) limits or purports to limit the ability of the Company or any of its Subsidiaries (or,

following the Closing, the Surviving Corporation, Parent or any of its Affiliates) to own, operate, sell, transfer, pledge or otherwise

dispose of any material properties or assets;

(viii) any

Contract that requires the Company or any of its Subsidiaries to purchase or obtain from any given Person either (1) a minimum or specified

amount of any product or service or (2) all or a material portion of the Company’s or any of its Subsidiaries’ requirements

for any product or service;

(ix) any

Contract that requires, during the remaining term of such Contract, either (A) annual payments to or from the Company or its Subsidiaries

of more than $1,000,000 or (B) aggregate payments to or from the Company or its Subsidiaries of more than $2,500,000 during the term

of such Contract;

(x) any

Contract (other than the organizational documents of the Company and its Subsidiaries) that relates to the formation, creation, governance

or control of, or the economic rights or obligations of the Company or any of its Subsidiaries in, any joint venture or other similar

arrangement involving a sharing of profits or expenses or payments or other triggering events based on revenues or profits of the Company

or its Subsidiaries;

(xi) any

Contract that (A) provides for the disposition or acquisition, directly or indirectly (whether by merger, consolidation, the sale of

equity interests, the sale of all or substantially all of the assets, or otherwise), of any business or any equity interests of any Person,

or (B) includes any earn-out or other similar contingent payment obligation of the Company or any of its Subsidiaries in excess of $1,000,000

outstanding as of the date hereof;

(xii) any

Contract with a Governmental Authority;

(xiii) any

Labor Agreement;

(xiv) any

Contract relating to the settlement or resolution of any litigation or other Proceeding that provides for any continuing material obligations

on the part of the Company or any of its Subsidiaries;

(xv) any

Contract (A) under which the Company or its Subsidiaries has granted or received a license or other right to any Intellectual Property

(excluding non-exclusive licenses or rights granted in the ordinary course of business), (B) relating to the acquisition, ownership,

or development of Intellectual Property, or (C) otherwise adversely affecting the Company’s or its Subsidiaries’ ability

to use, enforce, or disclose any Intellectual Property (excluding non-exclusive end-user licenses for unmodified, commercially available,

off-the-shelf software that are provided in executable form only and used solely for the Company’s and its Subsidiaries’

internal business purposes, with an aggregate replacement cost of less than $500,000); and

(xvi) any

Contract relating to any material Indebtedness or any security interest in any material assets or properties of the Company or any of

its Subsidiaries.

(each

Contract constituting any of the foregoing types described in clauses (i)-(xv), a “Material Contract”).

(b) The

Company has made available to Parent or its Representatives a true, complete and correct copy of each Material Contract (including any

material amendments, attachments or supplements thereto). Except for breaches, violations or defaults which would not reasonably be expected

to have, individually or in the aggregate, a Material Adverse Effect, (a) each of the Material Contracts is valid and in full force and

effect and constitutes a legal, valid, binding and enforceable obligation of the Company or its Subsidiaries party thereto and, to the

Knowledge of the Company, of the other parties thereto (subject to the Bankruptcy and Equity Exception), and (b) neither the Company

nor any of its Subsidiaries, nor to the Company’s Knowledge any other party to a Material Contract, has violated any provision

of, or taken or failed to take any act which, with or without notice, lapse of time, or both, would constitute a breach or default under

the provisions of such Material Contract or result in the right to terminate, amend or cancel such Material Contract or cause or permit

the acceleration or other material changes of any right or obligation or the loss of any material benefit thereunder by the Company or

its Subsidiaries, and neither the Company nor any of its Subsidiaries has received notice that it has breached, violated or defaulted

under any Material Contract.

Section

4.22 Related Party Transactions. Except

as set forth in the Company SEC Documents, to the Knowledge of the Company, since the Applicable Date, there have been no transactions,

or series of related transactions, agreements, arrangements or understandings in effect, nor are there any currently proposed transactions,

or series of related transactions, agreements, arrangements or understandings, that would be required to be disclosed under Item 404(a)

of Regulation S-K.

Section

4.23 Brokers. Except

for Truist Securities, Inc., there is no investment banker, broker, finder or other intermediary that has been retained by or is authorized

to act on behalf of the Company or any of its Subsidiaries that is entitled to any fee or commission from the Company or any of its Affiliates

in connection with the Transactions.

Section

4.24 Opinion of the Company’s Financial Advisor.

The Company Board has received the opinion of Truist Securities, Inc., financial advisor to the Company,

to the effect that, as of the date of such opinion and based on and subject to the matters, assumptions, qualifications and limitations

set forth therein, the Merger Consideration is fair, from a financial point of view, to holders of Company Stock (other than holders

who execute a Voting Agreement in connection with the Merger, Parent, Merger Subsidiary, and their respective affiliates).

Section

4.25 Takeover Laws. The

Company has taken all action necessary to exempt the Merger, this Agreement and the Transactions from the requirements of any Takeover

Laws.

Section

4.26 Insurance. The

Company has furnished to Parent complete and accurate copies of all material (x) insurance policies, binders and insurance contracts

that are maintained by or for the benefit of the Company and its Subsidiaries and (y) self-insurance programs and arrangements relating

to the business, assets and operations of the Company and its Subsidiaries as of the date of this Agreement (collectively, the “Insurance

Policies”). Except as would not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect,

(a) each such Insurance Policy is in full force and effect with all premiums due having been paid in full, and the Company is not in

default under any Insurance Policy, (b) neither the Company nor any of its Subsidiaries has received any written or, to the Company’s

Knowledge, oral notice of cancellation, termination, non-renewal or denial of coverage with respect to any Insurance Policy, (c) none

of the policy limits under any of the Insurance Policies have been eroded by the payment of claims and (d) since the Applicable Date

there has not been any claim that has been denied or rejected by any insurer and not successfully appealed and covered.

Section

4.27 No Other Representations and Warranties. Except

for the representations and warranties expressly made by the Company in this Article 4 or in any certificate delivered by the

Company pursuant to this Agreement, neither the Company nor any other Person makes any representation or warranty of any kind whatsoever,

express or implied, at law or in equity, with respect to the Company, any of its Subsidiaries or their respective business, operations,

assets, liabilities, condition (financial or otherwise) or the Transactions, notwithstanding any other statements made or the delivery

or disclosure to the Parent and Merger Subsidiary or any of their respective Representatives of any documentation, forecasts or other

information with respect to any one or more of the foregoing.

Section

4.28 Exclusivity of Parent Representations and Warranties.

The Company, on behalf of itself and its Subsidiaries, acknowledges and agrees that, except for the

representations and warranties expressly set forth in Article 5 or in any certificate delivered by Parent pursuant to this Agreement:

(i) neither Parent nor Merger Subsidiary (or any other Person) makes, or has made, any representation or warranty relating to Parent,

Merger Subsidiary or any of their businesses, operations or otherwise in connection with this Agreement or the Transactions; (ii) no

Person has been authorized by Parent, Merger Subsidiary or any of its or their respective Representatives to make any representation

or warranty relating to the Parent, Merger Subsidiary or any of their businesses or operations or otherwise in connection with this Agreement

or the Transactions, and if made, such representation or warranty must not be relied upon by the Company, any of its Subsidiaries or

any of their respective Representatives as having been authorized by the Parent, Merger Subsidiary or any of its or their respective

Representatives (or any other Person); and (iii) the representations and warranties made by the Parent in this Agreement are in lieu

of and are exclusive of all other representations and warranties, including any express or implied or as to merchantability or fitness

for a particular purpose, and the Parent hereby disclaims any other or implied representations or warranties, notwithstanding the delivery

or disclosure to Company or its Subsidiaries or any of their respective Representatives of any documentation or other information (including

any financial information, supplemental data or financial projections or other forward-looking statements).

Section

4.29 No Reliance. The

Company, on behalf of itself and its Subsidiaries, acknowledges and agrees that, except for the representations and warranties expressly

set forth in Article 5, it is not acting (including, as applicable, by entering into this Agreement or consummating the Transaction)

in reliance on: (i) any other representation or warranty, express or implied; (ii) any estimate, projection, prediction, data, financial

information, memorandum, presentation or other materials or information provided or addressed to the Company or any of its Representatives,

including any materials shared by Parent or Merger Subsidiary in connection with the Merger, or in any other forum or setting; or (iii)

the accuracy or completeness of any other representation, warranty, estimate, projection, prediction, data, financial information, memorandum,

presentation or other materials or information.

Article

Representations and Warranties of Parent

Except

as set forth in the Parent Disclosure Schedule (each section of which qualifies the correspondingly numbered representation and warranty

or covenant to the extent specified therein, provided that any disclosure set forth with respect to any particular section shall be deemed

to be disclosed in reference to all other applicable sections of this Agreement if the relevance of such disclosure to such other sections

is reasonably apparent on its face), Parent hereby represents and warrants to the Company as follows:

Section

5.1 Corporate Existence and Power. Each

of Parent and Merger Subsidiary is a corporation duly incorporated, validly existing and in good standing under the laws of its jurisdiction

of incorporation and has all corporate powers and all governmental licenses, authorizations, permits, consents and approvals required

to carry on its business as now conducted, except for those licenses, authorizations, permits, consents and approvals the absence of

which would not reasonably be expected to have, individually or in the aggregate, a Parent Material Adverse Effect. Since the date of

its incorporation, Merger Subsidiary has not engaged in any activities other than in connection with or as contemplated by this Agreement.

Section

5.2 Corporate Authorization. The

execution, delivery and performance by Parent and Merger Subsidiary of this Agreement and the consummation by Parent and Merger Subsidiary

of the Transactions are within the corporate powers of Parent and Merger Subsidiary and have been duly authorized by all necessary corporate

action. This Agreement constitutes a legal, valid and binding agreement of each of Parent and Merger Subsidiary, enforceable against

Parent and Merger Subsidiary in accordance with its terms, subject to the Bankruptcy and Equity Exception.

Section

5.3 Governmental Authorization. The

execution, delivery and performance by Parent and Merger Subsidiary of this Agreement and the consummation by Parent and Merger Subsidiary

of the Transactions require no action by or in respect of, or filing with, any Governmental Authority, other than (i) the filing of a

certificate of merger with respect to the Merger with the Secretary of State of the State of Texas and appropriate documents with the

relevant authorities of other states in which Parent is qualified to do business, (ii) compliance with any applicable requirements of

the HSR Act and those filings set forth in Section 8.1(b) of the Company Disclosure Schedule, (iii) compliance with any applicable

requirements of the 1934 Act and any other state or federal securities laws and (iv) any actions or filings the absence of which would

not reasonably be expected to have, individually or in the aggregate, a Parent Material Adverse Effect.

Section

5.4 Non-contravention. The

execution, delivery and performance by Parent and Merger Subsidiary of this Agreement and the consummation by Parent and Merger Subsidiary

of the Transactions do not and will not (i) contravene, conflict with, or result in any violation or breach of any provision of the certificate

of incorporation or bylaws of Parent or Merger Subsidiary, (ii) assuming compliance with the matters referred to in ‎Section

5.3, contravene, conflict with or result in any violation or breach of any provision of any Applicable Law, (iii) assuming compliance

with the matters referred to in ‎Section 5.3,

require any consent or other action by any Person under, constitute a default under, or cause or permit the termination, cancellation,

acceleration or other change of any right or obligation or the loss of any benefit to which Parent or any of its Subsidiaries is entitled

under any provision of any Contract binding upon Parent or any of its Subsidiaries or (iv) result in the creation or imposition of any

Lien on any asset of the Parent or any of its Subsidiaries, with only such exceptions, in the case of each of clauses (ii) through (iv),

as would not reasonably be expected to have, individually or in the aggregate, a Parent Material Adverse Effect.

Section

5.5 Disclosure Documents.

(a) The

information supplied by Parent for inclusion in the Proxy Statement will not, at the time the Proxy Statement and any amendment or supplement

thereto is first mailed to the stockholders of the Company and at the time of the Company Stockholder Meeting, contain any untrue statement

of a material fact or omit to state any material fact required to be stated therein or necessary in order to make the statements therein,

in light of the circumstances under which they were made, not misleading. The representations and warranties contained in this ‎Section

5.5(a) will not apply to statements or omissions included or incorporated by reference in the Proxy Statement based upon information

supplied by the Company or any of its Representatives specifically for use or incorporation by reference therein.

(b) The

Registration Statement will, when filed, comply as to form in all material respects with the applicable requirements of the 1933 Act.

At the time the Registration Statement is filed with the SEC, the Registration Statement, as supplemented or amended, if applicable,

will not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary

in order to make the statements therein, in light of the circumstances under which they were made, not misleading. The representations

and warranties contained in this Section 5.5(b) will not apply to statements or omissions included or incorporated by reference in the

Registration Statement based upon information supplied by the Company, its Subsidiaries or any of their Representatives specifically

for use or incorporation by reference therein.

Section

5.6 SEC Filings and the Sarbanes-Oxley Act.

(a) Parent

has filed with or furnished to the SEC, on a timely basis, all material reports, schedules, forms, statements, prospectuses, registration

statements, certifications and other documents required to be publicly filed or furnished by Parent, including pursuant to the 1933 Act,

the 1934 Act or the Sarbanes-Oxley Act, since the Applicable Date (collectively, together with any exhibits and schedules thereto and

other information incorporated therein, the “Parent SEC Documents”).

(b) As

of its filing date or on the date on which it was furnished (or, if amended, as of the date of such amendment), each Parent SEC Document

complied as to form in all material respects with the applicable requirements of the 1933 Act, the 1934 Act and the Sarbanes-Oxley Act,

as the case may be.

of its filing date or on the date on which it was furnished (or, if amended, as of the date of such amendment), each Parent SEC Document

filed pursuant to the 1933 Act, the 1934 Act and the Sarbanes-Oxley Act did not contain any untrue statement of a material fact or omit

to state any material fact required to be stated therein or necessary in order to make the statements made therein, in the light of the

circumstances under which they were made, not misleading.

(d) Parent

and each of its officers are in compliance in all material respects with the applicable provisions of the Sarbanes-Oxley Act. The management

of Parent has complied in all material respects with Rule 13a-15 or 15d-15 under the 1934 Act, and designed, and maintained at all times

since the Applicable Date, disclosure controls and procedures to ensure that material information relating to Parent, including its consolidated

Subsidiaries, is recorded, processed and made known on a timely basis to the management of Parent and any other individuals responsible

for the preparation of the Parent’s filings with the SEC. Since the Applicable Date, no executive officer of Parent has failed

to make the certifications required of such executive officer under Sections 302 or 906 of the Sarbanes-Oxley Act with respect to the

Parent SEC Documents.

Section

5.7 Brokers. Except

for Centerview Partners LLC, whose fees will be paid by Parent, there is no investment banker, broker, finder or other intermediary that

has been retained by or is authorized to act on behalf of Parent who might be entitled to any fee or commission from the Company or any

of its Affiliates upon consummation of the Transactions.

Section

5.8 Financing.

(a) Parent

has delivered to the Company a true, complete and correct copy of the fully executed debt commitment letter, together with any related

fee letters (in the case of the fee letters, redacted solely for confidential provisions related to the amount or percentage basis points

of fees (including in “flex” terms) and other commercially sensitive economic terms), dated as of the date of this Agreement,

by and among the Debt Financing Sources party thereto and Parent, providing for debt financing as described therein (together with all

exhibits, schedules and annexes thereto, the “Debt Commitment Letter”), pursuant to which, upon the terms and subject

to the conditions set forth therein, the Debt Financing Sources party thereto have agreed to lend amounts set forth therein (the “Debt

Financing”).

(b) As

of the date of this Agreement, the Debt Commitment Letter is in full force and effect and constitutes the valid, binding and enforceable

obligation of Parent and, to the knowledge of Parent, the other parties thereto, enforceable in accordance with its terms, subject to

the Bankruptcy and Equity Exception. As of the date of this Agreement, there are no conditions precedent related to the funding of the

full amount of the Debt Financing, other than the conditions precedent expressly set forth in the Debt Commitment Letter. As of the date

of this Agreement, the Debt Commitment Letter has not been amended or modified in any respect, and the respective commitments contained

therein have not been terminated, reduced, withdrawn or rescinded in any respect and, to the knowledge of Parent, except as expressly

permitted under Section 7.6(a), no such termination, reduction, withdrawal or rescission is contemplated by Parent, or any other

party thereto. As of the date of this Agreement, except for the Debt Commitment Letter and the related fee letter, there are no side

letters or other Contracts or arrangements (written or oral) related to the funding or investing, as applicable, of the financing contemplated

pursuant to the Debt Commitment Letter other than as expressly set forth in the Debt Commitment Letter furnished to the Company pursuant

to this Section 5.7.

of the date hereof, assuming the satisfaction of the conditions precedent in Section 9.1 and Section 9.2, Parent has no

reason to believe that (i) any of the conditions precedent expressly set forth in the Debt Commitment Letter that are required to be

satisfied on or prior to the Closing Date will not be satisfied on a timely basis or (ii) the Debt Financing in the aggregate amounts

contemplated by the Debt Commitment Letter to be funded on the Closing Date will not be available to Parent on the Closing Date, and,

to the Parent’s Knowledge, there does not exist any fact or event as of the date hereof that would reasonably be expected to cause

such conditions to funding not to be satisfied.

(d) Parent

or an Affiliate of Parent on its behalf has fully paid or caused to be paid any and all commitments or other fees and amounts required

by the Debt Commitment Letter to be paid on or prior to the date of this Agreement, and, to the Parent’s Knowledge, there does

not exist any fact or event as of the date hereof that would reasonably be expected to make any of the assumptions or any of the statements

set forth in the Debt Commitment Letter inaccurate in any material respect or that would reasonably be expected to cause the Debt Commitment

Letter to be ineffective.

(e) Assuming

(x) the Debt Financing is funded in accordance with the Debt Commitment Letter (including after giving effect to any “flex”

provisions) and (y) satisfaction of all of the conditions to the obligations of Parent set forth in Section 9.1 and Section

9.2, proceeds from the Debt Financing when aggregated together with other sources of immediately available funds, will provide Parent

with cash proceeds on the Closing Date sufficient to enable Parent to perform all of its obligations under this Agreement and to consummate

the Transactions. Each of Parent and Merger Subsidiary affirms that it is not a condition to the Closing or to any of its other obligations

under this Agreement that the Parent and Merger Subsidiary obtain financing for, or related to, any of the Transactions.

Section

5.9 Solvency. Assuming

(i) the satisfaction of the conditions to Parent’s obligation to consummate the Merger, (ii) the accuracy of the representations

and warranties set forth in Article 4 of this Agreement (for this purpose, such representations and warranties shall be true and

correct in all material respects) and (iii) after giving effect to the Transactions, any alternative financing, the payment of the aggregate

Merger Consideration, any repayment or refinancing of debt contemplated in this Agreement and the payment of all related fees and expenses,

the Surviving Corporation, on a consolidated basis and taken as a whole, will be Solvent as of the Effective Time and immediately after

the consummation of the Transactions. For purposes of this Agreement, “Solvent” when used with respect to any Person, together

with its Subsidiaries on a consolidated basis and taken as a whole, means that, as of any date of determination, (A) the amount of the

“fair saleable value” of the assets of such Persons will, as of such date, exceed (1) the value of all “liabilities

of such Persons, including contingent and other liabilities,” as of such date, as such quoted terms are generally determined in

accordance with Applicable Laws of the United States governing determinations of the insolvency of debtors, and (2) the amount that will

be required to pay the probable liabilities of such Person on its existing debts (including a reasonable estimate of the amount of all

contingent liabilities) as such debts become absolute and matured, (B) such Persons will not have, as of such date, an unreasonably small

amount of capital to carry on their businesses as presently conducted and (C) such Persons will be able to pay their liabilities, including

contingent and other liabilities, as they become absolute and mature.

Section

5.10 Ownership of Company Stock. Parent

and its Affiliates (as such term is defined in Rule 13d-3 promulgated under the 1934 Act) do not directly or indirectly beneficially

own (as such term is defined in Rule 13d-3 promulgated under the 1934 Act) five percent (5%) or more of the outstanding shares of Company

Stock or other securities of the Company (assuming for this purpose the full exercise of any options, warrants or other rights to acquire

Company Stock or other securities of the Company held by such persons).

Section

5.11 Stockholder and Management Arrangements. As

of the date hereof, other than this Agreement, the Voting Agreements and any ancillary agreements entered into hereunder or thereunder,

neither Parent or Merger Subsidiary nor any of their respective Affiliates is a party to any Contract, or has authorized, made or entered

into, or committed or agreed to enter into, any formal or informal arrangements or other understandings (whether or not binding) with

any stockholder, director, officer, employee or other Affiliate of the Company or any of its Subsidiaries (a) relating to (i) this Agreement

or the Transactions; (ii) the Company or (iii) the Surviving Corporation or any of its Subsidiaries, businesses or operations (including

as to continuing employment) from and after the Effective Time; or (b) pursuant to which (i) any such holder of shares of Company Stock

would be entitled to receive consideration of a different amount or nature than the Merger Consideration in respect of such holder’s

shares of Company Stock; or (ii) any Person (including any stockholder, director, officer, employee or other Affiliate of the Company)

has agreed to provide, directly or indirectly, equity investment to Parent, Merger Subsidiary or the Company to finance any portion of

the Transactions.

Section

5.12 Exclusivity of Representations and Warranties;

(a)

No Other Representations and Warranties. Each of Parent

and Merger Subsidiary, on behalf of itself and its Subsidiaries, acknowledges and agrees that, except for the representations and warranties

expressly set forth in Article 4 or in any certificate delivered by the Company pursuant to this Agreement: (i) neither the Company

nor any of its Subsidiaries (or any other Person) makes, or has made, any representation or warranty relating to the Company, its Subsidiaries

or any of their businesses, operations or otherwise in connection with this Agreement or the Transactions; (ii) no Person has been authorized

by the Company, any of its Subsidiaries or any of its or their respective Representatives to make any representation or warranty relating

to the Company, its Subsidiaries or any of their businesses or operations or otherwise in connection with this Agreement or the Transactions,

and if made, such representation or warranty must not be relied upon by Parent, Merger Subsidiary or any of their respective Representatives

as having been authorized by the Company, any of its Subsidiaries or any of its or their respective Representatives (or any other Person);

and (iii) the representations and warranties made by the Company in this Agreement are in lieu of and are exclusive of all other representations

and warranties, including any express or implied or as to merchantability or fitness for a particular purpose, and the Company hereby

disclaims any other or implied representations or warranties, notwithstanding the delivery or disclosure to Parent, Merger Subsidiary

or any of their respective Representatives of any documentation or other information (including any financial information, supplemental

data or financial projections or other forward-looking statements).

(b) No

Reliance. Each of Parent and Merger Subsidiary, on behalf of itself and its Subsidiaries, acknowledges and agrees that, except for

the representations and warranties expressly set forth in Article 4, it is not acting (including, as applicable, by entering into

this Agreement or consummating the Transaction) in reliance on: (i) any other representation or warranty, express or implied; (ii) any

estimate, projection, prediction, data, financial information, memorandum, presentation or other materials or information provided or

addressed to Parent, Merger Subsidiary or any of their respective Representatives, including any materials or information made available

in the electronic data room hosted by or on behalf of the Company in connection with the Merger, in connection with presentations by

the Company’s management or in any other forum or setting; or (iii) the accuracy or completeness of any other representation, warranty,

estimate, projection, prediction, data, financial information, memorandum, presentation or other materials or information.

Article

Covenants of the Company

The

Company agrees that:

Section

6.1 Conduct of the Company.

(a) Except

as required by Applicable Law, as expressly contemplated by this Agreement, or as set forth in Section 6.1 of the Company Disclosure

Schedule, from the date hereof until the Effective Time (or such earlier date and time on which this Agreement is terminated pursuant

to Article 10), unless Parent otherwise consents in writing (such consent not to be unreasonably withheld, conditioned or delayed),

the Company shall, and shall cause each of its Subsidiaries to, use commercially reasonable efforts to (i) conduct its business in the

ordinary course consistent with past practices and (ii) maintain and preserve intact its business organization, to retain the services

of its present officers and key employees, and to preserve the good will of its customers, suppliers and other Persons with whom it has

business relationships; provided, however, that no action taken or omitted to be taken by the Company or any of its Subsidiaries

with respect to the matters specifically addressed by Section 6.1(b) shall be deemed to be a breach of this Section 6.1(a)

unless such action would constitute a breach of Section 6.1(b).

(b) Except

with the prior written consent of Parent (which consent shall not be unreasonably withheld, conditioned or delayed), as expressly contemplated

by this Agreement, as set forth in Section 6.1 of the Company Disclosure Schedule, or as required by Applicable Law, from the

date hereof until the Effective Time (or such earlier date and time on which this Agreement is terminated pursuant to Article 10),

the Company shall not, nor shall it permit any of its Subsidiaries to:

(i) amend,

modify, waive or otherwise alter its certificate of incorporation, bylaws or other similar organizational documents;

(ii) (A)

split, combine or reclassify any shares of its capital stock, (B) make, declare, set aside or pay any dividend or other distribution

(whether in cash, stock or property or any combination thereof) in respect of its capital stock, except for dividends by any of its wholly-owned

Subsidiaries to the Company or to any other wholly-owned Subsidiary of the Company or (C) redeem, repurchase or otherwise acquire or

offer to redeem, repurchase, or otherwise acquire any Company Securities or any Company Subsidiary Securities;

(iii) (A)

issue, authorize, grant, sell, transfer, pledge or otherwise dispose of or encumber any Company Securities, Company Subsidiary Securities

or any securities convertible or exchangeable into or exercisable for any Company Securities or Company Subsidiary Securities, including

any options, warrants, stock appreciation rights, shares of restricted stock, restricted stock units, performance-based restricted stock

units, in each case other than issuance of (x) any shares of Company Stock upon exercise of any Company Options that are outstanding

as of the date of this Agreement, or (y) any Company Subsidiary Securities to the Company or any other Subsidiary of the Company; or

(B) amend, modify or waive any material terms of any Company Securities, Company Subsidiary Securities or any options, warrants, restricted

stock units, performance-based restricted stock units, restricted stock or other rights to acquire any shares of its capital stock or

any securities convertible or exchangeable into or exercisable for any shares of its capital stock (including, for the avoidance of doubt,

by reducing the exercise price and/or extending the expiration date of any such options, warrants or other rights);

(iv) directly

or indirectly acquire or purchase (by merger, consolidation, acquisition of stock or assets or otherwise) any corporation or partnership

or other business organization, or a material amount of the assets, securities, properties, interests or businesses of such Person, other

than (A) pursuant to Contracts existing as of the date hereof or (B) the purchase of raw materials, supplies, equipment or other similar

assets in the ordinary course of business;

(v) merge,

consolidate, statutorily convert, transfer, continue, domesticate or redomesticate the Company or any of its Subsidiaries with any Person

or otherwise or adopt a plan of complete or partial liquidation or resolutions providing for a complete or partial liquidation, dissolution,

restructuring, recapitalization or other reorganization of the Company or any of its Subsidiaries;

(vi) directly

or indirectly sell, lease, license, pledge transfer or otherwise dispose of or encumber (whether by merger, consolidation, other business

combination, sale or otherwise) all or any material portion of its assets, securities, properties, interests or businesses, other than

(A) pursuant to Contracts existing as of the date hereof, (B) the sale of inventory in the ordinary course of business, (C) the sale

or transfer of aged or obsolete inventory, or (D) assets or properties sold, leased or transferred pursuant to this clause (D) having

a value of less than $250,000 individually or $1,000,000 in the aggregate;

(vii) make

any material loans, advances or capital contributions to, or investments in, any other Person, other than (A) in connection with actions

permitted by Section 6.1(b)(iv), (B) extensions of credit to customers in the ordinary course of business, (C) advances to directors,

officers and other employees for travel and other business-related expenses, in each case in the ordinary course of business and in compliance

with the Company’s (or applicable Subsidiary of the Company’s) policies related thereto, or (D) loans, advances or capital

contributions to, or investments in, wholly-owned Subsidiaries of the Company;

(viii) (A)

incur any Indebtedness or issue any debt securities, (B) assume, guarantee or endorse, or otherwise become liable or responsible for

(whether directly, contingently or otherwise), any Indebtedness of any Person (other than a wholly owned Subsidiary of the Company),

or (C) redeem, repurchase, cancel or otherwise acquire any Indebtedness (directly, contingently or otherwise), except in each case for

(1) letters of credit issued for the benefit of Company customers (2) capital leases, or (3) other Indebtedness or guarantees having

a value of less than $250,000 individually or $1,000,000 in the aggregate, in each case, incurred in the ordinary course of business

consistent with past practices;

(ix) other

than as required by an Employee Plan as in effect on the date hereof and disclosed to Parent, (A) grant, announce or accelerate the vesting

or payment of any compensatory equity award or increase any severance or termination pay (or amend any existing severance pay or termination

arrangement) or grant any retention bonus or enter into any retention arrangement, in each case for the benefit of any of the employees,

directors, or other service providers of the Company or its Subsidiaries, (B) establish, adopt, terminate or materially amend any Employee

Plan (other than general changes to the Company’s health and welfare plans made during the open enrollment process in the ordinary

course of business) or any service, consulting, deferred compensation or other similar Contract (or any Contract which, if in existence

as of the date hereof, would constitute an Employee Plan), (C) increase compensation or bonus opportunity payable or to become payable

or benefits provided under an Employee Plan or otherwise to a current or former employee of the Company or its Subsidiaries with annual

base salary of less than $200,000, in each case except for increases in the ordinary course of business with respect, or (D) terminate

(other than for cause) the employment of, furlough or temporarily layoff or hire or promote any officer, director, employee or consultant,

unless such hiring is in the ordinary course of business consistent with past practice and is with respect to officers, directors, employees

or consultants having an annual base salary not to exceed $200,000;

(x) change

the Company’s accounting policies, practices, principles methods or procedures, except as required by concurrent changes in GAAP

or in Regulation S-X of the 1934 Act;

(xi) make,

change or revoke any material Tax election, adopt or change any accounting method for Tax purposes, agree to any extension or waiver

of the statute of limitations relating to a material amount of Taxes, file any amendment to any material Tax Return in respect of Taxes,

enter into any “closing agreement” described in Section 7121 of the Code, surrender any right to claim a material Tax refund,

or settle or compromise any material Tax liability;

(xii) waive,

release, assign, settle or compromise any material rights, claims or Proceeding involving or against the Company or any of its Subsidiaries,

other than any such settlement that involves no remedies other than the payment of monetary damages not in excess of $250,000 individually

or $1,000,000 in the aggregate;

(xiii) (A)

other than new Contracts with customers or suppliers entered into in the ordinary course of business consistent with past practice, enter

into any Contract that, if in existence on the date of this Agreement, would have been a Material Contract or (B) materially modify or

amend or terminate any Material Contract (other than, in each case, the expiration or renewal of any Material Contract in accordance

with its terms);

(xiv) except

as provided for in the Company’s budget for such fiscal year (a correct and complete copy of which has been provided to Parent,

or which will be provided to Parent for any subsequent fiscal year), make or authorize any capital expenditures in excess of $1,000,000,

individually or in the aggregate, or authorize any capital expenditure that would result in post-Closing obligations of the Surviving

Company in excess of $1,000,000, individually or in the aggregate;

(xv) waive

or release any noncompetition, non-solicitation, nondisclosure, noninterference, non-disparagement or similar obligations of any current

or former officer, employee or consultant, except, solely in respect of rank-and-file non-management current or former employees or consultants,

in the ordinary course of business consistent with past practices, or forego enforcement of any such obligations under any existing agreement

or arrangement;

(xvi) (A)

negotiate, modify, extend, or enter into any Labor Agreement or (B) recognize or certify any labor union, labor organization, works council,

or group of employees as the bargaining representative for any Company Employees; or

(xvii) agree,

resolve or commit to do any of the foregoing.

For

the avoidance of doubt, nothing contained in this Agreement shall give Parent, directly or indirectly, the right to control or direct

the operations of the Company, the Company’s business, or any employee of the Company prior to the Closing Date.

Section

6.2 Company Stockholder Meeting. (a)

The Company and Parent shall coordinate in good faith with respect to establishing a record date to be used for determining Company stockholders

entitled to vote at the Company Stockholder Meeting in accordance with the Company organizational documents, including running a broker

search(es) following initial submission to the SEC of the preliminary Proxy Statement. Promptly following the Clearance Date, the Company

shall by resolutions of the Company Board cause a meeting of its stockholders (the “Company Stockholder Meeting”)

to be duly called and held as soon as reasonably practicable (but in no event later than forty-five (45) days after the Clearance Date)

for the purpose of obtaining the Company Stockholder Approval. Once established, the Company shall not change the record date for the

Company Stockholder Meeting without the prior written consent of Parent (such consent not to be unreasonably withheld, delayed or conditioned)

or as required by Applicable Law. Subject to ‎Section 6.3, the Company Board shall (i) include the Company Board Recommendation

in the Proxy Statement, (ii) use its reasonable best efforts, including engaging a nationally recognized proxy solicitation firm pursuant

to a written engagement letter with customary terms (including with respect to compensation payable to the proxy solicitation firm) to

solicit or cause to be solicited from its stockholders proxies in favor of the adoption of this Agreement and to obtain the Company Stockholder

Approval, and (iii) otherwise comply with all Applicable Laws relating to such meeting. Notwithstanding anything to the contrary in this

Agreement, to the fullest extent permitted by Applicable Law, the Company shall not adjourn or postpone the Company Stockholder Meeting

without the prior written consent of Parent; provided, however,

if on a date for which the Company Stockholder Meeting is scheduled, the Company has not received proxies representing a sufficient number

of shares of Company Stock to constitute a quorum and to obtain the Company Stockholder Approval, whether or not a quorum is present,

nothing will prevent the Company from postponing or adjourning the Company Stockholder Meeting, after consultation with Parent: (i) for

up to ten (10) Business Days, to allow additional solicitation of votes in order to obtain the Company Stockholder Approval; (ii) if

there are holders of an insufficient number of shares of the Company Stock present or represented by proxy at the Company Stockholder

Meeting to constitute a quorum at the Company Stockholder Meeting; (iii) if the Company is required to postpone or adjourn the Company

Stockholder Meeting by applicable Law or a request from the SEC or its staff; or (iv) in order to give the Company’s stockholders

sufficient time to evaluate any information or disclosure that the Company has sent to the Company’s stockholders or otherwise

made available to the Company’s stockholders (including in connection with any Adverse Recommendation Change in accordance with

this Agreement), as reasonably determined to be necessary by the Company Board, after consultation with Parent and outside legal counsel.

To the fullest extent permitted by Applicable Law, the Company shall, if requested by Parent, postpone or adjourn the Company Stockholder

Meeting (A) if there are holders of an insufficient number of shares of the Company Stock present or represented by proxy at the Company

Stockholder Meeting to constitute a quorum at the Company Stockholder Meeting or (B) to allow additional solicitation of votes in order

to obtain the Company Stockholder Approval. The Company shall, unless there has been an Adverse Recommendation Change (to the extent

permitted under Section 6.3), use reasonable best efforts to cooperate with Parent and keep Parent reasonably informed regarding

its solicitation efforts and voting results following the dissemination of the Proxy Statement to its stockholders. Without the prior

written consent of Parent, the adoption of this Agreement and the Transactions (including the Merger) shall be the only matter (other

than procedural matters including stockholder approval of golden parachute compensation and adjournments) that the Company shall propose

to be acted on at the Company Stockholder Meeting. Except as otherwise expressly provided in this Agreement, the Company’s obligations

pursuant to this Section 6.2, including the Company’s obligation to hold the Company Stockholder Meeting, shall not be affected

by the notice, commencement, public proposal, public disclosure or communication to the Company, Parent or any other Person of any purchase

or acquisition of the Company by any Person, or the making of an Adverse Recommendation Change.

Section

6.3 No Solicitation; Other Offers.

(a) General

Prohibitions. Except as expressly permitted by Section 6.3(b), from the date hereof until the Effective Time, neither the

Company nor any of its Subsidiaries shall, nor shall the Company or any of its Subsidiaries authorize or permit any of its or their respective

directors, officers, employees, consultants, investment bankers, attorneys, accountants and other advisors or representatives (collectively,

“Representatives”) to, directly or indirectly, (i) solicit, initiate or induce, or knowingly take any action to facilitate,

assist in or encourage the submission or announcement of, any Acquisition Proposal, (ii) enter into or participate in any discussions

or negotiations with, furnish any non-public information relating to the Company or any of its Subsidiaries to, or afford access to the

business, properties, assets, personnel, books or records of the Company or any of its Subsidiaries to any Third Party or its Representatives

in connection with or in furtherance of any Acquisition Proposal, (iii) (A) fail to make, or withdraw or qualify or modify in a manner

adverse to Parent, the Company Board Recommendation, (B) adopt, approve, endorse, recommend or otherwise declare advisable (or propose

to adopt, approve, endorse, recommend or otherwise declare advisable) any Acquisition Proposal (it being understood that it shall be

considered a modification of the Company Board Recommendation adverse to Parent if (1) any Acquisition Proposal structured as a tender

or exchange offer is commenced and the Company Board fails to publicly recommend against, acceptance of such tender or exchange offer

by the Company stockholders in any solicitation or recommendation statement on Schedule 14D-9 filed by the Company with the SEC in connection

with such tender offer or exchange offer, or (2) any Acquisition Proposal is publicly announced (other than by the commencement of a

tender or exchange offer) and the Company Board fails to issue a public press release within ten (10) Business Days of such public announcement

providing that the Company Board reaffirms the Company Board Recommendation), (C) make any public statement inconsistent with the Company

Board Recommendation or (D) fail to include the Company Board Recommendation in the Proxy Statement (any of the foregoing in this clause

(iii), an “Adverse Recommendation Change”), (iv) accept, approve, recommend or enter into any agreement in principle,

merger agreement, acquisition agreement, option agreement, letter of intent, memorandum of understanding, or other similar agreement,

arrangement or understanding (whether or not written or oral, binding or non-binding) relating to an Acquisition Proposal (other than

an Acceptable Confidentiality Agreement) (any such agreement, an “Alternative Acquisition Agreement”), or (v) resolve,

agree, publicly propose or publicly announce an intention to do any of the foregoing.

(b) Exceptions.

(i) Exception

for Diligence and Discussions. Notwithstanding Section 6.3(a) or any other provision of this Agreement, if, after the date

hereof and prior to obtaining the Company Stockholder Approval, the Company or any of its Representatives has received a bona fide,

written Acquisition Proposal that is not a result of a breach of this Section 6.3, then, subject to the Company’s compliance

with the provisions of this Section 6.3(b), (x) the Company and its Representatives may make inquiries solely for the purpose

of clarifying the terms of such Acquisition Proposal and (y) if the Company Board, acting reasonably and in good faith, has determined,

based on the information then available and (1) after consultation with the Company’s financial advisor and outside legal counsel,

that such Acquisition Proposal constitutes or would reasonably be expected to lead to a Superior Proposal and (2) after consultation

with the Company’s outside legal counsel, the failure by the Company to take such action would be reasonably likely to be inconsistent

with its fiduciary duties under applicable Law, then the Company and its Representatives may (A) engage in negotiations or discussions

with the Third Party making such Acquisition Proposal and its Representatives and (B) furnish to such Third Party or its Representatives

non-public information relating to the Company and its Subsidiaries and afford access to the business, properties, assets, personnel,

books and records of the Company and its Subsidiaries pursuant to an Acceptable Confidentiality Agreement; provided that all such

information (to the extent that such information has not been previously provided or made available to Parent) is provided or made available

to Parent, as the case may be, prior to or substantially concurrently with the time it is provided or made available to such Third Party

or its Representatives. From and after the date hereof, the Company shall promptly (and in any event within twenty-four (24) hours) after

such determination advise Parent in writing if the Company determines to begin providing information or engaging in discussions or negotiations

relating to any Acquisition Proposal pursuant to this Section 6.3(b). Furthermore and notwithstanding any other provision of this

Agreement, except as expressly permitted by this Section 6.3, from the date hereof until the Effective Time, the Company shall

not, and shall cause its Subsidiaries and its and their respective Representatives not to, directly or indirectly, (1) terminate or grant

a waiver, amendment or release under any “standstill” or similar provisions (including provisions that restrict or prohibit

the making or soliciting of any offer or proposal), (2) grant any waiver, amendment or release under any Takeover Laws, or (3) resolve,

agree or publicly propose to do any of the foregoing.

(ii) Exception

for Superior Proposal. Notwithstanding any other provision of this Agreement, but subject to compliance with this Section 6.3,

at any time prior to obtaining the Company Stockholder Approval, if (A) the Company has received a bona fide, written Acquisition

Proposal that is not a result of a breach of this Section 6.3 and (B) the Company Board, acting reasonably and in good faith,

has determined, based on the information then available and (1) after consultation with the Company’s financial advisor and outside

legal counsel, that such Acquisition Proposal constitutes a Superior Proposal and (2) after consultation with the Company’s outside

legal counsel, the failure by the Company to take such action would be reasonably likely to be inconsistent with its fiduciary duties

under applicable Law, then the Company Board may make an Adverse Recommendation Change with respect to such Superior Proposal and/or

cause the Company to terminate this Agreement pursuant to and in accordance with ‎Section 10.1(d) and enter into a definitive

Alternative Acquisition Agreement in respect of such Superior Proposal.

(iii) Exception

for Intervening Events. Notwithstanding any other provision of this Agreement, but subject to compliance with Section 6.3(c),

at any time prior to obtaining the Company Stockholder Approval, if the Company Board, acting reasonably and in good faith, has determined,

based on the information then available and after consultation with the Company’s outside legal counsel, that the failure to take

such action would be reasonably likely to be inconsistent with its fiduciary duties under Applicable Law, the Company Board may, in response

to an Intervening Event, make an Adverse Recommendation Change.

(iv) Compliance

with Rule 14e-2(a). In addition, nothing contained herein shall prevent the Company Board from (i) complying with Rule 14e-2(a) under

the 1934 Act with regard to an Acquisition Proposal so long as any action taken or statement made to so comply is consistent with this

Section 6.3 or (ii) issuing a customary “stop, look and listen” disclosure or similar communication of the type contemplated

by Rule 14d-9(f) under the 1934 Act; provided that the foregoing shall in no way eliminate or modify the effect that any such

disclosure or communication would otherwise have under this Agreement or permit the Company Board to effect an Adverse Recommendation

Change except in accordance with Section 6.1(b)(ii) or Section 6.1(b)(iii).

Notices.

(i) At

any time until the Effective Time, the Company shall notify Parent promptly (and in any event no later than within one (1) Business Day)

after receipt by the Company (or any of its Representatives) of (A) any Acquisition Proposal, (B) any request for non-public information

relating to the Company or any of its Subsidiaries or for access to the business, properties, assets, personnel, books or records of

the Company or any of its Subsidiaries by any Third Party that could reasonably be expected to make, or has made, an Acquisition Proposal,

or (C) any discussions or negotiations that are sought to be initiated or continued with the Company or any of its Subsidiaries or any

of its or their respective Representatives from any Person (other than Parent or Merger Subsidiary or their Affiliates) with respect

to any Acquisition Proposal, including in such notification, a copy (if in writing) of documents and other materials or written summary

of material terms (if oral) relating to such expression of interest, proposal, offer or request for information, and the identity of

the Person from which such expression of interest, proposal, offer or request for information was received. The Company shall keep Parent

reasonably informed, on a reasonably prompt basis, of the status of any such Acquisition Proposal (including any copies (if in writing)

of documents and other materials or written summaries of material terms (if oral) of any proposed agreements and amendments or modifications

thereto, and a copy of any other documents provided by the relevant counterparty relating thereto) and the status of any discussions

or negotiations regarding any such Acquisition Proposal, and in the case of any material modification to the terms of any such Acquisition

Proposal, the Company shall notify Parent of such material modification promptly (and in any event within one (1) Business Day) of the

Company’s or any of its Subsidiaries’ or any of its or their respective Representatives’ knowledge of any such material

modification.

(ii) Prior

to taking any action described in Section 6.3(b)(ii) or Section 6.3(b)(iii), the Company shall notify Parent of its intent

to take such proposed action, which notice shall specify, as applicable, the (A) the basis for such proposed action, (B) identity of

the Person making any Superior Proposal and describe the material terms and conditions thereof in reasonable detail (including any proposed

draft Alternative Acquisition Agreement) or (C) describe in reasonable detail the facts, events, changes or developments in circumstances

giving rise to an Intervening Event. After delivery of such notice, the Company shall, and shall cause its Representatives to, negotiate

with Parent and its Representatives (to the extent Parent desires to do so) reasonably and in good faith for a period ending at 11:59

p.m. (New York City time) on the fourth (4th) Business Day immediately following the date of such notice (the “Notice

Period”) in furtherance of making commercially reasonable amendments or modifications to the terms and conditions of this Agreement

such that (x) the Superior Proposal giving rise to such notice would no longer constitute a Superior Proposal or (y) the Intervening

Event giving rise to such notice would no longer provide the basis for an Adverse Recommendation Change. If the financial or other material

terms of the relevant Acquisition Proposal are materially amended or modified, then the Company will deliver to Parent a new notice pursuant

to this clause (ii), except that the Notice Period shall instead end at 11:59 p.m. (New York City time), on the second (2nd)

Business Day immediately following the date such new notice is delivered to Parent (but no such new notice will shorten the initial Notice

Period). Notwithstanding anything to the contrary in this Agreement, the Company shall not take any action described in Section 6.1(b)(ii)

or Section 6.1(b)(iii) unless, after the end of the Notice Period, the Company’s Board of Directors, acting reasonably and

in good faith, has determined, (1) after consultation with the Company’s financial advisor and outside legal counsel and taking

into account any amendments or modifications to the terms and conditions of the Agreement proposed by Parent, that such Acquisition Proposal

continues to constitute a Superior Proposal and (2) after consultation with the Company’s outside legal counsel, the failure to

take such action would be reasonably likely to be inconsistent with its fiduciary duties under applicable Law.

(iii) Notwithstanding

anything to the contrary in this Agreement, the giving of a notice required by or otherwise complying with this Section 6.3(c)

shall not constitute an Adverse Recommendation Change.

(d) Application

of this Provision to Representatives. Any violation of the restrictions on the Company set forth in this ‎Section 6.3

by any Representative of the Company or any of its Subsidiaries shall be a breach of this ‎‎Section 6.3 by the Company.

(e) Obligation

to Terminate Discussions. Subject to this Section 6.3, on the date hereof, the Company and its Subsidiaries shall, and shall

cause its and their respective directors and officers, and shall instruct its and their respective Representatives (including the Company’s

financial advisor and its Representatives) to, (i) cease immediately and cause to be terminated any and all existing activities, discussions

or negotiations, if any, with any Third Party and its Representatives with respect to any Acquisition Proposal, (ii) cease providing

any information to any Third Party or its Representatives with respect to the Company or any of its Subsidiaries, or their respective

businesses, properties, assets, personnel, books or records, in connection with any Acquisition Proposal, (iii) promptly request that

all copies of all confidential information that the Company or any of its Representatives have distributed or made available to any such

Third Party in connection with their consideration of any Acquisition Proposal (and all analyses and other materials prepared by or on

behalf of such Third Party that contains, reflects or analyzes that information) be promptly destroyed or returned to the Company, to

the extent required by any confidentiality or similar agreement with such Third Party, and (iv) cause any physical or virtual data room

to no longer be accessible to or by any such Third Party or its Representatives. The Company shall promptly inform its and its Subsidiaries’

Representatives of the Company’s obligations under this ‎Section 6.3.

(f) Certain

Definitions. As used in this Agreement, the following terms shall have the following meanings:

(i) “Acceptable

Confidentiality Agreement” means a confidentiality agreement that (A) is in effect as of the date hereof or (B) is effected

after the date hereof and contains provisions (including confidentiality and use terms) that are no less favorable in any substantive

respect to the Company than those contained in the Confidentiality Agreement (other than with respect to any standstill or similar provision);

provided that such confidentiality agreement does not contain provisions that (A) prohibit the Company from providing any information

to Parent in accordance with Section 6.3 or otherwise prohibit the Company from complying with its obligations under this Agreement,

including the provisions of Section 6.3, or (B) require the Company to negotiate exclusively with any party thereto;

(ii) “Intervening

Event” means a fact, event, change or development in circumstances that materially affects the business, assets or operations

of the Company and its Subsidiaries, taken as a whole, and that (A) was not known, or reasonably foreseeable by, to the Company Board

on or prior to the date hereof (or, if known or reasonably foreseeable, the consequences or magnitude of which were not known, or reasonably

foreseeable by, to the Company Board on or prior to the date hereof), and becomes known to the Company Board prior to obtaining the Company

Stockholder Approval and (B) does not involve or relate to (1) an Acquisition Proposal, (2) any changes in the market price or trading

volume of the Company, (3) any changes in the Company’s credit ratings or (4) the Company meeting, failing to meet, or exceeding

published or unpublished revenue or market consensus earnings projections, in each case, in and of itself; provided, that the

underlying causes of any of the changes referred to in the foregoing clauses (2) through (4) may be considered and taken into account

for determining whether an Intervening Event has occurred, to the extent not otherwise excluded from this definition; and

(iii) “Superior

Proposal” means a bona fide written Acquisition Proposal that (A) is received after the date of this Agreement, (B)

is for at least a majority of the outstanding shares of Company Stock or all or substantially all of the consolidated assets of the Company

and its Subsidiaries that (i) is on terms that the Company Board, acting reasonably and in good faith, has determined, after considering

the advice of the Company’s financial advisor and outside legal counsel and taking into account all the terms and conditions of

the Acquisition Proposal, are more favorable to the Company’s stockholders than the terms of this Agreement, (ii) is reasonably

likely to be consummated on the proposed terms (taking into account any legal, regulatory, financial and other aspects of such Acquisition

Proposal that the Company Board considers relevant), and (iii) for which financing, to the extent required, is then committed or reasonably

likely to be available.

Section

6.4 Access to Information. Subject

to Applicable Law and the Confidentiality Agreement, from the date hereof until the earlier to occur of the Effective Time and the termination

of this Agreement pursuant to Article 10, upon reasonable advance notice, the Company shall (i) afford Parent and its Representatives

reasonable access during normal business hours to the offices, properties, personnel, and books and records of the Company and its Subsidiaries;

and (ii) furnish to Parent and its Representatives such financial and operating data and other information concerning the business and

operations of the Company and its Subsidiaries as Parent and its Representatives may reasonably request; provided,

that the Company shall not be obligated to provide such access or furnish such data or other information pursuant to this Section

6.4 if the Company determines, in its reasonable judgment, that doing so would reasonably be expected to (A) violate Applicable Law

or any Contract to which the Company or any Subsidiary thereof is a party (provided that the Company shall use its commercially reasonable

efforts to provide such access or make such disclosure in a manner that does not violate such Applicable Law or Contract, including using

commercially reasonable efforts to obtain any necessary third-party consents), (B) waive the protection of an attorney-client privilege,

attorney work product protection or other legal privilege (provided that the Company shall use its commercially reasonable efforts to

allow for such access or disclosure (or as much of it as possible) in a manner that does not result in a loss of such privilege), (C)

be adverse to the interests of the Company or any of its Subsidiaries in any pending or threatened Proceeding against any member of the

Parent Group or (D) involve documents or information relating to (x) the Company’s interactions with other prospective buyers of

the Company that occurred prior to the date of this Agreement, (y) the Company’s evaluation or negotiation of this Agreement or

the Transactions, or (z) the Company’s analysis, valuation, or consideration of the Transactions. Any investigation conducted by

Parent and its Representatives pursuant to this Section 6.4 shall be conducted in a manner that does not (i) unreasonably interfere

with the conduct of the business or operations of the Company or any of its Subsidiaries or (ii) create an unreasonable risk of damage

or destruction to any property or assets of the Company or any of its Subsidiaries. Any access to the offices or other properties of

the Company or any of its Subsidiaries granted pursuant to this Section 6.4 will be subject to the Company’s and its Subsidiaries’

reasonable security measures and insurance requirements, and will not include the right of Parent or any of its Representatives to (and

neither Parent nor its Representative shall) conduct or cause to be conducted any sampling, testing or other invasive investigation of

the air, soil, soil gas, surface water, groundwater, building materials or other environmental media. The terms and conditions of the

Confidentiality Agreement will apply to any information obtained by Parent or any of its Representatives in connection with any investigation

conducted pursuant to the access contemplated by this Section 6.4.

Section

6.5 Resignations. At

the written request of Parent, the Company shall cause any director or officer of the Company or any director or officer of any of the

Company’s Subsidiaries to resign in such capacity, with such resignations to be effective as of the Effective Time and to be delivered

to Parent at or prior to the Closing.

Section

6.6 Payoff Letters; Lien Releases; Transaction Expenses.

(a) At

or prior to the Closing, the Company shall use its commercially reasonable efforts to, no less than seven (7) days prior to the anticipated

Closing Date, obtain and deliver to Parent (x) customary payoff letters executed by the holders of Indebtedness set forth in Section

6.6(a) of the Company Disclosure Schedule, and (y) any termination statements on Form UCC-3 or other releases and terminations reasonably

necessary to evidence the satisfaction and release of all Liens and guarantees on the assets or properties of the Company or any Subsidiary

of the Company.

(b) The

Company shall use its commercially reasonable efforts to deliver to Parent, at least three (3) Business Days prior to the Closing Date,

invoices from the vendors set forth in Section 6.6(b) of the Company Disclosure Schedule to evidence the full payment and satisfaction

of such transaction expenses as of the Closing.

Section

6.7 Financing Cooperation.

(a) Prior

to the Closing, the Company and its Subsidiaries shall use their reasonable best efforts, and shall cause their respective officers,

directors, employees and representatives to use their reasonable best efforts, to provide such customary cooperation as may be reasonably

requested by Parent in connection with the Debt Financing and is customarily provided for borrowers in financings of the type contemplated

by the Debt Commitment Letter, at Parent’s sole expense, including, without limitation, using reasonable best efforts to: (i) participate

in a reasonable number of meetings, presentations and due diligence and other sessions with the Debt Financing Sources or other potential

providers of the Debt Financing at reasonable times and upon reasonable notice to be agreed, (ii) provide assistance with the preparation

of bank information memoranda, lender presentations and similar materials required in connection with the Debt Financing and execute

and deliver one or more customary representation or authorization letters with respect to the foregoing in form and substance reasonably

satisfactory to the Company, (iii) reasonably assist Parent in the preparation of definitive financing documents with respect to the

Debt Financing, (iv) provide reasonably promptly to Parent and its Debt Financing Sources such additional financial and other pertinent

information regarding the Company and its Subsidiaries that is readily available or in their possession and customary for financing of

the type similar to the Debt Financing, in each case, as is reasonably requested in connection with the Debt Financing, (v) execute and

deliver reasonable and customary certificates and other documentation required by the Debt Financing Sources and the definitive financing

documents with respect to the Debt Financing, subject to the occurrence of the Closing and solely by such officers that remain with the

Company after the Closing, (vi) reasonably facilitate the pledging of collateral, including taking all actions reasonably necessary to

establish bank and other accounts and blocked account agreements in connection with the foregoing; provided, that any obligations

contained in all such agreements and documents shall be executed and effective no earlier than the Closing, (vii) provide at least five

(5) Business Days prior to the Closing Date all documentation and other information about the Company and its Subsidiaries as is required

by bank regulatory authorities under applicable “know-your-customer” and anti-money laundering rules and regulations, including

the USA PATRIOT Act and, as applicable, any beneficial ownership regulations, to the extent requested in writing by Parent at least ten

(10) Business Days prior to the Closing Date, (viii) [reserved], (ix) cooperate in satisfying the conditions precedent set forth in the

Debt Commitment Letter or any definitive financing documents relating to the Debt Financing to the extent satisfaction thereof requires

the cooperation, or is within the control of, the Company and its Subsidiaries or their respective representatives and (x) taking customary

organizational company actions, subject to and only effective upon the occurrence of the Closing, reasonably requested by Parent to permit

the consummation of the Debt Financing. The conditions precedent set forth in Section 9.2(a), as applied to the Company’s

obligations under this Section 6.7, shall be deemed to be satisfied unless the financing contemplated by the Debt Commitment Letter

has not been obtained as a direct result of the Company’s failure to undertake reasonable best efforts with respect to its obligations

under this Section 6.7, taken as a whole.

(b) Notwithstanding

anything to the contrary, neither the Company, any of its Subsidiaries, nor any of their respective officers, directors, employees or

representatives, will be required to (i) adopt resolutions to authorize the Debt Financing or execute and deliver any definitive financing

documents, in each case, the effectiveness of which is not conditioned upon the occurrence of the Closing (other than the representation

or authorization letters described in clause (a)(ii) above), or cause any definitive financing documents to be signed by any officer

or director of the Company or any of its Subsidiaries that is not contingent on the occurrence of the Closing, (ii) take any action that

would reasonably be expected to conflict with, or violate, any of the Company’s or its Subsidiaries’ organization documents

or applicable law or result in a breach of the terms of this Agreement, (iii) (A) pay any commitment fee or other similar fee in connection

with the Debt Financing prior to the Closing or (B) incur any other liability or obligation in connection with the Debt Financing prior

to the Closing for which it will not be reimbursed or indemnified by or on behalf of Parent on or prior to the Closing Date, (iv) provide

access to or disclose information that the Company determines could jeopardize any attorney-client privilege of, or conflict with in

any material respect any confidentiality requirements applicable to, the Company or any of its Affiliates, (v) cooperate or take other

actions in connection to the Debt Financing to the extent it would interfere unreasonably with the business or operation of the Company

or any of its Subsidiaries, (vi) consent to any grant of any Lien on or security interest in the assets of the Company or any of its

Subsidiaries the effectiveness of which is not conditioned upon the occurrence of the Closing or the pre-filing of UCC-1 financing statements

prior to the Closing in connection therewith or (vii) prepare (x) pro forma financial information, including pro forma cost savings,

synergies, capitalization or other pro forma adjustments desired to be incorporated into any pro forma financial information or (y) projections,

risk factors or other forward-looking statements relating to all or any component of the Debt Financing.

of the Company, the Company’s Subsidiaries and their respective Representatives shall be required to take any action that would

subject such Person to actual or potential liability, to bear any cost or expense or to pay any commitment or other similar fee or make

any other payment or incur any other liability or provide or agree to provide any indemnity prior to the Closing in connection with their

performance of their respective obligations under this Section 6.7. Parent will indemnify and hold harmless the Company and its

Subsidiaries and their respective officers, directors, employees and representatives from and against all liabilities, losses, damages,

claims, costs, expenses, interest, awards, judgments and penalties actually suffered or incurred by any of them in connection with the

performance of their respective obligations under this Section 6.7, in each case, except for any such liabilities, losses, damages,

claims, costs, expenses, interest, awards, judgments and penalties that arise from the bad faith, gross negligence or fraud of, or Willful

Breach by, the Company or any of its Subsidiaries or any of their respective officers, directors, employees or representatives. Parent

will promptly (and in any event, within ten (10) Business Days) upon written request by the Company, reimburse the Company and its Subsidiaries

for all reasonable and documented out-of-pocket costs and expenses incurred by the Company or its Subsidiaries in connection with the

cooperation contemplated by this Section 6.7.

(d) The

Company hereby consents to the use of its and its Subsidiaries’ logos in connection with the Debt Financing; provided that such

logos are used solely in a manner that is not intended to, nor reasonably likely to, harm or disparage the Company or any of its Subsidiaries

or the reputation or goodwill thereof.

Article

Covenants of Parent

Parent

agrees that:

Section

7.1 Conduct of Parent. Parent

shall not, and shall cause its Subsidiaries not to, from the date of this Agreement to the Effective Time, take any action or fail to

take any action that is intended to, or would reasonably be expected to, individually or in the aggregate, prevent, materially delay

or materially impede the ability of Parent and Merger Subsidiary to consummate the Merger or the other Transactions.

Section

7.2 Obligations of Merger Subsidiary. Parent

shall execute a written consent approving and adopting this Agreement and the Transactions in its capacity as the sole stockholder of

Merger Subsidiary and take all other actions necessary to cause Merger Subsidiary to perform its obligations under this Agreement and

to consummate the Merger and the other Transactions on the terms and conditions set forth in this Agreement.

Section

7.3 Voting of Shares. Parent

shall vote all shares of Company Stock beneficially owned by it or any of its Subsidiaries in favor of the approval and adoption of this

Agreement and the Transactions at the Company Stockholder Meeting.

Section

7.4 Director and Officer Liability.

(a) For

six (6) years after the Effective Time, Parent shall cause to be maintained in effect provisions in the Surviving Corporation’s

certificate of incorporation and bylaws (or in such documents of any successor to the Surviving Corporation) regarding elimination of

liability of directors and officers, indemnification of officers, directors and employees and advancement of expenses, in each case,

existing in favor of the present and former officers, directors and employees of the Company (each, an “Indemnified Person”)

in respect of acts or omissions occurring at or prior to the Effective Time, that are no less advantageous to the intended beneficiaries

than the corresponding provisions in existence in the Company’s certificate of incorporation and bylaws on the date of this Agreement.

(b) Prior

to the Effective Time, the Company shall or, if the Company is unable to, Parent shall cause the Surviving Corporation as of the Effective

Time to, obtain and fully pay the premium for the non-cancellable extension of the directors’ and officers’ liability coverage

of the Company’s existing directors’ and officers’ insurance policies and the Company’s existing fiduciary liability

insurance policies (collectively, “D&O Insurance”), in each case for a claims reporting or discovery period of

at least six (6) years from and after the Effective Time with respect to any claim related to any period or time at or prior to the Effective

Time (including in connection with this Agreement or the transactions or actions contemplated hereby) from an insurance carrier with

the same or better credit rating as the Company’s current insurance carrier with respect to D&O Insurance with terms, conditions,

retentions and limits of liability that are no less favorable than the coverage provided under the Company’s existing policies

with respect to any actual or alleged error, misstatement, misleading statement, act, omission, neglect, breach of duty or any matter

claimed against a director or officer of the Company or any of its Subsidiaries by reason of him or her serving in such capacity at or

prior to the Effective Time. If the Company or the Surviving Corporation for any reason fail to obtain such “tail” insurance

policies as of the Effective Time, the Surviving Corporation shall continue to maintain in effect, for a period of at least six (6) years

from and after the Effective Time, the D&O Insurance in place as of the date hereof with respect to claims arising out of or relating

to events that occurred before or at the Effective Time, with the Company’s current insurance carrier or with an insurance carrier

with the same or better credit rating as the Company’s current insurance carrier with respect to D&O Insurance with terms,

conditions, retentions and limits of liability that are no less favorable than the coverage provided under the Company’s existing

policies as of the date hereof (but excluding cyber ransomware coverage), or the Surviving Corporation shall purchase from the Company’s

current insurance carrier or from an insurance carrier with the same or better credit rating as the Company’s current insurance

carrier with respect to D&O Insurance comparable D&O Insurance for such six-year period with terms, conditions, retentions and

limits of liability that are no less favorable than as provided in the Company’s existing policies as of the date hereof (but excluding

cyber ransomware coverage); provided that in no event shall Parent or the Surviving Corporation be required to expend for such

policies pursuant to this sentence an aggregate amount in excess of 300% of the amount per annum the Company paid in its last full fiscal

year, which amount is set forth in ‎Section 7.4(b) of the Company Disclosure Schedule; and provided further that if

the aggregate premiums of such insurance coverage exceed such amount, the Surviving Corporation shall be obligated to obtain a policy

with the greatest coverage available, with respect to matters occurring prior to the Effective Time, for a cost not exceeding such amount.

Parent, the Surviving Corporation or any of its successors or assigns (i) consolidates with or merges with or into any other Person and

shall not be the continuing or surviving Person of such consolidation or merger, or (ii) transfers or conveys all or substantially all

of its properties and assets to any Person, then, and in each such case, to the extent necessary, proper provision shall be made so that

the successors and assigns of Parent or the Surviving Corporation, as the case may be, shall assume the obligations set forth in this

‎Section 7.4.

(d) The

rights of each Indemnified Person under this ‎Section 7.4 shall be in addition to any rights such Person may have under the

certificate of incorporation or bylaws of the Company or any of its Subsidiaries, or under the TBOC or any other Applicable Law or under

any agreement of any Indemnified Person with the Company or any of its Subsidiaries, and nothing herein shall modify, abridge, narrow

or restrict any such rights. These rights shall survive consummation of the Merger and are intended to benefit, and shall be enforceable

by, each Indemnified Person, and such Indemnified Person’s successors, heirs and representatives. Each Indemnified Person shall

be a third-party beneficiary of this Section 7.4. The Surviving Corporation shall pay all reasonable expenses, including reasonable

attorneys’ fees, that may be incurred by any Indemnified Person in enforcing its indemnity, advancement and other rights under

this Section 7.4. Notwithstanding any other provision of this Agreement, this Section 7.4 shall survive the consummation

of the Merger indefinitely and shall be binding, jointly and severally, on all successors and assigns of Parent and the Surviving Corporation,

and shall be enforceable by each Indemnified Person and their successors, heirs or representatives.

Section

7.5 Employee Matters.

(a) For

a period of twelve (12) months following the Effective Time (the “Continuation Period”), Parent shall provide or cause

the Surviving Corporation to provide to individuals who are Company Employees immediately prior to the Effective Time and continue to

be employed immediately following the Effective Time by Parent or the Surviving Corporation or any Subsidiary thereof (each, a “Continuing

Employee”), (i) annual base salary or wages and incentive opportunities that are each no less favorable in the aggregate than

those provided to such Continuing Employees immediately prior to the Effective Time, and (ii) other employee benefits that are substantially

comparable in the aggregate to those provided to such Company Employees by the Company or the applicable Subsidiary immediately prior

to the Effective Time.

(b) With

respect to each employee benefit plan, program or arrangement established or maintained by Parent, Surviving Corporation or any of its

respective affiliates (each, a “Surviving Corporation Plan”) to the extent such plan replaces coverage under a comparable

Employee Plan in which such Continuing Employee participates immediately prior to the Effective Time, Parent shall, and shall cause the

Surviving Corporation to, give or cause to be given to each Continuing Employee credit for eligibility, vesting and level of benefit

purposes (but not for benefit accrual under any defined benefit plan or retiree welfare benefit plan or vesting under any equity compensation

plan or change in control plan), for each Continuing Employee’s service with the Company or any of its Subsidiaries (as well as

service with any predecessor employer of the Company or any such Subsidiary, to the extent service with the predecessor employer is recognized

by the Company or such Subsidiary) prior to the Effective Time; provided, however, that such service need not be recognized to

the extent that such recognition would result in any duplication of benefits for the same period of service.

respect to any Surviving Corporation Plan that is a welfare benefit plan in which any Continuing Employee is eligible to participate

after the Effective Time, Parent shall, and shall cause the Surviving Corporation to, use commercially reasonable efforts (i) waive all

limitations as to preexisting conditions and exclusions and waiting periods and actively-at-work requirements with respect to participation

and coverage requirements applicable to such employees and their eligible dependents and beneficiaries, to the extent such limitations

were waived, satisfied or did not apply to such employees or eligible dependents or beneficiaries under the corresponding welfare Employee

Plan in which such employees participated immediately prior to the Effective Time and (ii) provide Continuing Employees and their eligible

dependents and beneficiaries with credit for any co-payments and deductibles paid in the calendar year prior to the Effective Time in

satisfying any analogous deductible or out-of-pocket maximum requirements to the extent applicable under any such plan.

(d) With

respect to the annual cash-based bonus for calendar year 2026 (the “Annual Bonus”), the following provisions shall

apply:

(i) The

Surviving Corporation shall pay the Annual Bonus to each Continuing Employee in accordance with Parent’s past practice regarding

timing of annual bonus payments, which shall be no later than March 30, 2027 (the “Customary Payment Date”), subject

to such Continuing Employee’s continued employment through the Customary Payment Date, except as otherwise provided in clause (ii)

below. Subject to clause (ii) below, the Annual Cash bonus shall pay out at the greater of (x) actual achievement against performance

metrics, measured as of December 31, 2026 or (y) at target level, in either case less any portion of the annual cash-based bonuses previously

paid for 2026.

(ii) Notwithstanding

anything to the contrary in this Agreement or in any Employee Plan:

(1) In

the event that the Surviving Corporation terminates the employment of a Continuing Employee without cause after the Closing but prior

to December 31, 2026, the Surviving Corporation shall pay such terminated Continuing Employee a pro-rata portion of such Continuing Employee’s

Annual Bonus (less any portion of the annual cash-based bonuses previously paid in 2026) at target level, calculated based on the number

of days elapsed in 2026 through and including the date of such employee’s termination, divided by 365, with such pro-rata amount

to be paid on the later of the Customary Payment Date and the date the Separation Agreement becomes effective; or

(2) In

the event that the Surviving Corporation terminates the employment of a Continuing Employee without cause on or after January 1, 2027

but prior to the Customary Payment Date, the Surviving Corporation shall pay such terminated Continuing Employee the greater of (x) actual

achievement against performance metrics, measured as of December 31, 2026 or (y) at target level, less any portion of the annual cash-based

bonuses previously paid for 2026, with such amount to be paid on the later of the Customary Payment Date and the date the Separation

Agreement becomes effective.

The

payment of any Annual Bonus under this clause (ii) shall be subject to the Continuing Employee within sixty (60) days of the date such

Continuing Employee’s termination without cause (x) first signing and, if applicable, not revoking a separation agreement containing

a general release of claims and nondisparagement in favor of the Surviving Corporation and affiliated persons and entities (a “Separation

Agreement”) and (y) remaining in compliance with any continuing obligations to the Surviving Corporation and its affiliated

entities with respect to confidentiality, return of property, noncompetition, and nonsolicitation.

(iii) For

the avoidance of doubt, (x) no portion of the Annual Bonus shall be paid at or in connection with the Closing, and the consummation of

the Merger shall not, in and of itself, accelerate the payment or vesting of any Annual Bonus amount and (y) nothing in this Section

7.5(d) shall create Annual Bonus eligibility for a Continuing Employee who was not eligible for an Annual Bonus as of the Effective Date.

(e) With

respect to any Continuing Employees whose principal place of employment is outside of the United States, Parent’s obligations under

this Section 7.5(e) shall be modified to the extent necessary to comply with Applicable Law where such Company Employees primarily

perform their duties.

(f) The

provisions of this Section 7.5 are solely for the benefit of the parties to this Agreement, and no Company Employee, Continuing

Employee or any other Person (including any beneficiary or dependent thereof) shall be regarded for any purpose as a Third Party beneficiary

of this Agreement, and no provision of this Section 7.5 shall (i) be deemed to guarantee employment for any period of time for,

or preclude the ability of Parent, the Company, the Surviving Corporation or their respective Subsidiaries to terminate, any Continuing

Employee for any reason or (ii) create such rights in any such Persons in respect of any benefits that may be provided, directly or indirectly,

under any Employee Plan or any compensation or benefit plan, program, agreement or policy of Parent or any of its Subsidiaries. Nothing

herein shall be construed as an amendment to, modification, termination or establishment of, any Employee Plan or compensation or benefit

plan, program, agreement or policy of Parent or any of its Subsidiaries.

Section

7.6 Financing.

(a) Parent

and Merger Subsidiary shall use their reasonable best efforts to take (taking into account the expected time for Closing), or cause to

be taken, all actions and do, or cause to be done, all things, necessary or advisable to obtain, no later than the Closing Date, the

proceeds of the Debt Financing on the terms and conditions described in the Debt Commitment Letter, including (i) maintaining in effect

the Debt Commitment Letter in accordance with and subject to the terms and conditions set forth therein (it being understood that the

Debt Commitment Letter may be replaced or amended as provided below); (ii) negotiating definitive financing agreements with respect to

the Debt Financing consistent with the terms and conditions contained in the Debt Commitment Letter (including, as necessary, any “flex”

provisions); (iii) satisfying on a timely basis (or obtaining a waiver of) all conditions in the Debt Commitment Letter and the definitive

financing agreements for the Debt Financing applicable to Parent or its Affiliates; (iv) complying with the covenants applicable to them

in the Debt Commitment Letter and in the definitive financing agreements for the Debt Financing; and (v) upon the satisfaction of the

conditions contained in the Debt Commitment Letter, cause the Debt Financing Sources to fund the Debt Financing at the Closing. Other

than amendments, modifications or supplements to add lenders, lead arrangers, bookrunners, syndication agents or similar entities as

parties to the Debt Commitment Letter, prior to the Closing, Parent shall not, without the prior written consent (which shall not be

unreasonably withheld, conditioned or delayed) of the Company, agree to or permit any amendment or modification to, or any waiver of

any material provision or remedy under, the Debt Commitment Letter or definitive financing agreements with respect to the Debt Financing

if such amendment, modification, waiver or remedy (A) would change the conditions precedent set forth therein, change the timing of the

funding of the commitments thereunder, reduce the cash amount of the funding commitments thereunder, or otherwise affect the ability

of Parent and Merger Sub to enforce their rights under the Debt Commitment Letter or consummate the transactions contemplated by this

Agreement or the timing of the Closing, in each case, in a manner that would reasonably be expected to (1) make the funding of the Debt

Financing (or the satisfaction of the conditions to obtaining the Debt Financing) less likely to occur or (2) materially delay or prevent

the Closing, (B), would waive any provision or remedy under the Debt Commitment Letter, (C) would have the effect of causing the early

termination of the Debt Commitment Letter, or (D) would reasonable be expected to prevent, impede or materially delay the consummation

of the Transactions. Upon the reasonable written request of the Company prior to the Closing Date, Parent shall keep the Company informed

on a reasonably current basis and in reasonable detail of the status of its efforts to arrange the Debt Financing.

(b) In

the event that any portion of the Debt Financing becomes unavailable on the terms and conditions in the Debt Commitment Letter, or the

Debt Commitment Letter or any of the definitive financing agreements with respect to the Debt Financing shall be withdrawn, repudiated,

terminated or rescinded, regardless of the reason therefor, Parent will use its reasonable best efforts to obtain alternative debt financing

from the same or other sources on terms and conditions that are not less favorable in any material respect to Parent than those contained

in the Debt Commitment Letter assuming any “flex” rights have been exercised. Parent and Merger Sub shall promptly deliver

to the Company true and complete copies of any debt commitment letter and related fee letter associated therewith (in the case of any

such fee letter, redacted in a manner consistent with the fee letters delivered in connection with the Debt Commitment Letter) pursuant

to which any such alternative source shall have committed to provide any alternative financing. In the event any alternative financing

is obtained in accordance with this Section 7.6(b) (“Alternative Financing”), references in this Agreement

to the “Debt Financing” shall also be deemed to refer to such Alternative Financing, and if one or more commitment letters

or definitive financing agreements are entered into or proposed to be entered into in connection with such Alternative Financing, references

in this Agreement to the “Debt Commitment Letter” and the “definitive financing agreements” shall also be deemed

to refer to such commitment letters and definitive financing agreements relating to such Alternative Financing, and all obligations of

Parent pursuant to this Section 7.6 shall be applicable thereto to the same extent as Parent’s obligations with respect

to the Debt Financing.

to the Closing Date, Parent shall promptly notify the Company in writing (i) after it becomes aware of the occurrence of any material

breach or material default (or any event or circumstance that, with or without notice, lapse of time or both, would give rise to any

material breach or material default) by any party to the Debt Commitment Letter or definitive agreement related thereto, (ii) after it

becomes aware of the receipt by Parent or Merger Subsidiary or any of their Affiliates or Representatives of any notice or other communication

from any Person with respect to any (A) actual or potential material breach, material default, termination (other than in accordance

with its terms) or repudiation by any party to the Debt Commitment Letter or any definitive agreement related thereto or any provision

of the financing contemplated pursuant to the Debt Commitment Letter or any definitive agreement related thereto (including any proposal

by any lender named in the Debt Commitment Letter to withdraw, terminate or make a material change in the terms of (including the amount

of financing contemplated by) the Debt Commitment Letter) or (B) material dispute or disagreement between or among any parties to the

Debt Commitment Letter or any definitive agreement related thereto, and (iii) if for any reason Parent or Merger Subsidiary believes

in good faith that (A) there is (or there is reasonably likely to be) a material dispute or disagreement between or among any parties

to the Debt Commitment Letter or any definitive agreement related thereto or (B) there is a material possibility that it will not be

able to obtain all or any portion of the financing contemplated in the Debt Commitment Letter.

Article

Covenants of Parent and the Company

The

parties hereto agree that:

Section

8.1 Regulatory Authorizations and Consents.

(a) Subject

to the terms and conditions of this Agreement, (i) the Company and Parent shall use their reasonable best efforts to take, or cause to

be taken, all actions and to do, or cause to be done, all things necessary, proper or advisable under Applicable Law to consummate the

Transactions, including preparing and filing as promptly as practicable with any Governmental Authority or other Third Party all documentation

to effect all necessary filings, notices, petitions, statements, registrations, submissions of information, applications and other documents,

including under any applicable Antitrust Laws, and (ii) the Company shall use its reasonable best efforts, and Parent shall use its reasonable

best efforts to cooperate with the Company, to take, or cause to be taken, all actions and to do, or cause to be done, all things necessary,

proper or advisable, in obtaining and maintaining all approvals, consents, registrations, permits, authorizations and other confirmations

required to be obtained from any Governmental Authority or other Third Party that are necessary, proper or advisable to consummate the

Transactions.

(b) In

furtherance and not in limitation of the foregoing, each of Parent and the Company shall make an appropriate filing of a Notification

and Report Form pursuant to the HSR Act and any other filings set forth in Section 8.1(b) of the Company Disclosure Schedule with

respect to the Transactions as promptly as practicable and in any event within ten (10) Business Days of the date hereof and will respond

as promptly as practicable to any requests for additional information and documentary material from any Governmental Authority and to

take all other actions necessary to cause the expiration or termination of the applicable waiting periods under the HSR Act and Antitrust

Laws as soon as practicable. Parent will pay all filing fees under the HSR Act and Antitrust Laws. Neither party will, and each will

cause their respective Affiliates not to, take any action that would reasonably be expected to adversely affect or materially delay the

approval of any Governmental Authority with respect to the Transactions. Neither party will extend directly or indirectly any waiting

period under the HSR Act (including by withdrawing and refiling any filing pursuant to the HSR Act) or enter into any agreement with

a Governmental Authority to delay or not to consummate the transactions contemplated hereby, except upon mutual agreement by Parent and

the Company.

party to this Agreement shall promptly notify the other parties hereto of any oral or written communication it receives from any Governmental

Authority relating to the matters that are the subject of Section 8.1, permit the other parties hereto to review in advance any

written communication proposed to be made by such party (or its Representatives) to any Governmental Authority and provide the other

parties hereto with copies of all correspondence, filings or other written communications between them or any of their Representatives,

on the one hand, and any Governmental Authority, on the other hand, with respect to this Agreement, subject to appropriate limitations

on the exchange of competitively sensitive information consistent with Antitrust Laws (it being understood that such information will

be made available on an outside counsel basis only). No party to this Agreement shall agree to participate in any meeting or substantive

discussion with any Governmental Authority in respect of any such filings, investigation or other inquiry unless, to the extent reasonably

practicable, it consults with the other parties hereto in advance and, to the extent reasonably practicable and permitted by such Governmental

Authority, gives the other parties hereto the opportunity to attend and participate at such meeting. Subject to the Confidentiality Agreement

and to appropriate limitations on internal valuation or the exchange of competitively sensitive information consistent with Antitrust

Laws (it being understood that such information will be made available on an outside counsel basis only), the parties to this Agreement

will coordinate and cooperate fully with each other in exchanging such information and providing such assistance as the other parties

hereto may reasonably request in connection with the foregoing and in seeking the expiration or termination of any applicable waiting

period.

(d) Parent

will, and will cause its Affiliates to, undertake reasonable best efforts to ensure that no (x) requirement for any non-action, consent

or approval of the Federal Trade Commission, the Antitrust Division of the United States Department of Justice or other Governmental

Authority, (y) decree, judgment, injunction, temporary restraining order or any other order in any Proceeding, or (z) other matter relating

to any antitrust or competition law would preclude the Closing by the End Date. In furtherance of the foregoing, the reasonable best

efforts of the Company and Parent under this Section 8.1 shall require that either party, in connection with the receipt of any

regulatory approval, offer or agree to (i) sell or hold separate and agree to sell, divest, license or to discontinue or limit, before

or after the Closing, any assets, businesses, licenses, rights or interest in any assets or businesses of (or held by) Parent, the Company,

or any of their respective Affiliates (or to consent to any sale, or agreement to sell, license or discontinuance or limitation by Parent

or the Company, as the case may be, of any of its assets, businesses, licenses or rights, including those of their respective Affiliates)

or (ii) agree to any conditions relating to, or changes or restriction in, the operations of any such asset, businesses, licenses or

rights ((i) and (ii) hereafter, a “Divestiture Action”) to the extent necessary to prevent the issuance of an Order

or the establishment of any Law preliminarily or permanently restraining, enjoining or prohibiting the consummation of the Transactions

by the End Date. Notwithstanding anything herein to the contrary, in no event will Parent or any of its Affiliates be required to propose

or agree to (or to consent to the Company or any of its Subsidiaries proposing or agreeing to) any Divestiture Action that would, if

such Divestiture Action were taken, reasonably be expected, individually or in the aggregate with any other Divestiture Actions, to have

a materially adverse effect on the aggregate net benefits expected to be received by Parent arising from the Transactions.

(e) In

the event any claim, action, suit, investigation or other Proceeding by any Governmental Authority or other Person is commenced which

questions the validity or legality of the Transactions under Antitrust Laws, the parties hereto agree to cooperate and use reasonable

best efforts to defend against such claim, action, suit, investigation or other Proceeding and, if any decree, judgment, injunction or

other order is issued in any such action, suit or other Proceeding, to use reasonable best efforts to have such injunction or other order

vacated, lifted, reversed or overturned and to cooperate reasonably regarding any other impediment to the consummation of the Transactions.

Section

8.2 Proxy Statement and Registration Statement.

(a) As

soon as reasonably practicable following the date hereof, (i) the Company and Parent shall cooperate in preparing, and the Company shall

file with the SEC the Proxy Statement relating to the matters to be submitted to holder of Company Stock at the Company Stockholder Meeting,

and (ii) the Company and Parent shall cooperate in preparing, and Parent shall file with the SEC, the Registration Statement (of which

the Proxy Statement will be a part). The Company and Parent shall use reasonable best efforts to cause the Registration and the Proxy

Statement to be filed with the SEC no later than thirty (30) days following the date hereof. The Company shall cause the Proxy Statement,

and Parent shall cause the Registration Statement, to comply as to form and substance in all material respects with Applicable Law. Each

of the Company and Parent shall use reasonable best efforts to ensure that none of the information supplied by it, any of its controlled

Affiliates or its or their respective Representatives for inclusion or incorporation by reference in the Proxy Statement or the Registration

Statement shall, (A) in the case of the Proxy Statement, at the time of filing with the SEC, on the date of mailing to stockholders of

the Company, or at the time of the Company Stockholders Meeting, and (B) in the case of the Registration Statement, at the time of filing

with the SEC, contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary

in order to make the statements therein, in light of the circumstances under which they were made, not misleading, provided, that

(1) the Company assumes no responsibility with respect to information supplied by or on behalf of Parent, its Subsidiaries or its or

their respective Representatives for inclusion or incorporation by reference to the Proxy Statement or the Registration Statement, and

(2) Parent and Merger Subsidiary assume no responsibility with respect to any information supplied by or on behalf of the Company or

any of its Subsidiaries or its and their respective Representatives for inclusion or incorporation by reference in the Proxy Statement

or the Registration Statement.

(b) Parent

and the Company shall each use its commercially reasonable efforts to cause the Registration Statement to become effective under the

Securities Act as soon as practicable after such filing, and Parent shall use commercially reasonable efforts to keep the Registration

Statement effective as long as is necessary to consummate the Merger. The Company shall use commercially reasonable efforts to file with

the SEC and disseminate to the Company Stockholders the Proxy Statement in definitive form, as promptly as practicable after the date

on which the Registration Statement becomes effective (such date, the “Clearance Date”).

of the Company and Parent shall notify the other promptly upon the receipt of any written or oral requests by the SEC or its staff for

an amendment or supplement to the Proxy Statement or the Registration Statement, any receipt of or comments from the SEC or its staff

thereon, and responses thereto or requests by the SEC or its staff for additional information. Prior to filing or mailing the Proxy Statement

(or any amendment or supplement thereto) or filing the Registration Statement (or any amendment or supplement thereto), or responding

to any comments of the SEC with respect to any of the foregoing, each of the Company and Parent (i) will provide the other with a reasonable

opportunity to review and comment on such document or response (including the proposed final version of such document or response), (ii)

will include in such document or response all comments reasonably proposed by the other, and (iii) will not file or mail such document

or respond to the SEC prior to receiving the approval of the other, which approval shall not be unreasonably withheld, conditioned or

delayed; provided, however, that with respect to documents filed by a party that are incorporated by reference in the Proxy Statement

or the Registration Statement, this right of approval shall apply only with respect to information relating to the other party, its Subsidiaries

and its Affiliates, their business, financial condition or results of operations or the Transactions. If, prior to the Company Stockholder

Meeting, any event occurs with respect to Company or any Subsidiary of Company, on the one hand, or Parent or Merger Subsidiary, on the

other hand, or any change occurs with respect to information supplied by or on behalf of Company or Parent, respectively, for inclusion

in the Proxy Statement or the Registration Statement or any information relating to Company, Parent or any of their Representatives shall

be discovered by Company, Parent or Merger Subsidiary, that, in each case, is required to be described in an amendment of, or a supplement

to, the Proxy Statement or the Registration Statement, Company or Parent, as applicable, shall promptly notify the other of such event,

and Company and Parent shall cooperate in the prompt filing with the SEC of any necessary amendment or supplement to the Proxy Statement

or the Registration Statement so that the Proxy Statement or the Registration Statement would not include any misstatement of a material

fact or omit to state any material fact necessary to make the statements therein, in light of the circumstances under which they were

made, not misleading, and, as required by Applicable Law, in disseminating the information contained in such amendment or supplement

to Company’s stockholders.

(d) Parent

and the Company shall each make all necessary filings with respect to the Merger and the Transactions under the 1933 Act and 1934 Act

and applicable state securities laws and the rules and regulations thereunder, except qualifying to do business in any jurisdiction in

which it is not now so qualified or filing a general consent to service of process in any such jurisdiction. Parent will advise the Company,

promptly after it receives notice thereof, of the time when the Registration Statement has become effective or any supplement or amendment

has been filed, the issuance of any stop order or the suspension of the qualification of the Parent Common Stock issuable in connection

with the Merger for offer or sale in any jurisdiction. Parent will use commercially reasonable efforts to have any such stop order or

suspension lifted, reversed or otherwise terminated (and the Company will cooperate as may be reasonably requested by Parent in writing

in connection therewith).

Section

8.3 Public Announcements. Parent

and the Company have agreed to the text of the joint press release announcing the signing of this Agreement. Parent and the Company shall

consult with each other before issuing any press release, having any communication with the press (whether or not for attribution), making

any other public statement or scheduling any press conference or conference call with investors or analysts with respect to this Agreement

or the Transactions and, except in respect of any public statement or press release as may be required by Applicable Law or any listing

agreement with or rule of the Nasdaq Capital Market, shall not issue any such press release or make any such other public statement or

schedule any such press conference or conference call without the consent of the other party; provided that

this Section 8.3 shall not restrict the Company from taking any actions expressly permitted under this Agreement in connection

with any Acquisition Proposal or Intervening Event.

Section

8.4 Further Assurances. At

and after the Effective Time, the officers and directors of the Surviving Corporation shall be authorized to execute and deliver, in

the name and on behalf of the Company or Merger Subsidiary, any deeds, bills of sale, assignments or assurances and to take and do, in

the name and on behalf of the Company or Merger Subsidiary, any other actions and things to vest, perfect or confirm of record or otherwise

in the Surviving Corporation any and all right, title and interest in, to and under any of the rights, properties or assets of the Company

acquired or to be acquired by the Surviving Corporation as a result of, or in connection with, the Merger.

Section

8.5 Notices of Certain Events. To

the extent reasonably practicable and permitted by Applicable Law, each of the Company and Parent shall promptly notify the other of:

(a) any

notice or other communication from any Person alleging that the consent of such Person is or may be required in connection with the Transactions;

(b) subject

to Section 8.1, any notice or other communication from any Governmental Authority in connection with the Transactions; and

Proceeding commenced or threatened against or otherwise affecting the Company or any of its Subsidiaries that would reasonably be expected,

individually or in the aggregate, to be materially adverse to the Company and its Subsidiaries, taken as a whole.

Section

8.6 Section 16 Matters. Prior

to the Effective Time, the Company, the Company Board and Parent shall use reasonable best efforts as may be required to cause the Transactions

and any disposition of Company Stock (including derivative securities with respect to Company Stock) or acquisition of Parent Common

Stock, in connection with the Transactions by each individual who is subject to the reporting requirements of Section 16(a) of the 1934

Act with respect to the Company to be exempt under Rule 16b-3 promulgated under the 1934 Act.

Section

8.7 Transaction Litigation. The

Company shall notify Parent promptly of the commencement of any stockholder litigation brought or threatened in writing against the Company,

any of its Subsidiaries or any of their respective present or former directors or officers arising out of or relating to this Agreement

or the Transactions (“Transaction Litigation”) and shall keep Parent reasonably and promptly informed (including by

providing copies of all pleadings with respect thereto) with respect to the status thereof. The Company shall not settle or offer to

settle any Transaction Litigation without the prior written consent of Parent (such consent not to be unreasonably withheld, conditioned

or delayed). The Company shall (a) give Parent reasonable opportunity to participate in the defense or settlement of any Transaction

Litigation, (b) consult in good faith with Parent with respect to the defense, settlement and prosecution of any Transaction Litigation,

and (c) direct its counsel to consider in good faith Parent’s advice, comments, recommendations and suggestions relating to proposed

strategy and other significant decisions with respect to such Transaction Litigation. The Company shall not cooperate with any Person

that may seek to restrain, enjoin, prohibit or otherwise oppose the Transactions, and the Company shall consider in good faith Parent’s

advice and recommendations with respect to any such effort to restrain, enjoin, prohibit or otherwise oppose the Transactions.

Section

8.8 Takeover Laws. If

the restrictions on business combinations in any Takeover Law (or provision in the certificate of incorporation or bylaws of the Company)

becomes, or may purport to be, applicable to this Agreement or the Transactions, each of Parent, Merger Subsidiary and the Company and

the members of their respective Boards of Directors shall use their respective reasonable best efforts to grant such approvals and take

such actions as are necessary so that the Transactions may be consummated by the date required by Section 2.1(b) on the terms

and conditions contemplated hereby and otherwise act to lawfully eliminate the restrictions on business combinations contained in any

Takeover Law (or provision in the certificate of incorporation or bylaws of the Company).

Section

8.9 Stock Exchange Listing; Delisting and Deregistration.

(a) Parent

shall use commercially reasonable efforts to cause the shares of Parent Common Stock to be issued in connection with the Merger to be

listed on the Nasdaq Stock Market (“Nasdaq”), subject to official notice of issuance, prior to the Effective Time,

and the Company shall reasonably cooperate with Parent in connection therewith, including by providing all information reasonably requested

by Parent in connection therewith.

(b) During

the period between the date of this Agreement and the Effective Time, the Company shall cooperate with Parent and use its reasonable

best efforts to take, or cause to be taken, all actions, and do or cause to be done all things, reasonably necessary, proper or advisable

on its part under Applicable Laws and rules and policies of the Nasdaq Capital Market to enable the delisting by the Surviving Corporation

of the Company Stock from the Nasdaq Capital Market and the deregistration of the Company Stock under the 1934 Act as promptly as practicable

after the Effective Time, and in any event no more than the first Business Day that occurs ten (10) days after the Closing Date.

Article

Conditions to the Merger

Section

9.1 Conditions to the Obligations of Each Party.

The obligations of the Company, Parent and Merger Subsidiary to consummate the Merger are subject to

the satisfaction or waiver (where permissible pursuant to Applicable Law) of the following conditions:

(a) the

Company Stockholder Approval shall have been obtained;

(b) no

Governmental Authority of competent jurisdiction shall have enacted, issued, promulgated, enforced or entered any Applicable Law (whether

temporary, preliminary or permanent) that restrains, enjoins or otherwise prohibits the consummation of the Merger that is still in effect;

any applicable waiting periods (and any extensions thereof) applicable to the Transactions under the HSR Act, and any commitment to,

or agreement with, any Governmental Authority in the United States to delay the consummation of, or not to consummate before a certain

date, the transactions contemplated by this Agreement, shall have expired or been terminated, and (ii) any approvals, consents, registrations,

permits, authorizations and other confirmations required to be obtained from any Governmental Authority under Antitrust Laws shall have

been obtained or deemed obtained and shall remain in full force and effect.

(d) the

Registration Statement shall have been declared effective by the SEC under the Securities Act, and no stop order suspending the Registration

Statement shall have been issued by the SEC; and

(e) the

shares of Parent Common Stock to be issued in connection with the Merger shall have been approved for listing on Nasdaq, subject to official

notice of issuance.

Section

9.2 Conditions to the Obligations of Parent and Merger

Subsidiary

The obligations of Parent and Merger Subsidiary to consummate the Merger are subject to the satisfaction or waiver (where permissible

under Applicable Law) of the following further conditions:

(a) the

Company shall have performed in all material respects all of its obligations hereunder required to be performed by it at or prior to

the Effective Time;

(b) (i)

all of the representations and warranties of the Company contained in the first and second sentence of Section 4.5(a), the second

sentence of Section 4.5(b), and the first sentence of Section 4.5(c) shall have been true and correct in all respects as

of the date of this Agreement and shall be true and correct in all respects (except, with respect to the second sentence of Section

4.5(a) and the second sentence of Section 4.5(b), for any de minimis inaccuracies) at and as of the Effective Time as if made

at and as of such time (other than representations and warranties that by their terms address matters only as of another specified time,

which shall be true only as of such time), (ii) all of the representations and warranties of the Company contained in Section 4.1,

Section 4.2 and Section 4.23 (disregarding all materiality and Material Adverse Effect qualifications contained therein)

shall have been true and correct in all material respects as of the date of this Agreement and shall be true and correct in all material

respects at and as of the Effective Time as if made at and as of such time (other than representations and warranties that by their terms

address matters only as of another specified time, which shall be true only as of such time) and (iii) all of the other the representations

and warranties of the Company contained in this Agreement (disregarding all materiality and Material Adverse Effect qualifications contained

therein) shall have been true and correct as of the date of this Agreement and shall be true and correct at and as of the Effective Time

as if made at and as of such time (other than representations and warranties that by their terms address matters only as of another specified

time, which shall be true only as of such time), with only such exceptions as have not had and would not reasonably be expected to have,

individually or in the aggregate, a Material Adverse Effect;

the date of this Agreement, there shall not have been a Material Adverse Effect; and

(d) Parent

shall have received a certificate signed by an executive officer of the Company to the foregoing effect.

Section

9.3 Conditions to the Obligations of the Company.

The obligations of the Company to consummate the Merger are subject to the satisfaction or waiver (where

permissible under Applicable Law) of the following further conditions:

(a) each

of Parent and Merger Subsidiary shall have performed in all material respects all of its obligations hereunder required to be performed

by it at or prior to the Effective Time;

(b) (i)

all of the representations and warranties of Parent contained in Section 5.1, Section 5.2, and Section 5.7 shall

have been true and correct in all material respects as of the date of this Agreement and shall be true and correct in all material respects

at and as of the Effective Time as if made at and as of such time (other than representations and warranties that by their terms address

matters only as of another specified time, which shall be true only as of such time) and (ii) all of the other representations and warranties

of Parent contained in this Agreement (disregarding all materiality and Parent Material Adverse Effect qualifications contained therein)

shall have been true and correct in all material respects as of the date of this Agreement and shall be true and correct at and as of

the Effective Time as if made at and as of such time (other than representations and warranties that by their terms address matters only

as of another specified time, which shall be true only as of such time), with only such exceptions as have not had and would not reasonably

be expected to have, individually or in the aggregate, a Parent Material Adverse Effect; and

Company shall have received a certificate signed by an executive officer of Parent to the foregoing effect.

Article

Termination

Section

10.1 Termination. This

Agreement may be terminated and the Merger may be abandoned at any time prior to the Effective Time (notwithstanding receipt of the Company

Stockholder Approval) as follows:

(a) by

mutual written agreement of the Company and Parent;

(b) by

either the Company or Parent, if:

(i) the

Merger has not been consummated on or before July 29, 2027 (the “End Date”), which each of the Company and Parent

may extend to a date not later than January 29, 2028 if the conditions set forth in Section 9.1(b) (if the Applicable Law or Order

relates to Antitrust Laws) or Section 9.1(c) shall not have been satisfied prior to the End Date; provided that the right

to terminate this Agreement pursuant to this Section 10.1(b)(i) shall not be available to a party if the failure of the Merger

to be consummated by such time was primarily caused by the failure of such party to perform any of its obligations under this Agreement;

(ii) any

Applicable Law shall have been enacted, issued, promulgated, enforced or entered by any Governmental Authority of competent jurisdiction

that restrains, enjoins or otherwise prohibits consummation of the Merger, or any Order by a court or other Governmental Authority of

competent jurisdiction permanently restraining, enjoining or otherwise prohibiting consummation of the Merger shall have become final

and non-appealable; provided that the right to terminate this Agreement pursuant to this Section 10.1(b)(ii) shall not

be available to a party if issuance, enforcement or entry of any such Applicable Law or Order, or such Order becoming final and non-appealable,

was primarily caused by the failure of such party to perform any of its obligations under this Agreement;

(iii) at

the Company Stockholder Meeting (including any adjournment or postponement thereof), the Company Stockholder Approval shall not have

been obtained; or

Parent, if at any time prior to obtaining the Company Stockholder Approval, an Adverse Recommendation Change shall have occurred;

(d) by

the Company, if at any time prior to obtaining the Company Stockholder Approval, (i) the Company has received a Superior Proposal that

is not a result of a material breach of Section 6.3 and (ii) the Company concurrently enters into a definitive Alternative Acquisition

Agreement concerning such Superior Proposal and, simultaneously with such termination, the Company pays the Termination Fee payable pursuant

to Section 11.4;

(e) by

Parent if (i) there shall have been a breach of any covenant or agreement on the part of the Company set forth in this Agreement or (ii)

any representation or warranty of the Company set forth in Article 4 of this Agreement has become inaccurate, that would, in either

case, (A) result in the conditions set forth in Section 9.2(a) or Section 9.2(b) not being satisfied, and (B) such breach

is not curable by the End Date or, if earlier, within thirty (30) days, or, if curable, is not cured by the End Date or, if earlier,

within thirty (30) days of notice by Parent to the Company of such breach; provided, that the right to terminate this Agreement

pursuant to this Section 10.1(e) shall not be available to Parent if Parent or Merger Subsidiary is then in breach of any covenant,

agreement, representation or warranty contained in this Agreement which breach would result in a failure of a condition set forth in

Section 9.1 or Section 9.3;

(f) by

the Company if (i) there shall have been a breach of any covenant or agreement on the part of Parent or Merger Subsidiary set forth in

this Agreement or (ii) any representation or warranty of Parent and Merger Subsidiary set forth in Article 5 of this Agreement

has become inaccurate, that would, in either case, (A) result in the conditions set forth in Section 9.3(a) or Section 9.3(b)

not being satisfied, and (B) such breach is not curable by the End Date or, if earlier, within thirty (30) days, or, if curable, is not

cured by the End Date or, if earlier, within thirty (30) days of notice by the Company to Parent of such breach; provided, that

the right to terminate this Agreement pursuant to this Section 10.1(f) shall not be available to the Company if the Company is

then in breach of any covenant, agreement, representation or warranty contained in this Agreement which breach would result in a failure

of a condition set forth in Section 9.1 or Section 9.2; or

(g) by

the Company if (i) all of the conditions set forth in Section 9.1 and Section 9.2 (other than conditions that by their

nature are to be satisfied at the Closing, so long as such conditions are capable of being satisfied at such time as if such time were

the Closing) have been satisfied, (ii) Parent fails to consummate the Merger by the date on which Parent is required to consummate the

Closing pursuant to Section 2.1(b), and (iii) the Company has irrevocably confirmed to Parent in writing (that has not been withdrawn

or revoked) that (A) all of the conditions set forth in Section 9.1 and Section 9.3 (other than conditions that by their

nature are to be satisfied at the Closing, so long as such conditions are capable of being satisfied at such time as if such time were

the Closing) have been satisfied or, to the extent permissible, waived by the Company, and (B) the Company is prepared, willing and able

to consummate the Closing, (iv) the Company shall have given Parent written notice at least three (3) Business Days prior to such termination

stating the Company’s intention to terminate this Agreement pursuant to this Section 10.1(g) and (v) Parent fails to consummate

the Merger within three (3) Business Days following the delivery of such notice.

The

party desiring to terminate this Agreement pursuant to this ‎Section 10.1 (other than pursuant to ‎Section 10.1(a))

shall give written notice of such termination to the other party specifying the provisions hereof pursuant to which such termination

is being effected and describing the basis therefor in reasonable detail. Except as otherwise set forth above, any valid termination

of this Agreement by either the Company or Parent pursuant to Section 10.1 shall be effective immediately upon the delivery of

such written notice by the terminating party to the other party.

Section

10.2 Effect of Termination. If

this Agreement is validly terminated pursuant to Section 10.1, this Agreement shall become void and of no effect and the Transactions

shall be abandoned without liability of any party (or any stockholder or Representative of such party) to any other party hereto; provided

that:

(a) The

provisions of this ‎Section 10.2, the indemnification and reimbursement obligations in Section 6.7(c), Section 8.3,

and Article 11 (and the corresponding definitions of any defined terms used in each of those sections) shall survive any termination

hereof pursuant to ‎Section 10.1.

(b) Neither

the Company nor Parent shall be relieved or released from any liabilities or obligations (which the parties acknowledge and agree shall

not be limited to reimbursement of expenses or out-of-pocket costs, and may include the benefit of the bargain lost the non-breaching

party (taking into consideration, to extent proven, opportunity costs, the time value of money and, in the case of the Company as the

non-breaching party, the Merger Consideration payable to the Company’s stockholders) arising out of its Willful Breach or fraud

prior to such termination. For purposes of this Agreement, “Willful Breach” means a material breach of this Agreement

that is the consequence of a deliberate action or omission by any party if such party has actual knowledge that the taking of such action

or the failure to take such action would be a material breach of this Agreement.

Article

Miscellaneous

Section

11.1 Notices

All notices, requests and other communications to any party hereunder shall be in writing (including electronic mail (“e-mail”)

transmission, so long as a receipt of such e-mail is requested and received) and shall be given,

to the Company, to:

Sanara

MedTech Inc.

1200

Summit Avenue, Suite 414

Fort Worth, Texas 76102

Attention: Seth Yon

E-mail: syon@sanaramedtech.com

with

a copy (which shall not constitute notice) to:

Alston

& Bird LLP

One Atlantic Center

1201 West Peachtree Street

Atlanta, GA 30309

Attention: J. Mark Ray; Kyle G. Healy; Tyler W. Pate

E-mail: mark.ray@alston.com; kyle.healy@alston.com; tyler.pate@alston.com

to the Parent or Merger Subsidiary, to:

MiMedx

Group, Inc.

1775

West Oak Commons Ct. NE

Marietta, GA 30062

Attention: William “Butch” Hulse

E-mail: BHulse@mimedx.com

with

a copy (which shall not constitute notice) to:

Greenberg

Traurig, P.A.

401 East Las Olas Blvd.

Suite

2000

Fort Lauderdale, FL 33301

Attention: Flora Perez and Matthew Miller

E-mail: perezf@gtlaw.com; millerma@gtlaw.com

to such other address as such party may hereafter specify for the purpose by notice to the other parties hereto. All such notices, requests

and other communications shall be deemed received on the date of receipt by the recipient thereof if received prior to 5:00 p.m. on a

Business Day in the place of receipt. Otherwise, any such notice, request or communication shall be deemed to have been received on the

next succeeding Business Day in the place of receipt.

Section

11.2 No Survival of Representations, Warranties and

Agreements. The representations, warranties and agreements contained herein and in any certificate or

other writing delivered pursuant hereto shall not survive the Effective Time, except that any covenants and agreements that are to be

performed in whole or in part after the Effective Time shall survive the Effective Time for the longest period permitted by Texas law.

Section

11.3 Amendments and Waivers.

(a) Any

provision of this Agreement may be amended or waived prior to the Effective Time if, but only if, such amendment or waiver is in writing

and is signed, in the case of an amendment, by each party to this Agreement or, in the case of a waiver, by each party against whom the

waiver is to be effective; provided that after the Company Stockholder Approval has been obtained there shall be no amendment

or waiver that would require the further approval of the stockholders of the Company under the TBOC without such approval having first

been obtained.

(b) No

failure or delay by any party in exercising any right, power or privilege hereunder shall operate as a waiver thereof nor shall any single

or partial exercise thereof preclude any other or further exercise thereof or the exercise of any other right, power or privilege. The

rights and remedies herein provided shall be cumulative and not exclusive of any rights or remedies provided by Applicable Law.

Section

11.4 Expenses and Termination Fee.

(a) General.

Except as otherwise provided herein, all costs and expenses incurred in connection with this Agreement shall be paid by the party incurring

such cost or expense.

(b) Termination

Fee.

(i) If

this Agreement is validly terminated by Parent pursuant to Section 10.1(c), then the Company shall pay to Parent the Termination

Fee within two (2) Business Days after such termination, by wire transfer of immediately available funds to an account designated in

writing by Parent.

(ii) If

this Agreement is validly terminated by the Company pursuant Section 10.1(d), then the Company shall pay to Parent the Termination

Fee concurrently with and as a condition to such termination, by wire transfer of immediately available funds to an account designated

in writing by Parent.

(iii) If

(A) this Agreement is validly terminated by Parent or the Company pursuant to ‎Section 10.1(b)(i) or Section 10.1(b)(iii)

or by Parent pursuant to Section 10.1(e); provided that in the case of termination by the Company pursuant to ‎Section

10.1(b)(i), the failure of the Merger to be consummated by the End Date did not result from a breach by Parent of any covenant, agreement,

representation or warranty contained in this Agreement which breach has resulted in a failure of a condition set forth in Section

9.1 or Section 9.3, (B) after the date of this Agreement and (x) prior to such termination in the case of a termination pursuant

to Section 10.1(b)(i) or Section 10.1(e) or (y) prior to the Company Stockholder Meeting in the case of a termination pursuant

to Section 10.1(b)(iii), an Acquisition Proposal shall have been publicly announced or otherwise been communicated to the Company

or the Company’s stockholders (in either case, whether or not withdrawn), and (C) within twelve (12) months following the date

of such termination, (x) the Company shall have entered into an agreement, arrangement or understanding with respect to an Acquisition

Proposal which is subsequently consummated or (y) an Acquisition Proposal shall have been consummated (provided that, for purposes

of this clause ‎(C), each reference to “20%” in the definition of Acquisition Proposal shall be deemed to be a reference

to “50%”), then the Company shall pay to Parent the Termination Fee, in immediately available funds to an account designated

in writing by Parent, immediately prior to the consummation of such Acquisition Proposal.

(iv) “Termination

Fee” means $9,660,336.00.

(v) The

parties agree and acknowledge that in no event shall the Company be required to pay the Termination Fee on more than one occasion.

Termination Fee.

(i) If

this Agreement is validly terminated by the Company pursuant to ‎Section 10.1(g), then Parent shall pay to the Company the

Parent Termination Fee within two (2) Business Days after such termination, by wire transfer of immediately available funds to an account

designated in writing by the Company.

(ii) “Parent

Termination Fee” means $22,540,785.00.

(d) Each

party acknowledges that the agreements contained in this Section 11.4 are an integral part of the Transactions and that, without

these agreements, the other parties would not enter into this Agreement. Accordingly, if the Company fails promptly to pay any amount

due pursuant to ‎Section 11.4(b) and Parent commences a legal Proceeding against the Company to enforce this Agreement that

results in a judgment against the Company for such amount, or if Parent commences a legal Proceeding against the Company as contemplated

by Section 11.4(f) that results in a judgment for monetary damages against the Company, the Company shall also pay any costs and

expenses incurred by Parent in connection with such legal Proceeding, together with interest on the amount of any unpaid fee, judgment,

cost or expense at the publicly announced prime rate as published by the Eastern Edition of The Wall Street Journal (the “Prime

Rate”) from the date such fee, judgment, cost or expense was required to be paid to (but excluding) the payment date (collectively,

the “Parent Enforcement Expenses”). If Parent fails promptly to pay any amount due pursuant to Section 11.4(c)

and the Company commences a legal Proceeding against Parent to enforce this Agreement that results in a judgment against Parent for such

amount, or if the Company commences a legal Proceeding against Parent or Merger Subsidiary as contemplated by Section 11.4(e)

that results in a judgment for monetary damages against Parent or Merger Subsidiary, Parent shall also pay any costs and expenses incurred

by the Company in connection with such Proceeding, together with interest on the amount of any unpaid fee, judgment, cost or expense

at the Prime Rate from the date such fee, judgment, cost or expense was required to be paid to (but excluding) the payment date (collectively,

the “Company Enforcement Expenses”).

(e) Notwithstanding

anything to the contrary in this Agreement, in the event that Parent and Merger Subsidiary fail to effect the Closing as and when required

pursuant to Section 2.1(b) or otherwise breach this Agreement or fail to perform hereunder (whether willfully, intentionally,

unintentionally or otherwise), then, except for an order of specific performance prior to the termination of this Agreement as permitted

by Section 11.12, (i) the Company’s sole and exclusive remedy (whether at law, in equity, in contract, in tort or otherwise)

against (A) Parent and Merger Subsidiary, (B) the former, current and future holders of any equity, partnership or limited liability

company interest, controlling persons, directors, officers, employees, agents, attorneys, Affiliates, members, managers, general or limited

partners, stockholders or assignees of Parent or Merger Subsidiary or (C) any future holders of any equity, partnership or limited liability

company interest, controlling persons, directors, officers, employees, agents, attorneys, Affiliates, members, managers, general or limited

partners, stockholders or assignees of any of the foregoing (collectively, the “Parent Group”) in respect of this

Agreement, any agreement executed in connection herewith, and the transactions contemplated hereby and thereby shall be (I) to terminate

this Agreement in accordance with Article 10 and collect, if due, the Parent Termination Fee pursuant to Section 11.4(c)

(including any Company Enforcement Expenses) from Parent, and (II) following the termination of this Agreement by either party, the Company’s

right to seek monetary damages (including any Company Enforcement Expenses) from Parent in the event of Parent’s or Merger Subsidiary’s

Willful Breach or fraud prior to the termination of this Agreement and (ii) upon payment of such amounts, no member of the Parent Group

shall have any further liability or obligation relating to or arising out of this Agreement, any agreement executed in connection herewith,

or the transactions contemplated hereby or thereby; provided, that, if the Company accepts the Parent Termination Fee pursuant

to Section 11.4(c) (plus any Company Enforcement Expenses that may be owing Company) from Parent, the acceptance thereof by the

Company shall be deemed to be liquidated damages for any and all losses or damages suffered or incurred by the Company in connection

with this Agreement and the Transactions (including as a result of Parent’s or Merger Subsidiary’s Willful Breach or fraud),

and the Company shall not thereafter be entitled to bring or maintain any Proceeding or make any claim against Parent, Merger Subsidiary

or any other member of the Parent Group for monetary damages); and provided, further, that in no event will the Company

be entitled to (x) payment of both monetary damages and the Parent Termination Fee or (y) both (1) payment of any monetary damages and/or

the Parent Termination Fee and (2) a grant of specific performance of this Agreement or any other equitable remedy against Parent or

Merger Subsidiary that results in the Closing.

(f) Notwithstanding

anything to the contrary in this Agreement, in the event that the Company fails to effect the Closing as and when required pursuant to

Section 2.1(b) or otherwise breaches this Agreement or fails to perform hereunder (whether willfully, intentionally, unintentionally

or otherwise), then, except for an order of specific performance prior to the termination of this Agreement as permitted by Section

11.12, (i) Parent’s and Merger Subsidiary’s sole and exclusive remedy (whether at law, in equity, in contract, in tort

or otherwise) against (A) the Company and its Subsidiaries, (B) the former, current and future holders of any equity, partnership or

limited liability company interest, controlling persons, directors, officers, employees, agents, attorneys, Affiliates, members, managers,

general or limited partners, stockholders or assignees of the Company or its Subsidiaries or (C) any future holders of any equity, partnership

or limited liability company interest, controlling persons, directors, officers, employees, agents, attorneys, Affiliates, members, managers,

general or limited partners, stockholders or assignees of any of the foregoing (collectively, the “Company Group”)

in respect of this Agreement, any agreement executed in connection herewith and the transactions contemplated hereby and thereby shall

be (I) to terminate this Agreement in accordance with Article 10 and collect, if due, the Termination Fee pursuant to Section

11.4(b) (including any Parent Enforcement Expenses) from the Company, and (II) following the termination of this Agreement by either

party, Parent’s right to seek monetary damages from the Company in the event of the Company’s Willful Breach or fraud prior

to the termination of this Agreement and (ii) upon payment of such amounts, no member of the Company Group shall have any further liability

or obligation relating to or arising out of this Agreement, any agreement executed in connection herewith or the transactions contemplated

hereby or thereby; provided, that, if Parent accepts the Termination Fee pursuant to Section 11.4(b) (plus any Parent Enforcement

Expenses that may be owing Parent) from the Company, the acceptance thereof by Parent shall be deemed to be liquidated damages for any

and all losses or damages suffered or incurred by Parent in connection with this Agreement and the Transactions (including as a result

of the Company’s Willful Breach or fraud), and Parent shall not thereafter be entitled to bring or maintain any Proceeding or make

any claim against the Company, any of its Subsidiaries or any other member of the Company Group for monetary damages); and provided,

further, that in no event will Parent and Merger Subsidiary be entitled to (1) payment of both monetary damages and the Termination

Fee, or (2) both (x) payment of any monetary damages and/or the Termination Fee and (y) a grant of specific performance of this Agreement

or any other equitable remedy against the Company that results in the Closing.

Section

11.5 Binding Effect; Benefit; Assignment.

(a) Except

as set forth in Section 7.4 and Section 10.2(b), the parties agree that their respective representations, warranties and

covenants set forth in this Agreement are solely for the benefit of the other parties in accordance with and subject to the terms of

this Agreement. This Agreement is not intended to, and will not, confer upon any other Person any rights or remedies hereunder, except

(i) as set forth in or contemplated by Section 7.4; and (ii) from and after the Effective Time, the rights of the holders of shares

of Company Restricted Stock and Company Options to receive the Restricted Stock Consideration or Option Consideration as set forth in

Article 2, as applicable.

(b) No

party may assign, delegate or otherwise transfer any of its rights or obligations under this Agreement without the consent of each other

party hereto, except that Parent or Merger Subsidiary may transfer or assign its rights and obligations under this Agreement without

the consent of the Company, in whole or from time to time in part, (i) to one or more of their Affiliates at any time; (ii) as security

for any financing, including, without limitation, the Debt Financing, at any time; and (iii) after the Effective Time, to any Person;

provided that such transfer or assignment shall not relieve Parent or Merger Subsidiary of its obligations hereunder or enlarge,

alter or change any obligation of any other party hereto or due to Parent or Merger Subsidiary.

Section

11.6 Governing Law

This Agreement, and all Proceedings (whether in contract, in tort or otherwise) that may be based upon, arise out of or relate to this

Agreement, or the negotiation, execution or performance of this Agreement or the Transactions, shall be governed by and construed in

accordance with the laws of the State of Texas, without regard to the conflicts of law rules of such state.

Section

11.7 Jurisdiction. All

Proceedings (whether at law, in contract, in tort or otherwise) arising out of or relating to this Agreement, the negotiation, validity

or performance of this Agreement or the Transactions shall be heard and determined exclusively in Texas State court located in Dallas,

Texas or, to the extent such court does not have jurisdiction, the U.S. District Court for the Northern District of Texas (Dallas Division),

and the parties irrevocably submit to the exclusive jurisdiction of such court (and, in the case of appeals, the appropriate appellate

court therefrom), in any such Proceeding and irrevocably waive the defense of an inconvenient forum to the maintenance of any such Proceeding.

The consents to jurisdiction set forth in this paragraph shall not constitute general consents to service of process in the State of

Texas and shall have no effect for any purpose except as provided in this paragraph and shall not be deemed to confer rights on any Person

other than the parties hereto. The parties agree that service of any court paper may be made in any manner as may be provided under Applicable

Law or court rules governing service of process in such court. The parties hereto agree that a final judgment in any such Proceeding

shall be conclusive and may be enforced in other jurisdictions by suit on the judgment or in any other manner provided by Applicable

Law.

Section

11.8 WAIVER OF JURY TRIAL. EACH

OF THE PARTIES HERETO HEREBY IRREVOCABLY WAIVES ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY PROCEEDING ARISING OUT OF OR RELATED TO THIS

AGREEMENT, THE GUARANTEE OR THE TRANSACTIONS.

Section

11.9 Counterparts; Effectiveness. This

Agreement may be signed in any number of counterparts, each of which shall be an original, with the same effect as if the signatures

thereto and hereto were upon the same instrument. Any such counterpart, to the extent delivered by .pdf, .tif, .gif, .jpeg or similar

attachment to electronic mail (any such delivery, an “Electronic Delivery”) shall be treated in all manner and respects

as an original counterpart and shall be considered to have the same binding legal effect as if it were the original signed version thereof

delivered in person. No party hereto shall raise the use of Electronic Delivery to deliver a signature or the fact that any signature

or agreement or instrument was transmitted or communicated through the use of Electronic Delivery as a defense to the formation of a

contract, and each such party forever waives any such defense, except to the extent such defense relates to lack of authenticity. This

Agreement shall become effective when each party hereto shall have received a counterpart hereof signed by all of the other parties hereto.

Until and unless each party has received a counterpart hereof signed by the other party hereto, this Agreement shall have no effect and

no party shall have any right or obligation hereunder (whether by virtue of any other oral or written agreement or other communication).

Section

11.10 Entire Agreement. This

Agreement and the Confidentiality Agreement constitute the entire agreement between the parties with respect to the subject matter of

this Agreement and supersede all prior agreements and understandings, both oral and written, between the parties with respect to the

subject matter of this Agreement.

Section

11.11 Severability. If

any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction or other Governmental Authority

to be invalid, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions of this Agreement shall remain

in full force and effect and shall in no way be affected, impaired or invalidated so long as the economic or legal substance of the Transactions

is not affected in any manner materially adverse to any party. Upon such a determination, the parties shall negotiate in good faith to

modify this Agreement so as to effect the original intent of the parties as closely as possible in an acceptable manner in order that

the Transactions be consummated as originally contemplated to the fullest extent possible.

Section

11.12 Specific Performance.

(a) The

parties hereto agree that irreparable damage would occur in the event any provision of this Agreement were not performed in accordance

with the terms hereof and that any breach of this Agreement would not be adequately compensated by monetary damages, and that the parties

shall be entitled to an injunction or injunctions to prevent breaches of this Agreement or to enforce specifically the performance of

the terms and provisions hereof, without proof of actual damages or inadequacy of legal remedy and without bond or other security being

required, in addition to any other remedy to which they are entitled at law or in equity. The pursuit of specific enforcement by any

party hereto will not be deemed an election of remedies or waiver of the right to pursue any other right or remedy (whether at law or

in equity) to which such party may be entitled at any time.

(b) Notwithstanding

anything herein to the contrary, it is acknowledged and agreed that the Company shall be entitled to seek specific performance of Parent’s

obligations to consummate the Merger if and only if (i) all of the conditions set forth in Section 9.1 and Section 9.2

(other than conditions that by their nature are to be satisfied at the Closing, so long as such conditions are capable of being satisfied

at such time as if such time were the Closing) have been satisfied as of the time when the Closing is required to have occurred pursuant

to Section 2.1(b), (ii) the proceeds of the Debt Financing have been funded (or will be funded in accordance with the terms thereof

at the Closing) in accordance with the terms of the Debt Commitment Letter, (iii) Parent fails to consummate the Merger by the date that

is three (3) Business Days after the date on which Parent is required to consummate the Closing pursuant to Section 2.1(b), and

(iv) the Company has irrevocably confirmed to Parent in writing (that has not been withdrawn or revoked) that (A) all of the conditions

set forth in Section 9.1 and Section 9.3 (other than conditions that by their nature are to be satisfied at the Closing,

so long as such conditions are capable of being satisfied at such time as if such time were the Closing) have been satisfied or, or the

extent legally permitted, waived by the Company, (B) the Company is prepared, willing and able to consummate the Closing, and (C) the

Closing will occur pursuant to Article 2 if specific performance is granted and the Debt Financing is funded in accordance with

the Debt Commitment Letter. For the avoidance of doubt, while the Company shall have the right to seek (i) an injunction, specific performance

or other equitable remedies in accordance with this Section 11.12 and (ii) payment of the Parent Termination Fee pursuant to Section

11.4(c), under no circumstances shall the Company, directly or indirectly, be permitted or entitled to receive both (A) a grant of

specific performance or other equitable relief to cause the Closing to be consummated and the aggregate Per Share Merger Consideration

to be paid, on the one hand, and (B) payment of the Parent Termination Fee and any Company Enforcement Expenses (if any), on the other

hand.

Section

11.13 No Recourse. This

Agreement may only be enforced against, and any claims or causes of action that may be based upon, arise out of or relate to this Agreement,

or the negotiation, execution or performance of this Agreement may only be made against the entities that are expressly identified as

parties hereto and no member of the Company Group and no member of the Parent Group shall have any liability for any obligations or liabilities

of the parties to this Agreement or for any claim (whether in tort, contract or otherwise) based on, in respect of, or by reason of,

the Transactions or in respect of any oral representations made or alleged to be made in connection herewith. In no event shall the Company

or any of its Affiliates or other member of the Company Group, on the one hand, and Parent, Merger Subsidiary or any of their respective

Affiliates or other member of the Parent Group on the other hand, and each member of the Company Group and each member of the Parent

Group agrees not to and to use commercially reasonable efforts to cause its respective controlled Affiliates and other members of the

Company Group or other members of the Parent Group, as applicable, not to, seek to enforce this Agreement against, make any claims for

breach of this Agreement against, or seek to recover monetary damages from, any member of the Parent Group or any member of the Company

Group, as applicable, that is not a party to this Agreement.

Section

11.14 Debt Financing Sources. Notwithstanding

anything herein to the contrary, the parties hereby agree that (a) no Debt Financing Source shall have any liability (whether in contract

or in tort, in law or in equity, or granted by statute) for any claims, causes of action, obligations or losses arising under, out of,

in connection with or related in any manner to this Agreement or based on, in respect of or by reason of this Agreement or its negotiation,

execution, performance or breach (provided that nothing in this Section 11.14 shall limit the liability or obligations of such

Debt Financing Source under any Debt Commitment Letter, the fee letter related thereto, any credit agreement or any other documents governing

or evidencing the Debt Financing or any other financing provided by any Debt Financing Source); (b) except as may be set forth in any

Debt Commitment Letter, the fee letter related thereto, any credit agreement or any other documents governing or evidencing the Debt

Financing, any credit facilities or other financing provided by any Debt Financing Source, any action of any kind or description (whether

at law, in equity, in contract, in tort or otherwise) involving any Debt Financing Source arising out of, in connection with, or relating

to the Debt Financing, or the performance of services thereunder shall be subject to the exclusive jurisdiction of a state or federal

court sitting in the City of New York (Borough of Manhattan), State of New York (and any appellate court thereof); (c) any interpretation

of any agreements related to the Debt Financing will be governed by, and construed and interpreted in accordance with, the laws of the

State of New York, without regard to principles of conflict of laws; (d) no party hereto will bring, permit any of their respective controlled

Affiliates to bring, or support anyone else in bringing, any such Action in any other court; (e) the waiver of rights to trial by jury

set forth in Section 11.8 applies to any such legal proceeding; (f) only Parent (including their permitted successors and assigns)

and the other parties to any Debt Commitment Letter, the fee letter related thereto, any credit agreement or any other agreements governing

the Debt Financing at their own direction shall be permitted to bring any claim against a Debt Financing Source for failing to satisfy

any obligation to fund the Debt Financing pursuant to the terms of any such agreement; (g) no amendment or waiver of this Section

11.14, Section 11.5, Section 11.8 or any of the defined terms used herein or therein, including, but not limited to,

the definitions of “Debt Financing” or “Debt Financing Sources” that is materially adverse to the Debt Financing

Sources in their capacity as such shall be effective without the prior written consent of the lenders party to the agreements governing

the Debt Financing to which such amendment is materially adverse; and (h) the Debt Financing Sources are express and intended third party

beneficiaries of this Section 11.14, Section 11.5, Section 11.8 and any of the provisions in this Agreement reflecting

the foregoing.

[The

remainder of this page has been intentionally left blank;

the next page is the signature page.]

WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed by their respective authorized officers as of the

date set forth on the cover page of this Agreement.

SANARA MEDTECH INC.

By:

/s/

Seth D. Yon

Name:

Seth

D. Yon

Title:

President

and Chief Executive Officer

MIMEDX GROUP, INC.

By:

/s/

Joseph H. Capper

Name:

Joseph

H. Capper

Title:

Chief

Executive Officer

MUSTANG MERGER SUB, INC.

By:

/s/

William “Butch” Hulse

Name:

William

“Butch” Hulse

Title:

Director

[Signature

Page to Merger Agreement]

EX-10.1

Filename: ex10-1.htm · Sequence: 3

Exhibit

10.1

VOTING

AGREEMENT

THIS

VOTING AGREEMENT, dated as of July 29, 2026 (this “Agreement”), is entered into by and among MiMedx Group, Inc. (“Parent”),

Sanara MedTech Inc. (the “Company”) and each Person identified on Exhibit A (each a “Stockholder”

and, collectively, the “Stockholders”).

RECITALS:

WHEREAS,

concurrently with the execution of this Agreement, Parent, Mustang Merger Sub, Inc. (“Merger Sub”); and the Company

have entered into an Agreement and Plan of Merger (the “Merger Agreement”), pursuant to which, among other things,

first, Merger Sub will merge with and into the Company, with the Company continuing as the surviving corporation of such merger (the

“Merger”);

WHEREAS,

as of the date hereof, each Stockholder either directly or through one of its affiliates is the record and beneficial owner of, and has

the right to vote and dispose of, the number of Company Common Shares set forth opposite such Stockholder’s name on Exhibit

A (the “Existing Shares”); and

WHEREAS,

as a material inducement to Parent to enter into the Merger Agreement, Parent has requested each Stockholder to agree, and each Stockholder

has agreed, to enter into this Agreement and abide by the covenants and obligations set forth herein with respect to the Covered Shares.

NOW

THEREFORE, in consideration of the foregoing and the mutual representations, warranties, covenants and agreements herein contained,

and intending to be legally bound hereby, the parties hereto agree as follows:

ARTICLE

GENERAL

Section

1.1 Defined Terms. The following capitalized terms, as used in this Agreement, shall

have the meanings set forth below. Capitalized terms used but not otherwise defined herein shall have the meanings ascribed thereto in

the Merger Agreement.

“Company

Board” means the board of directors of the Company.

“Contemplated

Transactions” means (i) all actions and transactions contemplated by the Merger Agreement, including the Merger, and (ii) all

actions and transactions contemplated by this Agreement.

“Covered

Shares” means the Existing Shares, together with any Company Shares that any Stockholder acquires, either beneficially or of

record, on or after the date of this Agreement, including any Company Shares received as distributions, as a result of a split, reverse

split, combination, merger, consolidation, reorganization, reclassification, recapitalization or similar transaction or upon exercise

of any option, benefit award, warrant or other security or instrument exercisable, convertible or exchangeable into Company Shares.

“Permitted

Transfer” means a Transfer of Covered Shares by any Stockholder: (a) if such Stockholder is an individual, (i) to any member

of such Stockholder’s immediate family, (ii) to any trust or other estate planning vehicle for the direct or indirect benefit of

such Stockholder or the immediate family of such Stockholder for bona fide estate planning purposes, (iii) by virtue of laws of descent

and distribution following the death of such Stockholder, (iv) by operation of law or pursuant to an order of a court or other regulatory

agency (including, for the avoidance of doubt, a domestic relations order, divorce settlement, divorce decree or separation agreement)

or (v) to a partnership, limited liability company or other entity of which such Stockholder and/or the immediate family of such Stockholder

are the legal and beneficial owners of all the outstanding equity securities or similar interests; (b) if such Stockholder is a corporation,

partnership, limited liability company or other entity, (I) to another corporation, partnership, limited liability company or other entity

that is an affiliate controlled by such Stockholder, (II) to one or more partners or members of such Stockholder or to an affiliate under

common control with such Stockholder or (III) to any investment fund or other entity controlling, controlled by, managing or managed

by or under common control with such Stockholder or affiliates of such Stockholder (including, for the avoidance of doubt, where such

Stockholder is a partnership, to its general partner or a successor partnership or fund, or any other funds managed by such partnership);

or (c) if such Stockholder is a trust or other estate planning vehicle, to any beneficiary of such Stockholder that receives Shares in

a distribution from it for no consideration; provided, however, that a Transfer referred to in in clauses (a) –

(c) shall be deemed a Permitted Transfer only if, as a precondition to such Transfer, the transferee agrees in a written document,

reasonably satisfactory in form and substance to Parent, to be bound by all of the terms of this Agreement (without modification or condition

other than the consummation of the Permitted Transfer).

“Support

Period” means that period from the date of this Agreement until the Expiration Time.

“Transfer”

means, directly or indirectly, to sell (including short sell), transfer, assign or otherwise dispose of (whether by merger or consolidation

(including by conversion into securities or other consideration as a result of such merger or consolidation), by tendering into any tender

or exchange offer, by testamentary disposition, by operation of law, by gift, or otherwise), either voluntarily or involuntarily, or

to enter into any option or other Contract with respect to the voting of or sale, transfer, conversion, assignment or other disposition

of (whether by merger or consolidation (including by conversion into securities or other consideration as a result of such merger or

consolidation), by tendering into any tender or exchange offer, by testamentary disposition, by operation of law or otherwise).

ARTICLE

VOTING

Section

2.1 Agreement to Vote.

(a)

During the Support Period, each Stockholder hereby irrevocably and unconditionally agrees that, at the Company Stockholder Meeting or

any other meeting of the Company’s stockholders (whether annual or special and whether or not an adjourned or postponed meeting,

however called, and including any adjournment or postponement thereof), and in any action by written consent of the Company’s stockholders,

in each case at which any of the matters set forth in clauses (ii) or (iii) below is put to the vote of stockholders of

the Company, such Stockholder shall, and shall cause any nominee and other holder of record of any of such Stockholder’s Covered

Shares to:

(i)

when any such meeting is held, appear at such meeting or otherwise cause all of such Stockholder’s Covered Shares to be counted

as present thereat for the purpose of establishing a quorum, and when action by written consent of the Company’s stockholders is

proposed, respond affirmatively to any such request for written consent;

(ii)

vote (or act by written consent), or cause to be voted at such meeting (or validly execute and return and cause such written consent

to be granted with respect to), all of such Stockholder’s Covered Shares in favor of (A) the adoption of the Merger Agreement and

approval of the transactions contemplated thereby, including the Merger, (B) each of the other actions expressly contemplated by the

Merger Agreement and (C) any proposal (to the extent permitted by Section 6.2 of the Merger Agreement) to adjourn, recess or postpone

the applicable meeting to a later date that is prior to the End Date if there are not sufficient votes at the applicable meeting to approve

the Merger; and

(iii)

vote (or act by written consent), or cause to be voted at such meeting (or validly execute and return and cause such written consent

to be granted with respect to), all of such Stockholder’s Covered Shares against the following actions (other than the Merger and

the Contemplated Transactions): (A) any action or proposal to amend or waive any provision of the Company Charter or Company Bylaws for

which the Stockholders have received at least 10 days’ prior written notice from either Parent or the Company that it reasonably

expects that such action or proposal would (1) result in a breach of any covenant, representation or warranty or any other obligation

or agreement of the Company contained in the Merger Agreement, or of any Stockholder contained in this Agreement, or (2) prevent, impede,

interfere with, delay, postpone, or adversely affect the consummation of the transactions contemplated by the Merger Agreement, including

the Merger; (B) any Acquisition Proposal or any agreement related thereto; and (C) any other action which is intended, or would reasonably

be expected, to result in any of the conditions to the consummation of the Merger under the Merger Agreement not being fulfilled.

(b)

[Reserved.]

Section

2.2 No Inconsistent Agreements. Each Stockholder

hereby represents, covenants and agrees that, except for this Agreement, such Stockholder has not (a) entered into, and shall not, until

this Agreement is terminated pursuant to Section 5.1, enter into any voting agreement or voting trust that is inconsistent with

this Agreement or (b) granted, and shall not, until this Agreement is terminated pursuant to Section 5.1, grant a proxy, consent

or power of attorney in any manner that would have the effect of preventing, materially delaying

or disabling such Stockholder from performing any of its obligations under this Agreement. Each Stockholder hereby further covenants

and agrees that, until this Agreement is terminated pursuant to Section 5.1, such Stockholder shall not take any other action

in its capacity as the record holder or beneficial owner of Covered Shares, that would reasonably be expected to prevent or materially

delay the consummation of the Contemplated Transactions or the performance by the Company of its obligations under the Merger Agreement.

Section

2.3 No Obligation to Exercise Options or Other Securities. Nothing in this Agreement

shall require any Stockholder to (a) convert, exercise or exchange any options, warrants or convertible securities in order to obtain

any underlying Company Shares or (b) vote, or execute any consent with respect to, any Company Shares underlying such options, warrants

or convertible securities that have not yet been issued as of the applicable record date for that vote or consent.

Section

2.4 Proxy Card. Prior to the Expiration Time, each Stockholder shall promptly (but

in any event no later than ten (10) Business Days prior to the Company Stockholder Meeting) execute and deliver to the Company or the

Company’s proxy solicitor (or cause the holders of record of such Stockholder’s Covered Shares to execute and deliver to

the Company or the Company’s proxy solicitor), any proxy card or voting instructions such Stockholder receives that is sent by

the Company to its stockholders soliciting proxies with respect to any matter described in Section 2.1 which shall be voted in

the manner described in Section 2.1, and such vote during the Support Period shall not be amended, withdrawn or rescinded.

ARTICLE

REPRESENTATIONS

AND WARRANTIES

Section

3.1 Representations and Warranties of Stockholders. Each Stockholder, severally

as to himself, herself or itself, and not jointly or jointly and severally, hereby represents and warrants to Parent as follows:

(a)

Organization; Authorization; Validity of Agreement; Necessary Action. If such Stockholder is an entity, such Stockholder is duly

organized and validly existing and in good standing under the Laws of its jurisdiction of organization. Such Stockholder has the requisite

power and authority and/or capacity to execute and deliver this Agreement and to carry out its obligations hereunder. The execution and

delivery by such Stockholder of this Agreement and the performance by such Stockholder of its obligations hereunder have been duly and

validly authorized by such Stockholder and no other actions or proceedings are required on the part of such Stockholder to authorize

the execution and delivery of this Agreement or the performance by such Stockholder of its obligations hereunder. This Agreement has

been duly executed and delivered by such Stockholder and, assuming the due authorization, execution and delivery of this Agreement by

Parent, constitutes a legal, valid and binding agreement of such Stockholder, enforceable against such Stockholder in accordance with

its terms, subject to the Bankruptcy and Equity Exception.

(b)

Ownership. As of the date hereof, such Stockholder is the record and beneficial owner of, and has good and valid title to, the

Existing Shares set forth opposite such Stockholder’s name on Exhibit A free and clear of any Liens (other than pursuant

to this Agreement or transfer restrictions under applicable securities Laws). The Covered Shares owned by such Stockholder will be beneficially

and legally owned by such Stockholder, except in the case of a Permitted Transfer of any Covered Shares. Except as provided for in this

Agreement, such Stockholder, directly or indirectly, has sole or shared voting power, sole or shared power of disposition, sole or shared

power to issue instructions with respect to the matters set forth in ARTICLE 2, and sole or shared power to agree to all of the

matters set forth in this Agreement, in each case, with respect to all of the Covered Shares owned by such Stockholder, except in the

case of a Permitted Transfer of Covered Shares. As of the date hereof, except for the Existing Shares, such Stockholder does not, directly

or indirectly, legally or beneficially own or have any option, warrant or other right to acquire any Company Common Shares or other securities

of the Company that are or may by their terms become entitled to vote or any securities that are convertible or exchangeable into or

exercisable for any securities of the Company that are or may by their terms become entitled to vote, nor is such Stockholder subject

to any Contract, other than this Agreement and the other Transaction Documents, that obligates such Stockholder to vote, acquire or dispose

of any securities of the Company.

(c)

No Violation. Neither the execution and delivery of this Agreement by such Stockholder nor its performance of its obligations

under this Agreement will (i) result in a violation or breach of, or conflict with any provisions of, or constitute a default (or an

event which, with notice or lapse of time or both, would constitute a default) under, or result in the termination or cancellation of,

any material Contract to which such Stockholder is a party, or give rise to a right of purchase under, or result in the creation of any

Lien (other than pursuant to this Agreement or transfer restrictions under applicable securities Laws) upon, the Existing Shares owned

by such Stockholder, (ii) violate any Law applicable to such Stockholder, or (iii) with respect to any Stockholder that is an entity,

result in a violation or breach of or conflict with its certificate of incorporation, certificate of formation, bylaws, operating agreement,

or other governing or constitutional documents, as applicable, except, in the case of clauses (i) and (ii), as would not, individually

or in the aggregate, reasonably be expected to prevent or materially delay the ability of such Stockholder to perform its obligations

hereunder.

(d)

Consents and Approvals. No consent, approval, order or authorization of, or registration, declaration or filing with, any Governmental

Entity is necessary to be obtained or made by such Stockholder in connection with its execution, delivery and performance of this Agreement,

except (i) as required by the rules and regulations promulgated under the Exchange Act, the Securities Act, or state securities, takeover

and “blue sky” Laws, (ii) compliance with any applicable requirements of the HSR Act and any other applicable Competition

Laws, (iii) the applicable rules and regulations of the SEC or any applicable stock exchange or (iv) as would not, individually or in

the aggregate, reasonably be expected to restrict in any material respect, prohibit, impair in any material respect or materially delay

the performance by such Stockholder of its obligations under this Agreement.

(e)

Reliance by Parent. Such Stockholder understands and acknowledges that Parent is entering into the Merger Agreement in reliance

upon such Stockholder’s execution and delivery of this Agreement and the representations, warranties, covenants and obligations

of such Stockholder contained herein.

(f)

Adequate Information. Such Stockholder acknowledges that it is a sophisticated party with respect to the Covered Shares and has

adequate information concerning the business and financial condition of the Company to make an informed decision regarding the transactions

contemplated by this Agreement and has, independently and without reliance upon Parent and based on such information as such Stockholder

has deemed appropriate, made its own analysis and decision to enter into this Agreement. Such Stockholder acknowledges that Parent has

not made and is not making any representation or warranty, whether express or implied, of any kind or character except as expressly set

forth in this Agreement or in the Merger Agreement.

(g)

Except for the representations and warranties expressly set forth in Section 2.2 or this Section 3.1 no Stockholder (nor

any other Person on behalf of any Stockholder) makes any express or implied representation or warranty in connection with the transactions

contemplated hereby, and each Stockholder hereby disclaims any other representations or warranties.

Section

3.2 Representations and Warranties of Parent. Parent hereby represents and warrants

to other parties hereto as follows:

(a)

Parent is duly organized and validly existing and in good standing under the Laws of its jurisdiction of organization.

(b)

Parent has the requisite power and authority to execute and deliver this Agreement and to carry out Parent’s obligations hereunder.

The execution and delivery of this Agreement by Parent and the consummation of the transactions contemplated hereby have been duly authorized

and approved by all requisite corporate action on the part of Parent and no other actions or proceedings are required on the part of

Parent to authorize the execution and delivery of this Agreement or the performance by Parent of its obligations hereunder. This Agreement

has been duly executed and delivered by Parent and, assuming the due authorization, execution and delivery of this Agreement by the other

parties hereto, constitutes a legal, valid and binding agreement of Parent, enforceable against Parent in accordance with its terms,

subject to the Bankruptcy and Equity Exception.

(c)

Parent acknowledges and agrees that no Stockholder has made, and no Stockholder is making, any representation or warranty of any kind

(express or implied) (and Parent acknowledges and agrees that it has not relied, and disclaims reliance, on any such representation or

warranty), except as expressly set forth in Section 2.2 or Section 3.1.

ARTICLE

OTHER

COVENANTS

Section

4.1 Prohibition on Transfers, Other Actions.

(a)

During the Support Period, except for any Permitted Transfer, each Stockholder shall not Transfer any of such Stockholder’s Covered

Shares. Any purported Transfer not in compliance with this Section 4.1(a) shall be null and void ab initio. Notwithstanding

the foregoing, (i) direct or indirect transfers of equity or other interests in any Stockholder by its equityholders is not prohibited

by this Section 4.1(a) and (ii) each Stockholder may make such Transfers of such Stockholder’s Covered Shares as Parent

may agree to in writing.

(b)

If during the Support Period any Stockholder attempts to Transfer (other than a Permitted Transfer) any of such Stockholder’s Covered

Shares in violation of Section 4.1(a), such Stockholder hereby unconditionally and irrevocably (during the Support Period) instructs

the Company to not, (i) permit any such Transfer on its books and records, (ii) issue a book-entry interest or a new certificate representing

any of the Covered Shares or (iii) record such vote (including by written consent). In furtherance of the foregoing, each Stockholder

hereby authorizes the Company to notify the Company’s transfer agent, and the Company agrees to notify its transfer agent, that

there is a stop transfer order with respect to all of such Stockholder’s Covered Shares (and that this Agreement places limits

on the voting and transfer of such Stockholder’s Covered Shares), subject to the provisions hereof and provided that any such stop

transfer order and notice will immediately be withdrawn and terminated by the Company following the Expiration Time.

(c)

During the Support Period, each Stockholder will not (solely in such Stockholder’s capacity as a stockholder of the Company) bring,

commence, institute, maintain, prosecute or voluntarily aid any legal action or proceeding which challenges the validity of or seeks

to enjoin the operation of any provision of the Merger Agreement or this Agreement; provided that such Stockholder shall not be prohibited

from enforcing any of its rights under this Agreement or bringing any claim against Parent and/or Company for a breach hereof. In addition,

each Stockholder agrees not to demand or commence an appraisal proceeding under Section 262 of the DGCL with respect to its Covered Shares.

(d)

During the Support Period, each Stockholder shall not, and shall cause its Affiliates and its and their respective Representatives (on

behalf of such Stockholder) not to, directly or indirectly, (i) solicit, initiate or induce, or knowingly take any action to facilitate,

assist in or encourage the submission or announcement of, any Acquisition Proposal or (ii) enter into or participate in any discussions

or negotiations with, furnish any non-public information relating to the Company or any of its Subsidiaries to, or afford access to the

business, properties, assets, personnel, books or records of the Company or any of its Subsidiaries to any Third Party or its Representatives

in connection with or in furtherance of any Acquisition Proposal. Notwithstanding the foregoing, to the extent that the Company is permitted

to engage in any of the foregoing activities pursuant to Section 6.3 of the Merger Agreement, any Stockholder may participate in such

activities and therefore shall not be subject to the restrictions in this Section 4.1(c) so long as such actions by such Stockholder

would otherwise be permitted to be taken by the Company pursuant to Section 6.3 of the Merger Agreement.

(e)

Each Stockholder shall, and shall cause its Affiliates, and shall direct its and their respective Representatives to, (i) cease immediately

and cause to be terminated any and all existing activities, discussions or negotiations, if any, with any Third Party and its Representatives

with respect to any Acquisition Proposal and (ii) cease providing any information to any Third Party or its Representatives with respect

to the Company or any of its Subsidiaries, or their respective businesses, properties, assets, personnel, books or records, in connection

with any Acquisition Proposal. Notwithstanding the foregoing, the restrictions in this Section 4.1(d) shall not apply with respect

to any discussions or negotiations with respect to the Transfer of Covered Shares permitted by Section 4.1(a).

(f)

For the avoidance of doubt, for the purposes of this Agreement, the Company shall not be deemed an Affiliate of any Stockholder, and

any officer, director, employee, agent or advisor of the Company (in each case, in their capacities as such), shall not be deemed a Representative

of any Stockholder.

Section

4.2 Further Assurances. Each of the parties hereto agrees that it will use its reasonable

best efforts to do all things reasonably necessary to effectuate this Agreement.

ARTICLE

MISCELLANEOUS

Section

5.1 Termination. This Agreement shall remain in effect until the earliest to occur

of (a) the termination of the Merger Agreement in accordance with its terms, (b) the Effective Time, (c) the termination of this Agreement

by written agreement of the parties hereto, (d) the Company Board effecting an Adverse Recommendation Change in accordance with the terms

of the Merger Agreement or (e) such date and time as the Merger Agreement shall have been, without the prior written consent of the Stockholders,

amended or supplemented, or any provision thereof waived, in a manner that changes the form of the consideration or reduces the amount

of the Merger Consideration payable (or issuable) in respect of any Covered Shares (other than, for the avoidance of doubt, adjustments

in accordance with the terms of the Merger Agreement or any increase in the Merger Consideration), in which case this Agreement shall

automatically terminate and be of no further force and effect with respect to all parties hereto (the time of such termination, the “Expiration

Time”). The representations, warranties and covenants of the Stockholders contained in this Agreement shall expire at the Expiration

Time. Nothing in this Section 5.1 and no termination of this Agreement shall relieve or otherwise limit any party of liability

for any breach of this Agreement occurring prior to such termination.

Section

5.2 No Ownership Interest. Nothing contained in this Agreement shall be deemed to vest in Parent any direct or indirect ownership

or incidence of ownership of or with respect to any Covered Shares. All rights, ownership and economic benefit relating to the Covered

Shares shall remain vested in and belong to each Stockholder, and Parent shall have no authority to direct any Stockholder in the voting

or disposition of any of the Covered Shares except as otherwise provided herein.

Section

5.3 Publicity. Each Stockholder hereby authorizes the Company and Parent to include

and disclose in any press release, the Registration Statement, the Proxy Statement, and in such other schedules, certificates, applications,

agreements or documents as Parent and the Company reasonably determine to be necessary or appropriate (as required by applicable Law)

in connection with the consummation of the Merger and the Contemplated Transactions, such Stockholder’s identity and ownership

of the Covered Shares, and the nature of such Stockholder’s commitments, arrangements and understandings pursuant to this Agreement.

Each Stockholder acknowledges that each of the Company and Parent may, in its sole discretion, file a form of this Agreement with the

SEC or any other Governmental Authority or securities exchange. Parent and the Company hereby authorize each Stockholder to disclose

this Agreement and the Contemplated Transactions in any reports required to be filed by such Stockholder or any of its affiliates under

the Exchange Act or otherwise as required by Law. Each party hereto agrees to promptly provide to the other parties any information it

may reasonably require for the preparation of any such disclosure documents, and each party agrees to promptly notify the other parties

of any required corrections with respect to any information supplied by such party specifically for use in any such disclosure document,

if and to the extent that any such information shall have become false or misleading in any material respect.

Section

5.4 Notices. All notices, requests and other communications to any party hereunder

shall be in writing (including electronic mail (“e-mail”) transmission, so

long as a receipt of such e-mail is requested and received) and shall be given,

to Parent, to:

MIMEDX

GROUP, INC.

1775

West Oak Common Ct. NE

Marietta,

GA 30062

Attention:

William “Butch” Hulse

E-mail:

BHulse@mimedx.com

with

copies to:

Greenberg

Traurig, P.A.

401

East Las Olas Blvd.

Suite

2000

Attention:

Flora Perez and Matthew Miller

E-mail:

perezf@gtlaw.com; millerma@gtlaw.com

to the Company (prior to the Closing), to:

SANARA

MEDTECH INC.

1200

Summit Avenue, Suite 414

Forth

Worth, Texas 76102

Attention:

Seth Yon

E-mail:

syon@sanaramedtech.com

with

copies to:

Alston

& Bird LLP

One

Atlantic Center

1201

West Peachtree Street

Atlanta,

GA 30309

Attention:

J. Mark Ray; Kyle G. Healy; Tyler w. Pate

E-mail:

mark.ray@alston.com; kyle.healy@alston.com; tyler.pate@alston.com

to any Stockholder, to the address set forth next to such Stockholder’s name on Exhibit A.

Section

5.5 Mutual Drafting; Interpretation. Each party to this Agreement has participated

in the drafting of this Agreement, which each such party acknowledges is the result of extensive negotiations between the parties. If

an ambiguity or question of intent or interpretation arises, this Agreement shall be construed as if drafted jointly by the parties,

and no presumption or burden of proof shall arise favoring or disfavoring any party by virtue of the authorship of any provision. For

purposes of this Agreement, whenever the context requires: the singular number shall include the plural, and vice versa; the masculine

gender shall include the feminine and neuter genders; the feminine gender shall include the masculine and neuter genders; and the neuter

gender shall include masculine and feminine genders. As used in this Agreement, the words “include” and “including”

and variations thereof, shall not be deemed to be terms of limitation, but rather shall be deemed to be followed by the words “without

limitation.” Except as otherwise indicated, all references in this Agreement to “Sections,” “Exhibits”

and “Annexes” are intended to refer to Sections of this Agreement and Exhibits and Annexes to this Agreement. The words “hereof,”

“hereto,” “hereby,” “herein,” “hereunder” and words of similar import, when used in this

Agreement, shall refer to this Agreement as a whole and not to any particular Section or Article in which such words appear. Unless otherwise

specifically provided for herein, the term “or” shall not be deemed to be exclusive. If the last day of a period of time

before which, within which or following which any act is to be done or step taken pursuant to this Agreement is not a Business Day, the

period shall end on the immediately following Business Day.

Section

5.6 Counterparts. This Agreement may be signed in any number of counterparts, each

of which shall be an original, with the same effect as if the signatures thereto and hereto were upon the same instrument. Any such counterpart,

to the extent delivered by .pdf, .tif, .gif, .jpeg or similar attachment to electronic mail (any such delivery, an “Electronic

Delivery”) shall be treated in all manner and respects as an original counterpart and shall be considered to have the

same binding legal effect as if it were the original signed version thereof delivered in person. No party hereto shall raise the use

of Electronic Delivery to deliver a signature or the fact that any signature or agreement or instrument was transmitted or communicated

through the use of Electronic Delivery as a defense to the formation of a contract, and each such party forever waives any such defense,

except to the extent such defense relates to lack of authenticity. This Agreement shall become effective when each party hereto shall

have received a counterpart hereof signed by all of the other parties hereto. Until and unless each party has received a counterpart

hereof signed by the other party hereto, this Agreement shall have no effect and no party shall have any right or obligation hereunder

(whether by virtue of any other oral or written agreement or other communication).

Section

5.7 Entire Agreement. This Agreement and the Confidentiality Agreement constitute

the entire agreement between the parties with respect to the subject matter of this Agreement and supersede all prior agreements and

understandings, both oral and written, between the parties with respect to the subject matter of this Agreement.

Section

5.8 Governing Law; Consent to Jurisdiction; Waiver of Trial by Jury.

(a)

This Agreement, and all Proceedings (whether in contract, in tort or otherwise) that may be based upon, arise out of or relate to this

Agreement, or the negotiation, execution or performance of this Agreement or the Transactions, shall be governed by and construed in

accordance with the laws of the State of Texas, without regard to the conflicts of law rules of such state.

(b)

All Proceedings (whether at law, in contract, in tort or otherwise) arising out of or relating to this Agreement, the negotiation, validity